Included in the invention are polynucleotides and the polypeptides encoded by such polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using the same.

Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.

BACKGROUND OF THE INVENTION The invention generally relates to nucleic acids and polypeptides encoded therefrom. More specifically, the invention relates to nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

SUMMARY OF THE INVENTION The present invention is based in part on nucleic acids encoding proteins that are members of the following protein families: intracellular protein-like Proteins, Sorting Nexin 6-like Proteins, 2310038H17RIK membrane (TmSP) protein-like Proteins, 573045I09RIK cyclin-like Proteins, cMob5 cancer specific proteins, LRP16 protein-like Proteins, Phosphatidylethanolamine-binding protein-like Proteins, Immunoglobulin-like LRR-domain containing Proteins, NUMB binding protein LNXp80-like Proteins, Zinc Finger Protein-like Proteins, Actin-Binding Protein Frabin-Alpha-like Proteins, Actin related protein 2/3 complex subunit lA-like Proteins, Hepatocellular Carcinoma Autoantigen-like Proteins, Hematopoietic Stem/Progenitor Cells Protein MDS029-like Proteins, TRAP-delta-like Proteins, INTSIG-5-like WD-40 repeats containing protein-like Proteins, Ferritin light chain-like Proteins, Leucine-rich protein 130-like Proteins, tumor protein p53-binding protein 2-like Proteins. The novel polynucleotides and polypeptides are referred to herein as NOVIa, NOVlb, NOV2a, NOV2b, NOV3a, NOV3b, NOV3c, NOV4a, NOV4b, NOV5a, NOV6a, NOV6b, NOV7a, NOV8a, NOV9a, NOVlOa, NOV1 la, NOV12a, NOV13a, NOV14a, NOV15a, NOV16a, NOV16b, NOV17a, NOV 17b, NOV 18a, NOV 18b, NOV 18c, NOV 19a, NOV 19b, NOV20a, NOV20b, NOV20c. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as"NOVX"nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated NOVX nucleic acid disclosed in SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33. In some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment ; homolog, analog or

derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NO : 2n, wherein n is an integer between 1 and 33. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NO : 2n-I, wherein n is an integer between 1 and 33. Also included in the invention is an oligonucleotide, e. g. , an oligonucleotide that includes at least 6 contiguous nucleotides of a NOVX nucleic acid (e. g. , SEQ ID NO : 2n-I, wherein n is an integer between I and 33) or a complement of said oligonucleotide.

The invention also encompasses isolated NOVX polypeptides (SEQ ID NO : 2n, wherein n is an integer between 1 and 33). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically-or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, e. g., a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically-or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid

probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, e. g. , a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

In another embodiment, the invention involves a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, the method including providing a cell expressing the polypeptide of the invention and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e. g., adrenoleukodystrophy, congenital adrenal hyperplasia, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, lupus erythematosus, psoriasis, lung disorders, liver disorders, rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, asthma, allergies, chronic obstructive pulmonary disease, immunodeficiencies, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, schizophrenia, depression, anxiety, pain, diabetes, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, asthma, emphysema, scleroderma, adult respiratory distress syndrome (ARDS), lymphedema, graft versus host disease (GVHD), pancreatitis. obesity,

ulcers, anemia, ataxia-telangiectasia, cancer, trauma, viral infections, bacterial infections, parasitic infections; and conditions related to transplantation, neuroprotection, fertility, or regeneration (in vitro and in vivo) and/or other pathologies and disorders of the like. Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing conditions including, e. g., those associated with homologs of a NOVX sequence, such as those listed in Table A.

The therapeutic can be, e. g., a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof.

The invention further includes a method for screening for a modulator of disorders or syndromes including, e. g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, e. g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal that recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity of NOVX polypeptide in the test

animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (e. g. , a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, e. g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (e. g. , a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, e. g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identity the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies"section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as"NOVX nucleic acids"or"NOVX polynucleotides"and the corresponding encoded polypeptides are referred to as"NOVX polypeptides"or"NOVX proteins. "Unless indicated otherwise, "NOVX"is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE A. Sequences and Corresponding SEQ ID Numbers SEQ SEQ NOVX Internal ID NO ID NO Assignment Identification (nuclei (amino c acid) acid) NOV I a CG 1 16579-01 1 2 anticancer protein, intracellular protein NOV 1 b CG 1166579-02 3 4 anticancer protein, intracellular protein NOV2a CG 126119-01 5 6 Sorting nexin 6 (TRAF4-associated factor 2) NOV2b CG126119-02 7 8 Sorting nexin 6-like Protein Hepatocellular carcinoma-associated antigen NOV3a CG137623-01 9 10 HCA557b ; 23 ! 0038Ht7RIK membrane (TmSP) protein NOV3b CG137623-02 I I I2 antigen HCA557b NOV3c CG137623-03 13 14 antigen HCA557b NOV4a CG) 37687-01 15 16573045I09RIK cyc) in-) ike Protein NOV4b CG 137687-02 I 7 18 cyclin-like Proteins NOV5a CG143198-01 19 20 150001 J06Rik protein ; Nuclear protein NOV6a CG144756-01 21 22 cMob5 cancer specific protein NOV6b CG144756-02 23 24 Suppression oftumorigenicity 16 protein NOV7a CG145473-01 25 26 LRP16 protein NOV8a CG145988-Ol 27 2g Phosphatidylethanolamine-binding protein ; Prostattc bmding prote ! n NOV9a CG146452-Ol 29 ; p LRR domain-containing Protein ; Immunoglobulin protein Membrane Binding-like Protein ; NUMB NOV Oa CG 146731-01 31 32 binding protein LNXp80 ; multi-PDZ-domain-containing protein NOV 1 1 a CG 147048-01 33 34 Zn Finger Protein ; RING finger protein 18 NOV12a CG147246-01 35 36 Actin-Binding Protein Frabin-Alpha ; GEF NOV 1 3a CG 147651-01 37 38 Suppressor of profilin/p41 of Actin related protein 2/3 complex (subunit I A) NOV 1 4a CG 149303-01 39 40 He atocellular Carcinoma Autoantigen NOV] 5a CG 149312-01 41 42 hematopoietic stem/progenitor cell protein MDS029 NOV 16a CG 150951-01 43 44 Translocon-associated protein, delta subunit precursor (TRAP-delta) NOV ! 6b CG ! 5095I-02 45 46 TRAP-delta-like Proteins NOV I 7a CG 173328-01 47 48 intracellular signaling (INTSIG-5) protein ; WD-40 repeat containing protein NOVUb CGH3328-02 49 50 WD-40 repeats containing protein NOV18a CG56101-01 51 52 ferritin light chain protein NOV18b CG56101-03 53 54 Ferritin light chain protein NOV 18c CG56101-02 55 56 ferritin light chain protein NOV 9a CG56620-01 57 58 leucine-rich protein (LRP 130) (GP130) NOV 19b CG56620-02 59 60 Leucine-rich protein Tumor suppressor p53-binding protein 2 NOV20a CG59323-01 61 62 (TP53BP2) (Bcl2-binding protein) ; APS-2 apoptosis stimu) ating protein 2 (ASSP) NOV20b CG59323-03 63 64 TP53BP2 ASSP NOV20c CG59323-02 65 66 TP53BP2 ; ASSP

Table A indicates the homology of NOVX polypeptides to known protein families.

Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A.

Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to: e. g. , adrenoleukodystrophy, congenital adrenal hyperplasia, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, lupus erythematosus, psoriasis, lung disorders, liver disorders, rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, asthma, allergies, chronic obstructive pulmonary disease, immunodeficiencies, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, schizophrenia, depression, anxiety, pain, diabetes, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, asthma, emphysema, scleroderma, adult respiratory distress syndrome (ARDS), lymphedema, graft versus host disease (GVHD), pancreatitis, obesity, ulcers, anemia, ataxia-telangiectasia, cancer, trauma, viral infections, bacterial infections, parasitic infections; and conditions related to transplantation, neuroprotection, fertility, or regeneration (in vitro and in vivo).

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

Consistent with other known members of the family of proteins, identified in column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families.

Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table A.

The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C.

Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e. g. detection of a variety of cancers.

Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

NOVX clones NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e. g. , by protein or gene therapy.

Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug

targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon.

In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of : (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33 ; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO : 2n, wherein n is an integer between 1 and 33 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of : (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 33 ; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 33, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between I and 33 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of

the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of : (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-l, wherein n is an integer between 1 and 33; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 33 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 33; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-l, wherein n is an integer between I and 33 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

NOVX Nucleic Acids and Polypeptides One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e. g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term"nucleic acid molecule"is intended to include DNA molecules (e. g., cDNA or genomic DNA), RNA molecules (e. g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature"form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein.

The product"mature"form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e. g., host cell) in which the gene product arises. Examples of such processing steps leading to a "mature"form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue I to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a"mature"form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term"probe", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e. g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- stranded or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term"isolated"nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid. Preferably, an"isolated"nucleic acid is free of sequences that naturally flank the nucleic acid (i. e. , sequences located at the 5'-and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0. 1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e. g., brain, heart, liver, spleen, etc.). Moreover, an"isolated"nucleic acid

molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals.

A nucleic acid molecule of the invention, e. g. , a nucleic acid molecule having the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e. g., as described in Sambrook, et al., (eds. ), MOLECULAR CLONING : A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, et al., (eds. ), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.) A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e. g. , using an automated DNA synthesizer.

As used herein, the term"oligonucleotide"refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, or a portion of this nucleotide sequence (e. g, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule

that is complementary to the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, thereby forming a stable duplex.

As used herein, the term"complementary"refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term"binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

A''fragment''provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence.

Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.

A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5' direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3' direction of the disclosed sequence.

A"derivative"is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An"analog"is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e. g. they differs from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin

and may have a similar or opposite metabolic activity compared to wild type. A "homolog"is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species.

Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e. g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A"homologous nucleic acid sequence"or"homologous amino acid sequence,"or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e. g. , frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms.

Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO : 2n-1, wherein n is an integer between I and 33, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

A NOVX polypeptide is encoded by the open reading frame ("ORF") of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be

translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG"start"codon and terminates with one of the three"stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e. g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e. g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12,25, 50, 100, 150, 200,250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33 ; or an anti-sense strand nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between I and 33 ; or of a naturally occurring mutant of SEQ ID N0 : 2n-1, wherein n is an integer between 1 and 33.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e. g. the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues that mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e. g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

"A polypeptide having a biologically-active portion of a NOVX polypeptide"refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX"can be prepared by isolating a portion of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described

below), expressing the encoded portion of NOVX protein (e. g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.

NOVX Nucleic Acid and Polypeptide Variants The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33.

In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO : 2n, wherein n is an integer between 1 and 33.

In addition to the human NOVX nucleotide sequences of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e. g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms"gene"and"recombinant gene"refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO : 2n-1, wherein

is an integer between 1 and 33. In another embodiment, the nucleic acid is at least 10,25, 50,100, 250,500, 750,1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term"hybridizes under stringent conditions"is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.

Homologs (i. e. , nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e. g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase"stringent hybridization conditions"refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0. 01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8. 3 and the temperature is at least about 30 °C for short probes, primers or oligonucleotides (e. g., 10 nt to 50 nt) and at least about 60 °C for longer probes, primers and oligonucleotides.

Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds. ), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N. Y. (1989), 6.3. 1-6. 3. 6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HC1 (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm

DNA at 65°C, followed by one or more washes in 0.2X SSC, 0. 01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a"naturally-occurring"nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e. g. , encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between I and 33, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55 °C, followed by one or more washes in IX SSC, 0. 1% SDS at 37 °C. Other conditions of moderate stringency that may be used <BR> <BR> are well-known within the art. See, e. g. , Ausubel, et al. (eds. ), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, SX SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0. 1 % SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e. g., as employed for cross-species hybridizations). See, e. g. , Ausubel, et al. (eds. ), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg. 1981.

Proc Natl Acad Sci USA 78: 6789-6792.

Conservative Mutations In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO : 2n-1, wherein n is an

integer between 1 and 33, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at"non-essential" amino acid residues can be made in the sequence of SEQ ID N0 : 2n, wherein n is an integer between 1 and 33. A"non-essential"amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an"essential"amino acid residue is required for such biological activity.

For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID N0 : 2n-1, wherein n is an integer between 1 and 33, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID N0 : 2n, wherein n is an integer between 1 and 33. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID N0 : 2n, wherein n is an integer between 1 and 33 ; more preferably at least about 70% homologous to SEQ ID N0 : 2n, wherein n is an integer between 1 and 33 ; still more preferably at least about 80% homologous to SEQ ID N0 : 2n, wherein n is an integer between 1 and 33; even more preferably at least about 90% homologous to SEQ ID N0 : 2n, wherein n is an integer between 1 and 33 ; and most preferably at least about 95% homologous to SEQ ID NO : 2n, wherein n is an integer between 1 and 33.

An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced any one of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at

one or more predicted, non-essential amino acid residues. A"conservative amino acid substitution"is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e. g., lysine, arginine, histidine), acidic side chains (e. g. , aspartic acid, glutamic acid), uncharged polar side chains (e. g. , glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e. g. , alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e. g. , threonine, valine, isoleucine) and aromatic side chains (e. g., tyrosine, phenylalanine, tryptophan, histidine).

Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved"strong"residues or fully conserved"weak"residues. The"strong"group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the"weak"group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein: protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof ; (e. g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e. g. , regulation of insulin release).

Interfering RNA In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including the 5'untranslated (UT) region, the ORF, or the 3'UT region. See, e. g. , PCT applications WO00/44895, W099/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, W002/16620, and W002/29858, each incorporated by reference herein in their entirety.

Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX gene include, e. g. , a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway.

According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e. g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes & Dev. 13 : 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.

The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3'overhang. The sequence of the 2-nt 3'overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3'overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3'overhang are deoxyribonucleotides. Using 2'-deoxyribonucleotides in

the 3'overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize and are most likely more nuclease resistant.

A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to NOVX mRNA is transcribed by a first promoter (e. g., a promoter sequence 3'of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e. g. , a promoter sequence 5'of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene.

In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner.

In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e. g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H 1. One example of a vector system is the GeneSuppressor RNA Interference kit (commercially available from Imgenex). The U6 and H I promoters are members of the type III class of Pol III promoters.

The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for HI promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine.

Cleavage at this position generates a 3'UU overhang in the expressed siRNA, which is similar to the 3'overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e. g., an approximately 50-nucleotide RNA stem-loop transcript.

A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression

vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy.

In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands.

A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to 100 nt downstream of the start codon.

Alternatively, 5'or 3'UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20 (23): 6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene.

In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene.

Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition,

expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e. g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility.

A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N 19) residues (e. g. , AA (Nl 9) TT).

A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA (N 19) TT is not present in the target sequence, an alternative target region would be AA (N21). The sequence of the NOVX sense siRNA corresponds to (N19) TT or N21, respectively. In the latter case, conversion of the 3'end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. Symmetric 3'overhangs may help to ensure that the siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e. g., Elbashir, Lendeckel and Tuschl (2001). Genes & Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition.

Alternatively, if the NOVX target mRNA does not contain a suitable AA (N21) sequence, one may search for the sequence NA (N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5' (N 19) TT, as it is believed that the sequence of the 3'-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J.

Cell Science 114: 4557-4565, incorporated by reference in its entirety.

Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 pg of the siRNA duplex is generally sufficient. Cells are typically

seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e. g. inversion versus vortexing) are also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used.

Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as within the scope of the present invention.

For a control experiment, transfection of 0.84 pg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 pg antisense siRNA has a weak silencing effect when compared to 0.84 pg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e. g. commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology.

Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting.

If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a

non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting.

An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues.

The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment.

Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e. g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA's to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX-) phenotype in the treated subject

sample. The NOVX-phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment.

In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below.

Production of RNAs Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 uM) in 10 mM Tris-HC1 (pH 7.5) with 20 mM NaCI were heated to 95° C for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e. g. , Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N. Y. (1989).

Lysate Preparation Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer's directions. dsRNA is incubated in the lysate at 30° C for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200: 1.

The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis.

In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a 32P-ATP. Reactions are stopped by the addition of 2 X proteinase K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13 : 3191-3197 (1999) ). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined.

The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer

for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques.

RNA Preparation 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, & Tuschl, Genes & Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milord, Mass. , USA) purification (Tuschl, et al., Biochemistry, 32: 11658-11668 (1993)).

These RNAs (20 uM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C followed by 1 h at 37° C.

Cell Culture A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1 : 5 with fresh medium without antibiotics (1-3 X 105 cells/ml) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3'ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.

The above method provides a way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in vivo transfection or gene therapy transfection techniques.

Antisense Nucleic Acids Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, or fragments, analogs or derivatives thereof. An"antisense"nucleic acid comprises a nucleotide sequence that is complementary to a"sense"nucleic acid encoding a protein (e. g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10,25, 50,100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a"coding region"of the coding strand of a nucleotide sequence encoding a NOVX protein. The term "coding region"refers to the region of the nucleotide sequence comprising codons that are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a"noncoding region"of the coding strand of a nucleotide sequence encoding the NOVX protein. The term"noncoding region"refers to 5'and 3'sequences that flank the coding region that are not translated into amino acids (i. e. , also referred to as 5'and 3'untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5,10, 15. 20, 25, 30, 35, 40,45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e. g., an antisense oligonucleotide) can be chemically

synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e. g. , phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, I-methylguanine, 1-methylinosine, 2, 2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 4-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3- (3-amino-3-N-2-carboxypropyl) uracil, (acp3) w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i. e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e. g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.

Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e. g., by linking the antisense nucleic acid molecules to

peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an cc-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual (3-units, the strands run parallel to each other. See, e. g. , Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e. g. , Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e. g., Inoue, et al., 1987. FEBS Lett. 215 : 327-330.

Ribozymes and PNA Moieties Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized.

These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme.

Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e. g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334 : 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i. e., SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA.

See, e. g., U. S. Patent 4,987, 071 to Cech, et al. and U. S. Patent 5,116, 742 to Cech, et al.

NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e. g., Bartel et al., (1993) Science 261: 1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e. g. , the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e. g. , Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N. Y. Acad. Sci. 660: 27-36; Maher, 1992.

Bioassays 14 : 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e. g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e. g. , Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms"peptide nucleic acids"or "PNAs"refer to nucleic acid mimics (e. g. , DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra ; Perry-O'Keefe, et al., 1996. Proc. Natl.

Acad. Sci. USA 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e. g. , inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e. g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e. g., Sl nucleases (See, Hyrup, et al., 1996. supra) ; or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra ; Perry-O'Keefe, et al., 1996. supra).

In another embodiment, PNAs of NOVX can be modified, e. g. , to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e. g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.

PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e. g. , 5'- (4-methoxytrityl) amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5'end of DNA. See, e. g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988.

PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5'PNA segment and a 3'DNA segment. See, e. g., Finn, et al., 1996. supra.

Alternatively, chimeric molecules can be synthesized with a 5'DNA segment and a 3'PNA segment. See, e. g. , Petersen, et al., 1975. Bioorg. Med Chem. Lett. 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e. g. , for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e. g. , Letsinger, et al., 1989. Proc. Natl. Acad Sci. U. S. A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No.

W088/09810) or the blood-brain barrier (see, e. g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e. g. , Krol, et al., 1988. BioTechniques 6: 958-976) or intercalating agents (see, e. g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e. g. , a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

NOVX Polypeptides A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO : 2n, wherein n is an integer between 1 and 33. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or

residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof.

Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An"isolated"or"purified"polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material"includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language"substantially free of cellular material"includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a"contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i. e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language"substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language"substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20%

chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e. g., the amino acid sequence of SEQ ID N0 : 2n, wherein n is an integer between 1 and 33) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide that is, for example, 10, 25,50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO : 2n, wherein n is an integer between 1 and 33. In other embodiments, the NOVX protein is substantially homologous to SEQ ID N0 : 2n, wherein n is an integer between I and 33, and retains the functional activity of the protein of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, and retains the functional activity of the NOVX proteins of SEQ ID NO : 2n, wherein n is an integer between I and 33.

Determining Homology Between Two or More Sequences To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e. g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the

molecules are homologous at that position (i. e., as used herein amino acid or nucleic acid "homology"is equivalent to amino acid or nucleic acid"identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48 : 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5. 0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33.

The term"sequence identity"refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term"percentage of sequence identity"is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e. g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i. e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term"substantial identity"as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX"chimeric protein"or"fusion protein"comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An"NOVX polypeptide"refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, whereas a"non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e. g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX

fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term"operatively-linked"is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e. g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e. g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.

A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional

techniques, e. g. , by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e. g., Ausubel, et al. (eds. ) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e. g. , a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i. e. , mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e. g. , discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade that includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (i. e. , mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e. g. , truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by. for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene

sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e. g. , for phage display) containing the set of NOVX sequences therein. There are a variety of methods that can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences.

Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e. g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323 ; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477.

Polypeptide Libraries In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S X nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived that encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the

frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e. g. , Arkin and Yourvan, 1992. Proc.

Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6: 327-331.

Anti-NOVX Antibodies Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term"antibody"as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i. e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.

Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab'and F (ab') 2 fragments, and an Fab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule.

Certain classes have subclasses as well, such as IgG,, IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO : 2n, wherein n is an integer between 1 and 33, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e. g. , a

hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate that regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e. g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

The term"epitope"includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (KD) is <I 1M, preferably zu 100 nM, more preferably zu 10 nM, and most preferably : 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies For the production of polyclonal antibodies, various suitable host animals (e. g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with

the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e. g. , aluminum hydroxide), surface active substances (e. g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants that can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e. g. , from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen that is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by Wilkinson (The Scientist, published by The Scientist, Inc. , Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies The term"monoclonal antibody" (MAb) or"monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256: 495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp.

59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J.

Immunol.. 133 : 3001 (1984); Brodeur et al. , Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc. , New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as

radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem. , 107: 220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U. S. Patent No. 4,816, 567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e. g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U. S. Patent No. 4,816, 567; Morrison, Nature 368, 812-13 (1994) ) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F (ab') 2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature, 332 : 323-327 (1988); Verhoeyen et al., Science, 239: 1534-1536 (1988) ), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.

(See also U. S. PatentNo. 5,225, 539. ) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al. , 1986; Riechmann et al. , 1988; and Presta, Curr. Op.

Struct. Biol., 2: 593-596 (1992) ).

Human Antibodies Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed"human antibodies", or"full'y human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al. , 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. I. iss. Inc.. pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80:

2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp.

77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227: 381 (1991); Marks et al., J. Mol. Biol., 222: 581 (1991) ). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e. g. , mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire.

This approach is described, for example, in U. S. Patent Nos. 5,545, 807; 5,545, 806; 5,569, 825; 5,625, 126; 5,633, 425; 5,661, 016, and in Marks et al. (Bio/Technology 10, 779-783 (1992) ); Lonberg et al. (Nature 368 856-859 (1994) ) ; Morrison (Nature 368, 812-13 (1994) ) ; Fishwild et al, ( Nature Biotechnology 14,845-51 (1996) ); Neuberger (Nature Biotechnology 14,826 (1996) ); and Lonberg and Huszar (Intern. Rev. Immunol.

13 65-93 (1995) ).

Human antibodies may additionally be produced using transgenic nonhuman animals that are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication W094/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal that provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells that secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to

obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U. S.

Patent No. 5,939, 598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U. S. Patent No. 5,916, 771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

Fab Fragments and Single Chain Antibodies According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e. g., U. S.

Patent No. 4,946, 778). In addition, methods can be adapted for the construction of Fab expression libraries (see e. g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F (ab) 2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F (ab') 2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.

Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305: 537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J. , 10 : 3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121: 210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e. g. tyrosine or tryptophan). Compensatory"cavities"of identical or similar size to the large side chain (s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e. g. alanine or

threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e. g. F (ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229: 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F (ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab'fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab'fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al. , J. Exp. Med. 175: 217-225 (1992) describe the production of a fully humanized bispecific antibody F (ab') 2 molecule. Each Fab'fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al. , J. Immunol. 148 (5): 1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.

The"diabody"technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker that is too short to allow pairing

between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152: 5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al. , J. Immunol. 147: 60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm that binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e. g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD 16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells that express a particular antigen. These antibodies possess an antigen-binding arm and an arm that binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies Heteroconjugate antibodies are also within the scope of the present invention.

Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U. S. Patent No. 4,676, 980), and for treatment of HIV infection (WO 91/00360 ; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U. S.

Patent No. 4, 676,980.

Effector Function Engineering It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e. g. , the effectiveness of the antibody in treating cancer. For

example, cysteine residue (s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC).

See Caron et al., J. Exp Med. , 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities.

See Stevenson et al. , Anti-Cancer Drug Design, 3 : 219-230 (1989).

Immunoconjugates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e. g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i. e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 2l2Bi, 131I, 13iIn, 90Y, and'86Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate I-ICL), active esters (such as disuccinimidyl suberate), aldehydes (such as gluteraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis- (p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2, 6-diisocyanate), and bis-active fluorine compounds (such as 1, 5-difluoro-2, 4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as

described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026.

In another embodiment, the antibody can be conjugated to a"receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a"ligand" (e. g. , avidin) that is in turn conjugated to a cytotoxic agent.

Immunoliposomes The antibodies disclosed herein can also be formulated as immunoliposomes.

Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82 : 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U. S. Pat. Nos. 4,485, 045 and 4,544, 545.

Liposomes with enhanced circulation time are disclosed in U. S. Patent No. 5, 013, 556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab'fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem. , 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome.

See Gabizon et al., J. National Cancer Inst., 81 (19): 1484 (1989).

Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Antibodies directed against a NOVX protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of a NOVX protein (e. g. , for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as "Therapeutics").

An antibody specific for a NOVX protein of the invention (e. g. , a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e. g. , in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e. g. , to, for example, determine the efficacy of a given treatment regimen.

Detection can be facilitated by coupling (i. e. , physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, p-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin ; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.

Antibody Therapeutics Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably

one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand that may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Pharmaceutical Compositions of Antibodies Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 9th ed. (Alfonso R. Gennaro. et al., editors) Mack Pub. Co. , Easton, Pa.: 1995 ; IN : Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends,

Harwood Academic Publishers, Langhorne, Pa. , 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e. g. , Marasco et al. , Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e. g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate), or poly (vinylalcohol)), polylactides (U. S. Pat. No. 3, 773, 919), copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT TM (injectable microspheres composed of

lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D- (-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

ELISA Assay An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e. g., Fab or F (ab) 2) can be used. The term"labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i. e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term"biological sample"is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term"biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in"ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed. ) Human Press, Totowa, NJ, 1995; "Immunoassay", Diamandis and Christopoulus, Academic Press, Inc. , San Diego, CA, 1996; and"Practice and Theory of Enzyme Immunoassays", Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

NOVX Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term"vector"refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a"plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e. g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e. g. , non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.

Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as"expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid"and"vector"can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e. g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked"is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence (s) in a manner that allows for expression of the nucleotide sequence (e. g. , in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term"regulatory sequence"is intended to includes promoters, enhancers and other expression control elements (e. g. , polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory

sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e. g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e. g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67 : 31-40), pMAL (New England Biolabs, Beverly, Mass. ) and pRIT5 (Pharmacia, Piscataway, N. J. ) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69 : 301-315) and pET I Id (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e. g, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e. g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector.

Examples of vectors for expression in yeast Sacchanomyces cerivisae include pYepSecl (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30 : 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e. g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Pool. 3 : 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e. g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e. g.,

tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33 : 729-740; Queen and Baltimore, 1983. Cell 33 : 741-748), neuron-specific promoters (e. g. , the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230 : 912-916), and mammary gland-specific promoters (e. g., milk whey promoter; U. S. Pat. No. 4,873, 316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e. g. , the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the a-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation.

That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e. g. , Weintraub, et al.,"Antisense RNA as a molecular tool for genetic analysis,"Revielvs-Trends in Genetics, Vol. 1 (1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms"host cell"and "recombinant host cell"are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of

such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms"transformation"and "transfection"are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e. g. , DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, el al. (MOLECULAR CLONING : A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. , 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e. g. , resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector.

Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e. g. , cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i. e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable

medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX. protein from the medium or the host cell.

Transgenic NOVX Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a"transgenic animal"is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a"homologous recombinant animal"is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e. g. , an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e. g. , by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i. e. , any one of SEQ ID NO : 2n-1, wherein n is an integer between I and 33, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence (s) can be

operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U. S. Patent Nos. 4, 736, 866; 4,870, 009; and 4,873, 191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared that contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e. g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e. g. , the cDNA of any one of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO : 2n-1, wherein n is an integer between 1 and 33, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i. e., no longer encodes a functional protein ; also referred to as a"knock out"vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e. g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'-and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'-and 3'-termini) are included in the

vector. See, e. g. , Thomas, et al., 1987. Cell 51 : 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e. g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e. g., Li, et al., 1992. Cell 69 : 915.

The selected cells are then injected into a blastocyst of an animal (e. g. , a mouse) to form aggregation chimeras. See, e. g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp.

113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr.

Opin. Biotechnol. 2: 823-829 ; PCT International Publication Nos.: WO 90/11354 ; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P 1. For a description of the cre/loxP recombinase system, See, e. g. , Lakso, et al., 1992. Proc. Natl. Acad. Sci.

USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251: 1351-1355.

If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of"double"transgenic animals, e. g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385 : 810-813. In brief, a cell (e. g. , a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e. g. , through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it

develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e. g., the somatic cell) is isolated.

Pharmaceutical Compositions The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as"active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier"is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e. g. , intravenous, intradermal, subcutaneous, oral (e. g. , inhalation), transdermal (i. e. , topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents ; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium

hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N. J. ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e. g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and

used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes ; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e. g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e. g. , with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be

prepared according to methods known to those skilled in the art, for example, as described in U. S. Patent No. 4,522, 811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e. g., U. S. Patent No. 5, 328, 470) or by stereotactic injection (see, e. g. , Chen, et al., 1994. Proc. Natl. Acad Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e. g. , retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e. g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e. g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e. g. ; diabetes (regulates insulin release) ; obesity (binds and transport lipids); metabolic disturbances

associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

Screening Assays The invention provides a method (also referred to herein as a"screening assay") for identifying modulators, i. e. , candidate or test compounds or agents (e. g. , peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e. g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound"library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e. g., Lam, 1997. Anticancer Drug Design 12: 145.

A"small molecule"as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e. g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U. S. A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U. S. A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261 : 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed.

Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33 : 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

Libraries of compounds may be presented in solution (e. g., Houghten, 1992.

Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354 : 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U. S. Patent No. 5, 223, 409), spores (Ladner, U. S. Patent 5,233, 409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990.

Science 249 : 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U. S. A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310 ; Ladner, U. S. Patent No. 5,233, 409. ).

In one embodiment, an assay is a cell-based assay in which a cell that expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with or'H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell that expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof on the cell surface with a known compound that binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially

bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e. g. , stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a"target molecule"is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell that expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e. g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i. e. intracellular Ca, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e. g. , luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound that binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e. g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound that binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples

of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton'i'X-100, Triton2'X-114, Thesit@, <BR> <BR> <BR> Isotridecypoly (ethylene glycol ether) n, N-dodecyl--N, N-dimethyl-3-ammonio-1-propane sulfonate, 3- (3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3- (3-cholamidopropyl) dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e. g. , at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e. g., biotinylation kit, Pierce Chemicals, Rockford, lll.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target

molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i. e. , statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as"bait proteins"in a two-hybrid assay or three hybrid assay (see, e. g., U. S. Patent No. 5,283, 317; Zervos, et al., 1993. Cell 72 : 223-232 ; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054 ; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993.

Oncogene 8 : 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins"or"NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e. g., GAL-4). In

the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey"or"sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the"bait"and the"prey"proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e. g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein that interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease ; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO : 2n-l, wherein n is an integer between 1 and 33, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human

chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e. g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes.

By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e. g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1, 000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection.

Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for

marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e. g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e. g. , Egeland, et al., 1987. Nature, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease.

Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence.

Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms, "described in U. S. Patent No.

5,272, 057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'-and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes.

Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO : 2n-1, wherein n is an integer between I and 33, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.

Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e. g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for

prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity.

For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as"pharmacogenomics").

Pharmacogenomics allows for the selection of agents (e. g. , drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e. g. , the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.) Yet another aspect of the invention pertains to monitoring the influence of agents (e. g. , drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e. g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO : 2n-l, wherein n is an integer between I and 33, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50,100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e. g. , Fab or F (ab') 2) can be used. The term"labeled", with regard to the probe or antibody, is intended

to encompass direct labeling of the probe or antibody by coupling (i. e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term"biological sample"is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a

suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e. g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a"test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e. g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e. g. , an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e. g. , wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the

integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene.

For example, such genetic lesions can be detected by ascertaining the existence of at least one of : (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art that can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e. g. , U. S. Patent Nos. 4,683, 195 and 4, 683, 202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e. g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994.

Proc. Natl. Acad Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res.

23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e. g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et Ql. 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177) ; Qp Replicase (see, Lizardi, et al 1988. BioTechnology 6: 1197), or any other nucleic acid

amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e. g. , U. S. Patent No. 5, 493, 531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e. g. , DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e. g. , Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence.

Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad.

Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e. g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e. g., PCT

International Publication No. WO 94/16101 ; Cohen, et al., 1996. Adv. Chromatography 36 : 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e. g. , Myers, et al., 1985. Science 230 : 1242. In general, the art technique of"mismatch cleavage"starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands.

For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S, nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidin in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e. g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called"DNA mismatch repair"enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e. g. , Hsu, et al., 1994. Carcinogenesis 15: 1657-1662.

According to an exemplary embodiment, a probe based on a NOVX sequence, e. g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell (s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e. g. , U. S.

Patent No. 5, 459, 039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility

between mutant and wild type nucleic acids. See, e. g., Orita, et al., 1989. Proc. Natl. Acad Sci. USA : 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal.

Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e. g., Keen, et al., 1991. Trends Genet. 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e. g., Myers, et al., 1985. Nature 313 : 495.

When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e. g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e. g., Saiki, et al., 1986.

Nature 324 : 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e. g. , Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer

where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e. g., Prossner, 1993. Tibtech. 11 : 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e. g. , Gasparini, et al., 1992. Mol. Cell Probes 6 : 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e. g. , Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5'sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e. g. , in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein.

However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e. g. , NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e. g. , those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

In conjunction with such treatment, the pharmacogenomics (i. e. , the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e. g. , drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages

and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent (s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.

See e. g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997.

Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e. g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C 19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent (s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e. g., drugs, compounds) on the expression or activity of NOVX (e. g. , the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials.

For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a"read out"or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e. g., compound, drug or small molecule) that modulates NOVX activity (e. g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i. e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression'pattern can serve as a

marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e. g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject ; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i. e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i. e., to decrease the effectiveness of the agent.

Methods of Treatment The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include but are not limited to, e. g. , those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

These methods of treatment will be discussed more fully, below.

Diseases and Disorders Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i. e.. reduce or inhibit) activity. Therapeutics that antagonize

activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof ; (ii) antibodies to an aforementioned peptide ; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are"dysfunctional" (i. e. , due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to"knockout"endogenous function of an aforementioned peptide by homologous recombination (see, e. g. , Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i. e. , inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i. e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof ; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e. g. , from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e. g. , by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e. g., Northern assays, dot blots, in situ hybridization, and the like).

Prophylactic Methods In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity.

Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a

disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell.

In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e. g. , by culturing the cell with the agent) or, alternatively, in vivo (e. g. , by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e. g., an agent identified by a screening assay described herein), or combination of agents that modulates (e. g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e. g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e. g. , preclampsia).

Determination of the Biological Effect of the Therapeutic In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, in vitro assays may be performed with representative cells of the type (s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type (s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e. g. , those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.

As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i. e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES Example A: Polynucleotide and Polypeptide Sequences, and Homology Data Example 1.

The NOV ! done was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table IA.

Table1A. NOV1SequenceAnalysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table I B.

Table IB. Comparison of NOVla against NOVlb. l NOVla Residues/ {Identities/ 1 Protein Sequence 1 1 Match Residues i Similarities for the Matched Region I"..,.,.,.... I NOV] B 1.. 158 79/158 (50%) 81. 238 180/158 (50%) Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.

Table 1C. Protein Sequence Properties NOV1a PSort 0. 4500 probability located in cytoplasm ; 0.3000 probability located in microbody analysis : (peroxisome) ; 0. 1000 probability located in mitochondrial matrix space ; 0.1000 probability located in lysosome (lumen) SignalP. No Known Signal Sequence Predicted analysis : A search of the NOV 1 a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.

Table 1D. GENESEQ Results for NOVla

NOVla Identities/ GENESEQ Protein/Organism/Length lPatent#, j. Residues/Similarities for 1 Expect Identifier Date] Match the Matched z Value Residues Region AAU72789Human anticancer protein #2-Homo ! 40.. 156 55/125 (44%) 2e-) 7 I sapiens,] 27 aa. [CN 1313298-A, 1 125 69/125 (55%) 1 l 319-SEP-2001]-. x I AAU27977} Human contig polypeptide sequence-40. 156 55/125 (44%) 2e-17 #130 Homo sapiens, 164 aa. 38.. 162 69/125 (55%) I [W0200 ! 64834-A2, 07-SEP-2001] ! AAU27805 Human full-length polypeptide 40.. 156 55/125 (44%) 32e-17 sequence #130-Hoi-no sapiens, 127 1.. 125 69/125 (55%) aa. [W0200164834-A2, 07-SEP-2001 ABP41776 Human ovarian antigen HNOKE42, 40.. 156 53/125 (42%) 7e-15 SEQ ! DNO : 2908-Homo sapiens, ; 22 146 67/125 (53%) 148 aa. [W0200200677-A 1, 03-JAN-2002] -------,.......... . n......... !. .. ., m,. . .... m----......... n. r.-,-.--------------.,. i,-..-------....-,--,... ... . . ........... i ;........ u-------..., ,.. i-.--rn.. j. .------....-.-,.. .... ... ----.- ; .........--.. r......... AAY73333 HTRM clone 1760185 protein 440. 156 53/125 (42%) 7e-15 sequence-Homo sapiens, 127 aa. 1 125 67/125 (53%) i [W09957144-A2, 11-NOV-1999]' w. . . u. ____.. r. .. y... _. ... .... m.,. _i.. w. _.. _.. _ In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1 E.

Table IE. Public BLASTP Results for NOVIa I-I Protein NOVla Identities/ Accession Protein/Organism/Length Similarities for the Number Match Matched Portion Residues Q8WU25 Hypothetical 13. 4 kDa protein-140.. 158 119/119 (100%) 41e-62 Hoi-no sapiens (Human), 119 aa. 1.. 119 119/119 (100%) . ß Q96HT8 Unknown (protein for MGC : 9651) ! 40.. 156 55/125 (44%) 17e-I 7e-17 (PP784)-Homo sapiens (Human), 4 1 125 4 69/125 (55%) 127 aa. 3 Q9Y605 T-cell activation protein-Homo 40.. 156 53/125 (42%) 2e-14 ! sapiens (Human),) 27aa. I.. 125 ! 67/125 (53%) a Q9CQL7 9130413122Rikprotein (RIKEN 440 156 54/133 (40%) J3e-10 cDNA 9130413122 gene)-Mus | 1 123 69/133 (51%) musculus (Mouse), 125 aa. H z K. o__ iQ9CX68 9130413122RIk protein-Mus 140.. 147 50/124 (40% 7e-09 j muscutus (Mouse) J 26 aa. 1.. 114 164/124 (51%) :"---... .- :--. ;. ;.-...---, -... -, I PFam analysis predicts that the NOV 1 a protein contains the domains shown in the Table IF.

Table IF. Domain Analysis of NOVla {Identities/ Pfam Domain NOVIa Match Region Similarities ; Expect Value i I < ß for the Matched Region s No Significant Matches Found To Publicly Searchable Domains Example 2.

The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.

Table 2A. NOV2 Sequence Analysis

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B.

Table 2B. Comparison of NOV2a against NOV2b. f i NOV2a Residues/Identities/ Match Residues Similarities for the Matched Region NOV2b 39.. 164 115/l26 (91%) 118/126 (93%) «. . .,..... u"_. _. M. . .. .... . .. .. w.. __... ___. _..... w__,.. _,.. . . "........

Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.

Table 2C. Protein Sequence Properties NOV2a PSort 0.6500 probability located in cytoplasm ; 0. 1000 probability located in mitochondrial analysis : matrix space; 0.1000 probability located in lysosome (lumen) ; 0.0000 probability Jocated in endop) asmic reticuium (membrane) SignalP No Known Signal Sequence Predicted analysis: A search of the NOV2a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.

Table 2D. GENESEQ Results for NOV2a NOVX 1 Identities/ GENESEQ Protein/Organism/Length [Patent Residues/".. Expect j, Similarities for the p Identifier Date] Match Resiciues Matched Region Resides AAB43157 Human ORFX ORF2921 polypeptide 1.. 436 3 436/436 (100%) 0. 0 sequence SEQ ID NO : 5842--Homo 25.. 460 436/436 (100%) sapiens, 460 aa. [W0200058473-A2, 05-OCT-2000] JABP4I7H Human ovarian antigen HPAMC60, 39.. 436 ; 390/398 (97%) 0. 0 SEQ 1D N0 : 2843-Homo sapiens,) 7.. 4) 4 391/398 (97%) 414 aa. [W0200200677-Al, ____. _. _,.... _. r-3-JAN-2002] ß AAY94209 | Human TRAF four associated factor 39.. 436 390/398 (97%) 0. 0 TFAF2-Homo sapiens, 406 aa. 9.. 406 391/398 (97%) [CA2245340-A 1, 19-FEB-2000] AAB07856 Amino acid sequence of Smad 1 39 436 390/398 (97%) 0. 0 interactor protein clone S 12-Homo 17 414 391/398 (97%) sapiens, 414 aa. [W0200047102-A2, 17-AUG-2000] . --. j . ,,, AAB58368 Lung cancer associated polypeptide 39.. 436 390/398 (97%) 0. 0 sequence SEQ ID 706-Homo 117 414 391/398 (97%) sapiens, 414 aa. [W0200055180-A2, 21-SEP-2000] In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E. <BR> <BR> <P> I<BR> Table 2E. Public BLASTP Results for NOV2a

NOV2a Protein 1 Identities/ , Residues/ p Accession tj Protein/Organism/Length l Match I Similarities for the 5 VXlpect Match Value Number I Matched Portion Number | Q9UNH7 Sorting nexin 6 (TRAF4-associated 9.. 436 1390/398 (97%) 0. 0 factor 2)-Homo sapiens (Human), 9.. 406 # 391/398 (97%) 406 aa. Q9CZ03 28 ! 0425K19Rik protein-Mus 39.. 436 ! 388/398 (97%) 0. 0 musculus (Mouse), 406 aa. 19.. 406 1391/398 (97%) Q Q9BUY3 Hypothetical 33. 6 kDa protein-e-163 Homo sapiens (Human), 290 aa. 1.. 290 290/290 (100%) Q9D8U8 Sorting nexin 5-Mus musculus' 48.. 429 5 254/382 (66%) | e-l 52 5 (Mouse), 404 aa. H7.. 398 ! 323/382 (84%) S 3 Q9Y5X3 Sorting nexin 5-Homo sapiens 148.. 429 252/382 (65%) e-152 (Human), 404 aa. 3 17 398 323/382 (83%) r ~o wZ PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F.

Table 2F. Domain Analysis of NOV2a Identities/ Pfam Domain NOV2a Match Region Similarities Expect Value j for the Matched Region , z H wA r 55 I PX l5 59 200 35/160 (22%) 4. 9e-t9 ) 06/160 (66%) j Example 3.

The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.

Table 3A. NOV3 Sequence Analysis NOV3c ALVPYEETTEFGLQKFHKPLATFSFANHTIQIRQDWRHLGVAAWWDAAIVLSTYLEMGAV EPRGRS AVELGAGTGLVGIVAALLGAHVTITDRKVALEFLKSNVQANLPPHIQTKTVVKELTWGQN LGSFSPGE ; FDLILGADIIYLEETFTDLLQTLEHLCSNHSVILLACRIRYERDNNFLAMLERQFIVRKV HYDPEKDV Protetn : HIYEAQKRNQKEDL Sequence Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 3B.

''Table 3B. Comparison of NOV3a against NOV3b and NOV3c.

Protein Sequence Identities/ Match Residues Similarities for the Matched Region NOV3b 1.. 71 71/71 (100%) 1.. 71 71/71 (100%) NOV3c 1.. 218 217/218 (99%) 1.. 218 217/218 (99%) Further analysis of the NOV3a protein yielded the following properties shown in Table 3C.

Table 3C. Protein Sequence Properties NOV3a PSort 0.8500 probability located in endoplasmic reticulum (membrane) ; 0. 7900 probability analysis : located in plasma membrane ; 0. 3520 probability located in microbody (peroxisome) ; 0. 1000 probability located in mitochondrial inner membrane SignalP No Known Signal Sequence Predicted analysis: A search of the NOVA protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3D.

! Table 3D. GENESEQ Results for NOV3a NOV3a Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value Residues Region d AAM4I5I7 ! Humanpo) ypeptideSEQIDNO).. 90 : 86/90 (95%) 3e-43 6448-Homo sapiens, 161 aa. 29.. 118 8 87/90 (96%) [W0200153312-A l, 26-JUL-2001 J i s AAM39731 Human polypeptide SEQ ID NO !).. 90 ! 86/90 (95%) 3e-43 : 2876-Homo sapiens, ! 33 aa. i].. 90 ! 87/90 (96%) [W0200 ! 533 ! 2-A), 26-JUL-200 !] i J ABB80681 Human transferase protein, 26199-30.. 215 77/204 (37%) 4e-23 Homo sapiens, 229 aa. 26.. 226 108/204 (52%) [W0200220801-A2, 14-MAR-2002] AAM40002 Human polypeptide SEQ ID NO 32.. 96 48/65 (73%) 3e-19 3147-Homo sapiens, 2505 aa. 1106 1170 4 55/65 (83%) | [WO200153312-A1, 26-JUL-2001] .. AAG27905 Arabidopsis thaliana protein 23.. 176 ; 54/170 (31%) 9e-17 fragment SEQ ID NO : 32925-15.. 183 J382/170 (47%) Arabidopsis thaliana, 325 aa. [EP1033405-A2, 06-SEP-2000] In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3E.

Table 3E. Public BLASTP Results for NOV3a

NOV3a Protein I Identities/ ! Residues/Expect Accession Protein/Organism/Length I Similarities for the a Match = Value Number Residues Matched Portion Kestdues Q8WXBI Hepatocellularcarcinollla-associatedll 218 4218/218 (100%) e-123 ß antigen HCA557b-Homo sapiens | 1 218 | 218/218 (100%) (Human), 218 aa. t ß s X BAC04229 CDNA FLJ36493 fis, clone i 1 2 1 8 217/218 (99%) S e-122 THYMU2018547-Homo sapiens {1 218 217/218 (99%) (Human), 218 aa. 'Q9CQLO il.. 218 1195/218 (89%) e-109 musculus (Mouse), 218 aa. 1.. 218 204/218 (93%) iQ8R2Y7 RlKENcDNA2310038H17gene-01 218 194/218 (88%) je-108 Mus musculus (Mouse), 218 aa. 1.. 218 203/218 (92%) Q95K98 Hypothetical 18. 5 kDa protein-47.. 218 155/172 (90%) 6e-82 Macaca fascicularis (Crab eating | 7 163 155/172 (90%) macaque) (Cynomolgus monkey), 163 axa.

PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3F.

Table 3F. Domain Analysis ofNOV3a I Identities/ ! Pfam Domain NOV3a Match Region Similarities Expect Value | for the Matched Region No Significant Matches Found To Publicly Searchable Domains Example 4.

The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A.

Table 4A. NOV4 Sequence Analysis

Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 4B.

Table 4B. Comparison of NOV4a against NOV4b. Protein Residues/Identities/ Match Residues Similarities for the Matched Region NOV4b 1.. 308 284/361 (78%) 1 359 285/361 (78%) 1, 1,,.. ., I I. I 11,...

Further analysis of the NOV4a protein yielded the following properties shown in Table 4C.

Table 4C. Protein Sequence Properties NOV4a PSort j 0. 4500 probability located in cytoplasm; 0.3000 probability located in microbody analysis : (peroxisome) ; 0. 1000 probability located in mitochondrial matrix space; 0. 1000 probability located in lysosome (lumen) SignalP No Known Signal Sequence Predicted analysis:

A search of the NOV4a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D.

Table4D. GENESEQResultsforNOV4a . NOV a Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region . r :, t AAM40020 Human polypeptide SEQ ID NO 1 308 226/345 (65%) X e-l 14 3 3165-Homo sapiens, 341 aa. 1 341 248/345 (71%) [W0200153312-AI, 26-JUL-2001] AAM41806 Human polypeptide SEQ ID NO 6.. 308 222/340 (65%) l e-l 12 6737-Homo sapiens, 352 aa. 17.. 352 244/340 (71%) [W0200] 533 ! 2-A !, 26-JUL-200 !] [W0200153312-Al, 26-JUL-2001) ABB12231 Human novel protein, SEQ ID 6 308 222/340 (65%) e-l 12 NO : 2601-Homo sapiens, 352 aa. 17.. 352 244/340 (71%) [W0200157188-A2, 09-AUG-2001] ................ ..... .....................,-,.,............... ,.., . ... ABB90124 j Humall polypeptide SEQ IDNO 59 308 197/287 (68%) e-102 J 2500-Homo sapiens, 287 aa. 1.. 287 213/287 (73%) 4 [W0200190304-A2, 29-NOV-2001] AAM85252 Human immune/haematopoietic 158.. 308 122/153 (79%) 7e-62 antigen SEQ ID N0 : 12845-Homo 7.. 159 131/153 (84%) sapiens, 159 aa. [W0200157182-A2, 09-AUG-2001] In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E.

Table 4E. Public BLASTP Results for NOV4a

Protein NOV4a Identities/ Residues/| Similarities for Expect Number Match the Matched Value .""Match the Matched Va ! ue dumber .. ,. Number Residues Portion BAC05160 CDNA FLJ40432 fis, clone 53 308 249/291 (85%) e-135 TEST12039227-Homo sapiens 1 289 249/291 (85%) (Human), 289 aa. ---------------------------------------------------- CAD39020 Hypothetical protein-Homo sapiens 1 308 226/345 (65%) e-l 14 (Human), 353 aa (fragment). 4 13. 353 248/345 (71%) -----------------------------i----------------------- : } Q8TEX2 Cyclin fold protein 1 variant b-l 1 308 226/345 (65%) 1 14 Homosapiens (lluman), 341 aa. 1 341 248/345 (71%) S S -" i Q95LR5 Hypothetical 34. 9 kDa protein-57 308 197/289 (68%) e-101 Macaca fascicularis (Crab eating 13 301 214/289 (73%) macaque) (Cynomolgus monkey), 301 aa Q95LK3 Hypothetical 23. 5 kDa protein-146.. 308 131/200 (65%) 4e-62 Macaca fascicularis (Crab eating 3 202 141/200 (70%) macaque) (Cynomolgus monkey), 202 aa.

PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4F.

Table 4F. Domain Analysis of NOV4a J Identities/ Pfam Domain NOV4a Match Region Similarities Expect Value for the Matched Region cyclin 71.. 234 25/179 (14%) 0. 00074 1 12/179 (63%)

Example 5.

The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.

Table SA. NOV5 Sequence Analysis Further analysis of the NOV5a protein yielded the following properties shown in Table 5B.

f Table 5B. Protein Sequence Properties NOV5a PSort 0.9920 probability located in nucleus ; 0.1000 probability located in mitochondrial analysis : matrix space; 0.1000 probability located in lysosome (lumen) ; 0.0000 probability located in endoplasmic reticulum (membrane) Signal ? No Known Signal Sequence Predicted analysis : A search of the NOV5a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5C.

Table 5C. GENESEQ Results for NOV5a NOVA GENESEQ Protein/Organism/Length {Patent Residues/", .. Expect a Similarities for the Identifier Date] Match Value Matched Region resides AAG67014 i Human sperm-specific protein EMI, 1.. 435 i 435/435 () 00%) 0. 0 4 EM6-48-Homo sapiens, 435 aa. 1.. 435 i 435/435 (100%) A [W0200 1 68685-A 1, 20-SEP-200 1] AAM78680 HumanproteinSEQIDN01342-1.. 435 ! 435/435 (t00%) 0. 0 Homo sapiens, 435 aa. 1.. 435 435/435 (100%) J [W0200157190-A2, 09-AUG-2001] AAG74995 Human colon cancer antigen protein 10 435-. 421/426 (98%) 0. 0 SEQ ID NO : 5759-Homo sapiens, 6.. 431. 422/426 (98%) 431 aa. [W0200122920-A2, 05-APR-2001] AAG62626 Human RNA helicase 43-Homo 53.. 435 370/386 (95%) g 0. 0 sapiens, 387 aa. 2.. 387 375/386 (96%) ' [W0200138368-Al, 1 31-MAY-2001] i-. a AAM79664 Human protein SEQ ID NO 3310-1. 352 ; 352/352 (100%)) 0. 0 Homo sapiens, 399 aa. 42.. 393 352/352 (100%) [W0200157190-A2, 09-AUG-2001].

In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5D.

Table 5D. Public BLASTP Results for NOV5a NOVSa Identities/ Protein-Residues/Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Number Residues Portion FQ9P068 iHSPC3M-Homosapiens (Human), 137.. 369 4 218/234 (93%) e-l 15 a 248 aa (fragment). 5.. 248 ! 222/234 (94%) 'Q9CW29 1500011J06Rik protein-Mus 69.. 278 202/210 (96%) e-l 10 4 musculus (Mouse), 255 aa (fragment). 18.. 227 210/210 (99%) .. Q9H864 CDNA FLJ13923 fis, clone 233.. 435 202/203 (99%) e-108 Y79AA1000539 (Hypothetical 22. 4 1.. 202 202/203 (99%) kDa protein)-Homo sapiens (Human), 202 aa. Q9CSJ3 150001 IJ06Rik protein-Mus 68.. 253 179/186 (96%) 3e-98 musculus (Mouse), 194 aa (fragment). 9.. 194 186/186 (99%) Q95TP3 LD33732p-Drosophila melanogaster 2.. 419 125/465 (26%) le-30 (Fruit fly), 492 aa. 33.. 471 204/465 (42%) PFam analysis predicts that the NOV5a protein contains the domains shown in the Table 5E.

Table 5E. Domain Analysis of NOV5a Identities/ Pfam Domain NOVSa Match Region Similarities Expect Value for the Matched Region No Significant Matches Found To Publicly Searchable Domains

Example 6.

The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A. l able 6A. NOV6 Sequence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 6B.

Table 6B. Comparison of NOV6a against NOV6b. v NOV6a Residues/Identities/ Match Residues Similarities for the Matched Region NOV6b i.. 153 5 13 6/206 (66%) 1 206 138/206 (66%)

Further analysis of the NOV6a protein yielded the following properties shown in Table 6C.

Table 6C. Protein Sequence Properties NOV6a PSort 0.7480 probability located in microbody (peroxisome); 0.6500 probability located in analysis : plasma membrane; 0.3000 probability located in Golgi body; 0. 2100 probability located in mitochondrial inner membrane r- SignalP Cleavage site between residues 50 and 51 analysis :

A search of the NOV6a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D.

Table 6D. GENESEQ Results for NOV6a NOV6a Identities/ GENESEQ Protein/Organism/Length IPatent Residues/Similarities for Expect Identifier #, Date], Match the Matched Value j Residues Region AAE07313 3 Human cancer-specific Mob-5 3j 1 153 152/154 (98%) 2e-83 (cMob-5) mutant protein-Homo i 1 154 152/154 (98%) : i sapiens, 154 aa. [W0200155170-A 02-AUG-2001] , i AAB Human PR03301 protein sequence j 1.. 153 I52/206 (73%) 3e-77 SEQ ID NO : 507-Homo sapiens, 206-il.. 206 152/206 (73%) aa. [W0200073454-AL i 'j 07-DEC-2000] l sO _w-ic-----------~-r--w _S AAB35268 Human mda-7 protein-Homo 1.. 153 152/206 (73%) 3e-77 sapiens, 206 aa. [W0200105437-A2, 1.. 206 152/206 (73%) ! 25-JAN-200 !] ; AAU29220 Human PRO polypeptide sequence 1 153 152/206 (73%) 3e-77 t ; # 197-Homo sapiens, 206 aa. 1.. 206 152/206 (73%) [W0200 1 68848-A2, 20-SEP-200 1]. = J AAY42304 S Human tumour suppressor protein 1 153 152/206 (73%) 3e-77 mda-7-Homo sapiens, 206 aa. 1.. 206 152/206 (73%) [W09947709-A2, 23-SEP-1999] r In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E.

I Table 6E. Public BLASTP Results for NOV6a

NOV6a Identities/ Residues/Similarities for Accession Protein/Organism/Length Match the Matched Value Number Residues Portion Q96KG4 Suppression of tumorigenicity 16 4 1 153 152/206 (73%) X 9e-77 protein-Homo sapiens (Human), 206 1.. 206 152/206 (73%) jaa. 3 Q13007 lnterleukin-24 precursor (Suppression 1.. 153 7 Of of tumorigenicity 16 protein) 1.. 206 152/206 (73%) ! (Me ! anoma differentiation associated 4 protein 7) (MDA-7)-Homo sapiens (Human), 206 aa. J 21.. 153 87/186 (46%) 2 e-') 7 Q925J3 Th2-specificcytokineFISP-Mus hi.. 153 87/186 (46%) 2e-37 muscuius (Mouse), 220 aa. 1135.. 220 103/186 (54%) Q925S4 Melanoma differentiation associated 32 153. 84/175 (48%) 3e-36 getie-7-Mus musculus (Mouse), 181 7.. 181 98/175 (56%) axa. , aa. 5 Q9WVP8 i C49a-Rattus norvegicus (Rat), 183 aa 26.. 153 80/181 (44%) e 6e-33 ! 4 l 3..] 8 3. 9 7/1 8 1 (5 %), | . _...... ___. _. _..... _... __.. . ..... ... _.. ____. _, ____. __. .. _. _.. _. _. __.. ,... .. y,.. 'T 183_rv__. ___ 97/, l^8, l.. (5,'%) __. _.. __... _ PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6F.

Table 6F. Domain Analysis of NOV6a Identities/ Pfam Domain NOV6a Match Region Similarities Expect Value for the Matched Region No Significant Matches Found To Publicly Searchable Domains Example 7.

The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.

Table 7A. NOV7 Sequence Analysis Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.

Table 7B. Protein Sequence Properties NOV7a PSort 0. 6106 probability located in mitochondrial matrix space; 0.5199 probability located t analysis : in mitochondrial intermembrane space; 0. 3430 probability located in microbody (peroxisome) ; 0. 142 probability located in mitochondrial inner membrane SignalP Cleavage site between residues 19 and 20 analysis : A search of the NOV7a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.

Table 7C. GENESEQ Results for NOV7a NOVX , Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Expect GENESEQ Residues/E, Kpect | Identifier X #, Datcl | Residues Matched Region Value :'Matched Region Residues- 3 AAY58613 j Protein regulating gene expression 8').. 291 209/209 (100%) e-I 18 1.. 209 209/209 (100%) j _.. a. ..... m.... . __. ., ____..... i.. W. __.. i. . >. __. u.. r.. [W09964596-A2, 16-DEC-1999] AAB58880 Breast and ovarian cancer associated 67.. 176 110/110 (100%) 3e-57 antigen protein sequence SEQ ID 3.. 112 110/110 (100%) 588-Homo sapiens, 133 aa. [W0200055 1 73-A 1, 21-SEP-2000] < ABB49353 Listeria monocytogenes protein 153.. 296'76/148 (51%) 8e-34 #2057-Listeria monocytogenes, 176 2.. 148 100/148 (67%) aa. [W0200177335-A2, 18-OCT-2001] AAU58306 Propionibacterium acnes 154.. 289 69/142 (48%) 8e-30 immunogenic protein #19202-79 218-. 94/142 (65%) Propionibacterium acnes, 246 aa. [W0200181581-A2, 01-NOV-2001] ABG03944 Novel human diagnostic protein 95.. 221 72/130 (55%) 1 e-29 #3935-Homo sapiens, 135 aa. 5.. 131 : 85/130 (65%) [W0200175067-A2, 11-OCT-2001] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.

Table 7D. Public BLASTP Results for NOV7a

] NOV7a Identities/ ! NOV7a Identities/ Accession iProtein/Organism/Length Match the Matched Value Number Residues Portion Q9UH96 i LRP16 (LRP16 protein)-Homo 1,. 313, 313/325 (96%) e-179 S, i75%) sapiens (Human), 325 aa. 1.. 325 313/325 (96%) Q9BQ69 a LRP16 protein-Homo sapiens 83. 313 J23t/243 (95%) e-30 (Human), 243 aa. 1.. 243 231/243 (95%) Q922B I Similar to LRP 16 protein-Mus 83.. 313. 210/243 (86%) e-l 18 musculus (Mouse), 243 aa. 1 243 i 221/243 (90%) g AAM45760 LRP16-like protein-Rattus 83.. 313 206/243 (84%) e-115 norvegicus (Rat), 243 aa. 1 243 218/243 (88%) a AAM73435 Histone macro-H2AI-related 151. 306 i 91/167 (54%) 6e-43 protein-Chlorobium tepidum TLS, 4 169'114/167 (67%) 172 aa.

PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7E.

Table 7E. Domain Analysis of NOV7a I Identities/ Pfam Domain NOV7a Match Region Similarities Expect Value for the Matched Region ____ _ A1 p _ _/124 43/0 __. ___... __ 94/124 (76%)--1

Example 8.

The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.

Table 8A. NOV8 Sequence Analysis Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.

Table 8B. Protein Sequence Properties NOV8a PSort 0. 5277 probability located in microbody (peroxisome); 03000 probability located in analysis: nucleus; 0.1725 probability located in lysosome (lumen) ; 0. 1000 probability located in mitochondrial matrix space SignalP No Known Signal Sequence Predicted analysis: A search of the NOV8a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.

Table 8C. GENESEQ Results for NOV8a NOV8a Identities/ j GENESEQ Protein/Organism/Length IPatent Residues/2 Similarities for Expect | Identifier #, Datel Match 4 the Matched Value Residues Region e- ) AAR64268 Phosphatidy) ethanolaminebinding l.. ! 79 : MI/) 80 (78%) 9e-79 protein-Homo sapiens, 187 aa. 1.. 180 3 152/180 (84%) [EP628631-A, 14-DEC-1994] AAE21677 Human phosphoethanolamine binding 1 179, i, 140/i 80 (77%) 5e-78 protein (PEBP)-Homo sapiens, 1 87 1 180 1 151/180 (83%) aa. [W0200218623-A2, 07-MAR-2002] AAR49943 Human hippocampal cholinergic 1 179 4 140/180 (77%) Se-78 neurotrophic peptide precursor-1.. 180 151/180 (83%) Homo sapiens, 187 aa. i [W09405788-A, 17-MAR-1994] r __ fAAR277) 8 HCNP precursor protein #2-Homo 1 179,. 140/180 (77%) Se-78 sapiens, 187 aa. [EPS I 1816-A, 1.. 18 151/180 (8-%) 04-NOV-1992] .. rt_. i AAE21676 | Mouse phosphoethanolamine binding 1 179. 125/180 (69%) le-69 X protein (PEBP)-Mus musculus, 187 1 1 80-, 142/180 (78%) aa. [W0200218623-A2, l 07-MAR-2002].'.

In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.

Table 8D. Public BLASTP Results for NOV8a NOV8a Identities/ Z. 1 NOV8a Identities/ Protein R'd Similarities for Expect Accession Proteln/Organlsm/Length Match the Matched Value . ° ° Match the Matched Vaque Number Residues Portion AAH3H02 Prostaticbindingprotein-Homosapiens 1.. H9 140/180 (77%) le-77 (Human), 187 aa. 1 180 | 151/180 (83%) S46485 phosphatidyiethanotamine-binding ! !. J79 ! 39/180 (77%) 2e-77 protein-crab-eating macaque, 187 aa.'1.. 180 1 S 1/180 (83%) P30086 Phosphatidylethanolamine-binding 3.. 1779 139/178 (78%) 3e-77 protein (PEBP) (Neuropolypeptide h3) 0 2 179 150/178 (84%) (Hippocampal cholinergic neurostimulating peptide) (HCNP) (Raf j kinase inhibitor protein) (RKIP)-Homo sapiens (Human), 186 aa. P48737 Phosphatidy) ethano) amine-binding 3.. 179 138/178 (77%) 4e-77 protein (PEBP)-Macaca fascicularis 2.. 179 150/178 (83%) (Crab eating macaque) (Cynomolgus monkey), 186 aa. P13696 Phosphatidylethanolamine-binding 3 179 134/178 (75%) le-73 protein (PEBP) (Basic cytosolic 21 kDa j 2 179 148/178 (82%) protein)-Bos taurus (Bovine),) 86 aa.

PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E.

Table 8E. Domain Analysis of NOV8a Identities/ Pfam Domain NOV8a Match Region Similarities Expect Value for the Matched Region PBP 3.. 171 71/201 (35%) 4. 7e-41 13 7/20 ! (68%) Example 9.

The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.

Table 9A. NOV9 Sequence Analysis Further analysis of the NOV9a protein yielded the following properties shown in Table 9B.

Table 9B. Protein Sequence Properties NOV9a PSort 1 0.4500 probability located in cytoplasm ; 0.3000 probability located in microbody X analysis : 4 (peroxisome) ; 0.1000 probability located in mitochondrial matrix space; 0. 1000 probability located in lysosome (lumen) SignalP No Known Signal Sequence Predicted analysis :

A search of the NOV9a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9C.

Table 9C. GENESEQ Results for NOV9a NOV9a Identities/ ! GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value 5 Residues Region AAM39906 HumanpoiypeptideSEQfDNO J4). J82 74/] 42 (52%) 2e-39 3051-Homo sapiens, 543 aa. 402.. 543 ; 1 1 1/142 (78%) [W0200153312-AI, 26-JUL-2001] ! AAUI7987 Human immunog) obu) inpo) ypeptide ! 4).. 182 74/142 (52%) 2e-39 I SEQ ID No 132-Homo sapiens, 277 l 136. 277', 1 1 1/142 (78%) aa. [W0200155315-A2, 02-AUG-2001] AAY70473 Humancyciicnucteotide-associated t4)..) 82 74/142 (52%) 2e-39 protein-l (CNAP-1)-Homo sapiens, 1567 708, 111/142 (78%) 708 aa. [W0200014248-A 1, I6-MAR-2000] i 16-MAR-2000] | AAM4 1692 Human polypeptide SEQ ID NO 41. 182 99 74/142 (52%) 6e-39 6623-Homo sapiens, 565 aa. 424.. 565 110/142 (77%) [W0200153312-A1, 26-JUL-2001] AAU83653 Human PRO protein, Seq ID No 124 39.. 179 76/141 (53%) 3e-37 -Homo sapiens, 546 aa. 398.. 538 104/141 (72%) [W0200208288-A2, 31-JAN-2002] In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9D.

Table 9D. Public BLASTP Results for NOV9a NOV9a j Identities/ Residues/Similarities for Expect Accession ! Protein/Organism/Length I ; match the Matched Value Number Residues Portion z s wn j CAD39133 Hypothetical protein-Homo sapiens 41.. 182 t4I/M2 (99%)) e-75 (Human), 622 aa (fragment). 1 142/142 (99%) Q9H5H8 CDNA : FLJ23420 fis, clone 41.. 182 141/142 (99%) le-75 HEP22352 (Hypothetical 50. 2 kDa 303.. 444 N42/) 42 (99%) protein)-Homo sapiens (Human), 444 aa. -. AAH3] 863 Hypotheticalprotehl-Musmusculus'^41 182 ßI18/142 (83%) T2e-62 | (Mouse), 330 aa (fragment). 189.. 330 132/142 (92%) Q8R502 ADt58-Musmuscu) us (Mouse), 4I.. 182 ! 73/142 (51%) 2e-39 803 aa. a 662.. 803 112/142 (78%) " | Q8VE36 Similar to hypothetical protein i 41.. 182 73/142 (51%) 2e-39 ! DKPZp586J] n9-Musmuscuius ! M6.. 287 1112/142 (78%) (Mouse), 287 aa (fragment).

PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9E.

Table 9E. Domain Analysis of NOV9a Identities/ Pfam Domain NOV9a Match Region Similarities'Expect Value for the Matched Region LRR 40.. 62 9/25 (36%) 0. 0068 21/25 (84%) _. LRR 63.. 85 13/25 (52%) zu 0. 15 17/25 (68%) v LRR 86.. 108 10/25 (40%) 0. 3 j J18/25 (72%)) LRR 109..] 31 10/25 (40%) 0. 62 19/25 (76%) Example 10.

The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.

Table 10A. NOV10 Sequence Analysis Further analysis of the NOVI Oa protein yielded the following properties shown in Table IOB.

Table lOB. Protein Sequence Properties NOVlOa PSort 0.3000 probability located in microbody (peroxisome); 0.3000 probability located in analysis: nucleus ; 0.1000 probability located in mitochondrial matrix space; 0. 1000 probability located in lysosome (lumen) SignalP No Known Signal Sequence Predicted analysis : A search of the NOV1 Oa protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table I OC.

Table 10C. GENESEQ Results for NOV10a NOVlOa Identitics/ GENESEQ Protein/Organism/Length (Patent Residues/, Similarities for Expect Identifier #, Datel Match,, the Matched Value Residues Region AAB65212 Human PRO1136 (UNQ574) protein 101.. 725 598/628 (95%) 0. 0 sequence SEQ ID NO : 219-Homo 5.. 632 603/628 (95%) sapiens, 632 aa. [W0200073454-Al, 07-DEC-2000] AAB87545 Human PROI 136-Homo sapiens, ! 0 !.. 725 598/628 (95%) 0. 0 632 aa. [W0200116318-A2, 5.. 632 : 603/628 (95%) 08-MAR-2001] AAU17394 Novel signal transduction pathway 101.. 725 : 598/628 (95%) 0. 0 protein, Seq ID 959-Homo sapiens, 69.. 696 603/628 (95%) 696 aa. [W0200154733-A1, 02-AUG-2001 AAU29106 Human PRO polypeptide sequence 101.. 725 598/628 (95%) 0. 0 83-Homo sapiens, 632 aa. 5.. 632 603/628 (95%) l [W0200168848-A2, 20-SEP-2001]. I | AAY66689 X Membralle-bound protein PRO1136-101 725 598/628 (95%) 0. 0 Homo sapiens, 632 aa. 5.. 632 i 603/628 (95%) [W09963088-A2, 09-DEC-1999] . __. _..... _.......... _. _......... _...... _.. ...-_...... _..... . _ :.. ___. _... _ : _.. : : : .. _. :.... _, In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table I OD.

Table 10D. Public BLASTP Results for NOVlOa Protein NOVlOa Identities/ -..., ,, ., Residues/SimHarities for Expect Accession Protein/Organism/Length Residues/Similarities for Expect Match the Matched Value Number ., r* Restdues Portion Residues Portion Q8TBB1 Similar to 1.. 725 721/728 (99%) 0. 0 multi-PDZ-domain-containing protein 1.. 728 721/728 (99%) - Homo sapiens (Human), 728 aa. Q96MJ7 CDNA FLJ32261 fis, clone 1 725 718/728 (98%) 0. 0 PROST1000343, highly similar to 1.. 728 718/728 (98%) Numb-binding protein LNXp80- Homo sapiens (Human), 728 aa. 070263 NUMB-binding protein LNX (Ligand 1 725 640/729 (87%) 0. 0 ofNUMB-protein X)-Mus musculus 1.. 728 673/729 (91%) (Mouse), 728 aa. AAH34737 Ligand of numb-protein X-Homo 101.. 725 598/628 (95%) 0. 0 sapiens (Human), 632 aa. 5.. 632 603/628 (95%) Q9BY20 Multi-PDZ-domain-containing protein 101.. 725 597/628 (95%) 0. 0 - Homo sapiens (Human), 632 aa. 5.. 632 602/628 (95%) w... . . w w _... ... _ s _ ___ __ [___ : a__X_o : _ |. 5 j *. _w4 PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10E.

Table 10E. Domain Analysis of NOV10a

j j Identities/ Pfam Domain NOVlOa Match Region Similarities | Expect Value for the Matched Region zf-C3HC4 41 77 14/53 (26%) 9. 8e-06 26/53 (49%) PDZ 274.. 358 26/86 (30%) 5. 7e-11 62/86 (72%) PDZ 381 463 28/84 (33%) 4. 7e-12 57/84 (68%) PDZ 1504 589 25/88 28/0 3. 8e-13 1-E \ O l 63/88 (72%) | PDZ 635 720 26/88 (30%) 0 1. 3e-14 66/88 (75%) Example 11.

The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.

Table 1lA NOV11 Sequence Analysis Further analysis of the NOV11a protein yielded the following properties shown in Table I IB.

Table 11B. Protein Sequence Properties NOVlla

Psort 0.4500 probability located in cytoplasm; 0. 3233 probability located in microbody analysis : (peroxisome); 0.1000 probability located in mitochondrial matrix space; 0.1000 probability located in lysosome (lumen) Signa) P No Known Signal Sequence Predicted analysis : A search of the NOV I 1 a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table I I C.

Table 11C. GENESEQ Results for NOV11a

NOVlla ! GENESEQ Protein/Organism/Length [Patent Residues/Expect ; > Similarities for the Identifier. #, Datel'Match j. Value Matched Region Residues l ABG15486. Novel human diagnostic protein 1. 56.. 246 191/191 (100%) e-l 1 1 #15477-Homo sapiens, 414 aa. 224.. 414 191/191 (100%) [W0200175067-A2, 11-OCT-2001]} ABG15487 Novei human diagnostic protein 24 169 ! 139/146 (95%) 2e-81 15478-Homo sapiens, 3 69 aa. 54.. 199 142/146 (97%) [W0200175067-A2, I I-OCT-2001 ;. AARI 5148 j Ro/SSA autoantigen-Homo 1 1 436 146/443 (32%) 4e-54 sapiens, 475 aa. [W09117171-A, 12.. 449 226/443 (50%) i 14-NOV-I991] AAB42919 Human ORFX ORF2683 4.. 436 138/461 (29%) 4e-53 polypeptide sequence SEQ ID 5.. 459 i 230/461 (48%) NO : 5366-Homo sapiens, 477 aa. [W0200058473-A2, 05-OCT-2000] --------.--------------------.----------------------- AAM48396 Human SSA-56kDa protein-Homo i 8.. 432,) 35/454 (29%) 5e-47 sapiens, 485 aa. [W0200188128-A1, 9.. 454 217/454 (47%) i 22-NOV-200 1] ij i ; jt In a BLAST search of public sequence databases, the NOV 11 a protein was found to have homology to the proteins shown in the BLASTP data in Table 11 D.

Table 11D. Public BLASTP Results for NOVlla NOVlla Identities/ Protein Accession Protein/Organism/Length Accession Protem/Organtsm/Length n.... n .. . Match the Matched Value Number Residues Portion ___ _- : Q96BQ3 Hypothetical 52. 3 kDa protein-1.. 438 438/446 (98%) 0. 0 Homo sapiens (Human), 446 aa. I.. 446 438/446 (98%) Q9NS80 RING finger protein 18 1 437 230/451 (50%) ; e-125 (Testis-specific ring-finger protein)-1 451 302/451 (65%)} f Homo sapiens (Human), 452 aa. BAC04185 CDNA FLJ36180 fis, clone 3.. 433 148/445 (33%) 7e-64 TEST12026605, weakly similar to 52 4.. 445 236/445 (52%) KDA RO PROTETN-Homo sapiens ; (Human), 468 aa. W w w it f Q9BSJ] | Similar to ring finger protein 18-h 168 437 J) 28/284 (45%) 3e-63 Homo sapiens (Human), 293 aa. 9.. 292 182/284 (64%) AAM63957 BIA] protein-Homo sapiens 4.. 433 1150/446 (33%) 3e-62 (Human), 468 aa. 15.. 442 (51%)

PFam analysis predicts that the NOV 11 a protein contains the domains shown in the Table HE.

Table HE. Domain Analysis of NOVlla Identities/ Pfam Domain NOVlla Match Region Similarities Expect Value for the Matched Region I zf-C3HC4 15 55 8/54 (33%) 5. 7e-10 35/54 (65%) m zf-Bbox 88.. 129 14/48 (29%) 1. 3e-06 26/48 (54%) SPRY 326.. 437 28/157 (18%) 5. 8e-09 77/157 (49%)

Example 12.

The NOV 12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.

Table 12A. NOV12 Sequence Analysis Further analysis of the NOV] 2a protein yielded the following properties shown in Table 12B.

Table 12B. Protein Sequence Properties NOV12a PSort 10. 7000 probability located in nucleus ; 0. 1000 probability located in mitochondrial analysis : 1 matrix space; 0.1000 probability located in lysosome (lumen) ; 0.0000 probability located in endoplasmic reticulum (membrane) SignaiP No Known Signal Sequence Predicted analysis :

A search of the NOV1 2a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12C.

Table 12C. GENESEQ Results for NOV12a X I l NOV12a t Identities/ ! GENESEQ j Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAU795) 5 Human guanine-nucieotide exchange).. 767 J 763/767 (99%) 0. 0 factor (GEF), 38646-Homo sapiens,).. 766 764/767 (99%) 766 aa. [W0200220765-A2, 14-MAR-2002] i = i AAY5) 248 Rat actin-binding protein frabin-N.. 767 634/767 (82%) 0. 0 Rattus sp, 766 aa. [JPI 1346775-A, 1 766 | 682/767 (88%) 2 21-DEC-1999] AALJ2) 630 ! Nove) human neoplastic disease 303.. 767 459/465 (98%) 0. 0 1 associated polypeptide #63-Homo 1 465 j 460/465 (98%) sapiens, 465 aa. [W0200155163-A I, f i ; 02-AUG-2001] i j. AAU 17094 Novel signal transduction pathway 467.. 767 298/301 (99%) e-178 protein, Seq ID 659-Homo sapiens, 19..'19 319 aa. [W0200154733-Al, 02-AUG-2001] AAU27818 Human full-length polypeptide 164.. 744 278/609 (45%) e-142 sequence #143-Homo sapiens, 725 120 706 378/609 (61%) aa. [W0200164834-A2, 07-SEP-2001) In a BLAST search of public sequence databases, the NOV 12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12D.

Table 12D. Public BLASTP Results for NOV12a NOV12a Identities/ Residues/Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion Q96M96 CDNA FLJ32732 fis, clone 1.. 767 762/767 (99%) 0. 0 TEST1200114 1, highly similar to 1.. 766 763/767 (99%) Rattus norvegicus actin-filament binding protein Frabin mRNA-Homo j sapiens (Human), 766 aa. <- Q9IZT5 Actin-binding protein frabin-alpha-1.. 767 642/767 (83%) 0. 0 3 Mus musculus (Mouse), 766 aa. L. 766 692/767 (89%) ! 088387 Actin-filament binding protein Frabin-1 767 h. 634/767 (82%) 0. 0 Rattus norvegicus (Rat), 766 aa. 1.. 766. 1682/767 (88%) Q9) ZT4 Actin-bindingproteinfrabin-beta-I.. 589 480/589 (81%) 0. 0 < Mus muscutus (Mouse), 603 aa. !.. 588 520/589 (87%) ; __ JQ9) ZT3 Actin-binding protein frabin-gamma-jl.. 504 402/504 (79%) JO. O ; Mus musculus (Mouse), 504 aa. 1.. 503 439/504 (86%) PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12E.

Table 12E. Domain Analysis of NOV12a Identities/ i Pfam Domain NOV12a Match Region Similarities Expect Value for the Matched Region RhoGEF J2I0.. 393 75/209 (36%) 4. 3e-57 155/209 (74%) 3 PH 424.. 522 30/99 (30%)]. 5e-) 6 <'80/99 (81%) DAGPE-bind 556.. 602 12/51 (24%) | 0. 63 28/51 (55%) FYVE 555.. 621 32/72 (44%) 1. 1 e-23 54/72 (75%) PH 645.. 741 23/97 (24%) 1. 2e-12 69/97 (71%) Example 13.

The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.

Table 13A. NOV13 Sequence Analysis Further analysis of the NOVI 3a protein yielded the following properties shown in Table 13B.

Table 13B. Protein Sequence Properties NOV13a

port 0. 7480 probability located in microbody (peroxisome); 0. 4321 probability located in analysis : : mitochondrial matrix space; 0.1127 probability located in mitochondrial inner .. membrane ; 0. 1127 probability located in mitochondrial intermembrane space SignalP No Known Signal Sequence Predicted analysis : A search of the NOV 13a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C.

Table 13C. GENESEQ Results for NOV13a NOV13a Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier #, Datel 0 Match the Matched Value 'Residues Region .. 3 | s ABG27943 Novel human diagnostic protein 7 3 378 329/395 (83%) 0. 0 #27934-Homo sapiens, 426 axa. 38.. 426 335/395 (84%) [W0200175067-A2, 11-OCT-2001] ABG27201 Novel human diagnostic protein 7 59 378 290/321 (90%) e-167 #27192-Homo sapiens, 314 aa. 1.. 314 292/321 (90%) [W0200175067-A2, 11-OCT-2001] ABG21182 Novel human diagnostic protein 48.. 370 276/355 (77%) e-155 #21173-Homo sapiens, 353 aa. 6.. 353 283/355 (78%) [W0200175067-A2, I I-OCT-2001 ABG34131 Human ARP2/3 complex 41Kd 5 377 235/377 (62%) e-140 subunit, P41-ARC-Homo sapiens, 4 371 293/377 (77%) 372 aa. [W0200222851-A2, i 21-MAR-2002] AAW67857 Human secreted protein encoded by 5.. 377 235/377 (62%) e-140 gene 51 clone HAPN080-Homo 4.. 371 293/377 (77%) sapiens, 372 aa. [W09842738-AI, 01-OCT. ! 998] ! ..........-------- In a BLAST search of public sequence databases, the NOV1 3a protein was found to have homology to the proteins shown in the BLASTP data in Table 13D.

Table 13D. Public BLASTP Results for NOV13a NOV13a Identities/ Protein. NOV13a Identities/t Residues/Similarities for Expect Protein ; Accession Protein/Organism/Length Match the Matched Value Number Residues Portion Q99PD4 Suppressor of profiliti/p4i of 3.. 378 335/376 (89%) fo. O actin-retated compiex 2/3-Rattus 2.. 370 342/376 (90%) norvegicus (Rat), 370 aa. Q9ROQ6 i SID329P (Actin related protein 2/3 3.. 378 334/376 (88%) 0. 0 d complex, subunit IA) (4] kDa)-Mus 2.. 370 342/376 (90%) musculus (Mouse), 370 aa. Q92747 Actin-reiated protein 2/3 comp) ex 3.. 378 336/376 (89%) 0. 0 Q92747 | Actin-related protein 2/3 complex 3 378 336/376 (89%) o. o subunit IA (SOP2-like protein)-2.. 370 341/376 (90%) Homo sapiens (Human), 370 aa. Q9BUOO Hypothetical 44. 0 kDa protein-Homo 5.. 377 235/377 (62%) e-140 sapiens (Human), 401 aa (fragment). 33.. 400 293/377 (77%) LS, 015143 3 ARP2/3 complex 41 kDa subunit 5 377 235/377 (62%) e-140 I (P41-ARC) (Actin-related protein 2/3 4.. 371 293/377 (77%) complex subunit 1 B)-Homo sapiens (Human), 372 aa. ' (Human), 372aa.

PFam analysis predicts that the NOV I 3a protein contains the domains shown in the Table 13E.

Table 13E. Domain Analysis of NOV13a Identities/ Pfam Domain NOV13a Match Region Similarities Expect Value for the Matched Region WD40 45.. 81 8/37 (22%) 0. 001 29/37 (78%) WD40 135 171 12/37 (32%) 0. 13 28/37 28, 37 (76%)

Example 14.

The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.

Table 14A. NOV14 Sequence Analysis Further analysis of the NOV14a protein yielded the following properties shown in Table 14B.

Table 14B. Protein Sequence Properties NOV14a PSort 10. 5050 probability located in cytoplasm; 0.3000 probability located in microbody analysis :'' (peroxisome) ; 0. 1000 probability located in mitochondrial matrix space; 0. 1000 probability located in lysosome (lumen) -.-- SignalP No Known Signal Sequence Predicted analysis:

A search of the NOV 14a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14C.

Table 14C. GENESEQ Results for NOV14a NOV14a Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value Residues Region H | ABG06795 Novel human diagnostic protein 1.. 555 #6786-Homo sapiens, 594 aa. 139.. 594 526/556 (94%) [W0200175067-A2, 11-OCT-2001] AAU16163 Human novel secreted protein, Seq ID 1.. 555 507/599 (84%) 0. 0 11 16 Homo sapiens, 620 aa. 22 620 526/599 (87%) [W0200155322-A2 02-AUG-2001] ABG06794 Novel human diagnostic protein 1.. 555 507/599 (84%) 0. 0 #6785-Homo sapiens, 614 aa. 16.. 614 526/599 (87%) [W0200175067-A2, Il-OCT-2001] w « AAY30649 A murine c-myc coding region 2.. 555 353/579 (60%) i'0. 0 determinant binding protein-Mus 1.. 577 442/579 (75%) musculus, 577 aa. [W09946594-A2, 16-SEP-1999] ABB75054 Human lung tumour L523S 2.. 544 343/567 (60%) 0. 0 recombinant protein sequence SEQ ID 1.. 566 424/567 (74%) NO : 449-Homo sapiens, 579 aa. [W0200200174-A2, 03-JAN-2002]

In a BLAST search of public sequence databases, the NOVI 4a protein was found to have homology to the proteins shown in the BLASTP data in Table 14D.

Table 14D. Public BLASTP Results for NOV14a Protein NOV14a Identities/ .. ,. . .. Residues/Similarities for Expect Accession Protein/Organism/Length Residues/Similarities for Expect Number Match the Matched Value Number .. .. Residues Portion {Q9Y6M 1 4 I lepatocellular carcinoma 1 555 507/556 (91%) 0. 0 alltoantigen-Homo sapiens (Human), 556 aa. 3 AAD09827 IGF-II MRNA-BINDING 2.. 555 506/598 (84%) 0. 0 PROTEIN 2-Homo sapiens 1.. 598 525/598 (87%) (Human), 598 aa. j 042254 Zipcode-binding protein-Gaiius 2.. 555 360/583 (61%) 0. 0 gallus (Cliicken), 576 aa. 1.. 576 440/583 (74%) AAD09826 IGF-HMRNA-BINDING 2.. 555 355/579 (61%) 0. 0 PROTEIN I-Homo sapiens 1.. 577 442/579 (76%) (Human), 577 aa. fo73932 VG] RNA binding protein variant D 2.. 55 ! 355/586 (60%) 0. 0 4-Xenopus laevis (African clawed {1 586 440/586 (74%) 3 i} frog), 594 aa. {.............

PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14E.

Table 14E. Domain Analysis of NOV14a Identities/ , Pfam Domain NOV14a Match Region Similarities Expect Value for the Matched Region rrm 5.. 71 24/78 (31%) 9. 3e-05 46/78 (59%) rrm 84.. 152 14/77 (18%) 73e-OS 8/77 (62%) i KH-domain 197 244 17/49 (35%) 3. 7e-06 38/49 (78%) KH-domain 278.. 329 19/52 (37%) 1. 9e-07 41/52 (79%) 'KH-domain 388 436 18/49 (37%) 4. 9e-05 33/49 (67%) , KH-domain 1469. 519 18/51 (35%) 43. 5e-08 42/51 (82%) Example 15.

The NOV 15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in table 15A.

Table 15A. NOV15 Sequence Analysis

Further analysis of the NOVI 5a protein yielded the following properties shown in Table 15B.

I Table 15B. Protein Sequence Properties NOVlSa PSort 0.8598 probability located in mitochondrial intermembrane space; 0.7605 probability analysis : located in mitochondrial matrix space; 0. 4691 probability located in microbody (peroxisome) ; 0.4392 probability located in mitochondrial inner membrane a Signal P. No Known Signal Sequence Predicted analysis : A search of the NOV15a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C.

Table 15C. GENESEQ Results for NOV15a NOVlSa Identities/ GENESEQ Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier #, Datel Match the Matched Value Residues Region ! AAY36X5 JExtended human secreted protein t 1 129 99/129 (76%) le-SO , sequence, SEQ ID NO. 500-Homo 1 108 103/129 (79%) sapiens, 108 aa. [W09931236-A2, 24-JUN-1999] AAW64556 Human osterocarcinoma cell line U-2 1 129 99/129 (76%) le-SO OS clone HP10305 protein-Homo 1.. 108 103/129 (79%) sapiens, 108 aa. [W09821328-A2, 22-MAY-1998] s s M AAY12490 Human 5'EST secreted protein SEQ 1.. 117 83/117 (70%) 7e-41 ID NO : 52 1-Homo sapiens, 96 aa. 1 96 88/117 (74%) [W09906548-A2, 11-FEB-1999] ABG17140 Novel human diagnostic protein 10 129 80/120 (66%) 3e-40 #17131-Homosapiens, 395aa. 297.. 395 87/120 (71 %) [W0200175067-A2, II-OCT-2001] abc Nove) human diagnostic protein 3 22., 129 78/108 (72%) 3 9e-39 # 17132-Homo sapiens, 105 aa. 19.. 105 81/108 (74%) [W0200175067-A23 I I-OCT-2001 In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D.

Table 15D. Public BLASTP Results for NOV15a

NOV15a Identities/ protein i Accession Protein/Organism/Length ! Access) on Protem/Organtsm/Length n/, .. t-n ;, ... . Match the Matched Value Number Residues Portion § Q9NZ45,. Uncharacterized hematopoietic.'1 129 99/129 (76%) 3e-50 stem/progenitor ceHs protein 1.. 108 ! 03/) 29 (79%) MDS029-Homo sapiens (Human 108 aa. Æ v 1 Q8WUQ5 Hypotlietical 12. 1 kDa protein-1.. 129 86/129 (66%) | 2e-43 . Homo sapiens (Human), 108 aa.. 1 108 97/129 (74%) Q9DOYO) 500009M05Rikprotein-Mus I2.. 128 53/119 (44%) 3e-19 l musculus (Mouse), 135 aa. 37 134 67/119 (55%) Q9CQB5 1500009MOSRik protein-Mus s 12.. 128 53/119 (44%) Se-19 1 musculus (Mouse), 135 aa. 37 134 67/119 (55%) AAH32300, i Similarto RIKEN cDNA 1 12 128 54/119 (45%) 7e-19 1500009M05 gene-Homo sapiens ; 37.. 134 66/119 (55%) (Human), 135 aa.

PFam analysis predicts that the NOVI 5a protein contains the domains shown in the Table 15E.

Table 15E. Domain Analysis of NOV15a ! luenllllesi/ffi ! Pfam Domain NOV15a Match Region 1 Similarities i Expect Value j for the Matched Region i i i No Significant Matches Found To Publicly Searchable Domains Example 16.

The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.

Table 16A. NOV16 Sequence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 16B.

Table 16B. Comparison of NOV16a against NOV16b. -- . NOV16aResidues/Ident) ties/ Match Residues Similarities for the Matched Region - !. Match Residues __. .. _. _ _.. NOVI6b 26 173 | 123/148 (83%) NOV 148 123/148 (83%) NOV'16b 23/I48 Further analysis of the NOVI 6a protein yielded the following properties shown in Table 16C.

Table 16C. Protein Sequence Properties NOV16a

PSort 0. 9190 probability located in plasma membrane; 0.2000 probability located in analysis : lysosome (membrane); 0. 1339 probability located in microbody (peroxisome); 0. 1000 probability located in endoplasmic reticulum (membrane) SignalP Cleavage site between residues 24 and 25 analysis : A search of the NOV16a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16D.

Table 16D. GENESEQ Results for NOV16a

NOV16a GENESEQ I Protein/Organism/Length IPatent. Residues/Identities/^, Expect Similarities for the Identifier Date] Match'Value Matched Region Residues AAG75579 Human colon cancer antigen protein ; 1.. 173 173/173 (100%) l e-95 SEQ ID NO : 6343-Homo sapiens, v 54.. 226 173/173 (100%) 226aa. [W0200) 22920-A2, 05-APR-2001 AAB43566 3Human cancerassociated protein,'] 173 173/173 (100%) g Ie-95 sequence SEQ ID NO : 1011-Homo i 15 187 173/173 (100%) sapiens, 187 aa. [W0200055350-A 21-SEP-2000] ABP42089 Human ovarian antigen HAZAG23, i 19 1 73 149/155 (96%) I e-82 SEQ IDNO : 3221-Homo sapiens, 11 155 150/155 (96%) 155 aa. [W0200200677-Al, 03-JAN-2002] AAB87645 Bovine mammary tissue derived ; ; 4.. 155 145/152 (95%) 1 e-80 protein #36-Bos taurus, 152 aa. 3'1 152 149/152 (97%) [W02001 14553-AI, O1-MAR-2001] X.. ~ AAB87646 Bovine mammary tissue derived ; 77 173 95/97 (97%) i 2e-5 1 protein #37-Bos taurus, 105 aa. v 9.. 105 97/97 (99%) [W0200114553-A I, 01-MAR-200 In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16E.

Table 16E. Public BLASTP Results for NOV16a . NOV16a.. Protein Identities/ Accession Protein/Organism/Length Residues/Similarities for the Expect Number. Matched Portion Value Residues P51571 Translocon-associated protein, delta 1.. 173 173/173 (100%) 4e-95 subunit precursor (TRAP-delta) 1.. 173 173/173 (100%) (Signal sequence receptor delta subunit) (SSR-delta)-Homo sapiens 4 (Human), 173 aa. t Q07984 Translocon-associated protein, delta 1.. 173 166/173 (95%) 9e-92 subunit precursor (TRAP-delta) 1.. 173 169/173 (96%) (Signal sequence receptor delta subunit) (SSR-deita)-Rattus norvegicus (Rat), 173 aa. Q9D8L3 Signal sequence receptor, delta-Mus 1 173 165/173 (95%) 3e-9 1 musctllus (Mouse),] 73 aa. 1 173 168/173 (96%) .-... ; Q9DC94 Signal sequence receptor, delta-Mus ; 1.. 173 164/173 (94%) 8e-91 musculus (Mouse), 173 aa. 1.. 173 168/173 (96%) Q62186 Translocon-associated protein, delta ; 1.. 173 164/173 (94%) 2e-89 subunitprecursor (TRAP-delta) i'l l72 167/173 (95%) (Signal sequence receptor delta subunit) (SSR-delta)-Mus musculus (Mouse), 172 aa. J PFam analysis predicts that the NOV 16a protein contains the domains shown in the Table 16F.

Table 16F. Domain Analysis of NOV16a Identities/ Pfam Domain NOV16a Match Region Similarities Expect Value for the Matched Region No Significant Matches Found To Publicly Searchable Domains Example 17.

The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.

|Table 17A. NOV17 Sequence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 17B.

Table 17B. Comparison of NOV17a against NOV17b. NOV17a Residues/Identities/ Match Residues Similarities for the Matched Region | NOV 1 7b 1 492 409/513 (79%) 1 513 409/513 (79%) f H. __.. ,... _, . .... _.. .. : ___.. _. ___.. _... . .... __.... _ . _..,... _.. x_. : , : . _... ... . _... _. .. _.. u :.. _. ., ..., .,..

Further analysis of the NOV1 7a protein yielded the following properties shown in Table 17C.

Table 17C. Protein Sequence Properties NOV17a j PSort 1 03000 probability located in microbody (peroxisome); 0 3000 probability located in analysis : l nucleus; 0. 1500 probability located in lysosome (lumen) ; 0.1000 probability located | in mitochondrial matrix space SignalP No Known Signal Sequence Predicted analysis: A search of the NOV17a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17D.

Table 17D. GENESEQ Results for NOV17a NOV17a Identities/ GENESEQ. Protein/Organism/Length [Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value Residues Region AAE23378. Fluman intracellular signaling 1 492 491/513 (95%) 0. 0 (INTSIG-5) protein-Homo sapiens, 1.. 513 491/513 (95%) 513 aa. [W0200231152-A2, 18-APR-2002] A-AE2-3374 Human intracellular signaling 1.. 414 413/435 (94%) 0. 0 ; (1NTSIG-1) protein-Homo sapiens, 1.. 435 413/435 (94%) 1, 435 aa. [W0200231152-A2, i 1 8-APR-2002] , _ AAM41955 ; Human polypeptide SEQ ID NO 109.. 492 383/405 (94%) 0. 0 6886-Homo sapiens, 446 aa. 42.. 446 383/405 (94%) i [W0200153312-A1, 26-JUL-2001] I AAM40 169'., Human polypeptide SEQ ID NO 140 482 328/364 (90%) 0. 0 . 3314-Homo sapiens, 359 aa. 1.. 356 329/364 (90%) ti' [W0200153312-A1, 26-JUL-2001] w r ABG07689 Novel human diagnostic protein 112.. 487 327/407 (80%) e-176 #7680-Homo sapiens, 429 aa. 1.. 407 332/407 (81%) [W0200175067-A2, I I-OCT-20011 In a BLAST search of public sequence databases, the NOV I 7a protein was found to have homology to the proteins shown in the BLASTP data in Table 17E.

Table 17E. Public BLASTP Results for NOV17a

r § w Identities/ 4 Protein i Residues/_ Similarities for Expect Accession Protein/Organism/Length Match the Matched Value Number Residues Portion E BAC04021 CDNA FLJ35698 fis, clone 0 L. 492, 490/513 (95%) 0. 0 SPLEN2019839, weakly similar to 107.. 619 490/513 (95%) TIPD PROTEIN-Homo sapiens a (Human), 619 aa. S BAC03485 ! CDNA FLJ33278 fis, clone f. 1 492. 489/513 (95%) 0. 0 ! ASTR02008508, weak) ysimiiarto ! !.. 5) 3 489/5] 3 (95%) TIPD PROTEIN-Homo sapiens | (Human), 513 aa. Q96D26 Hypothetical 52. 5 kDa protein-16.. 49 ! 90/478 (39%) 2e-95 Homo sapiens (Human), 472 aa. 5.. 469 278/478 (57%) Q9BR1 1 Hypothetical 52. 6 kDa protein-16 49 ; 190/478 (39%) 2e-95 Homo sapiens (Human), 472 aa. 5.. 469 J 278/478 (57%) Q96JV 5 CDNA FLJ] 4948 fis, clone 1.. 491 191/493 (38%) 3e-95 PLACE2000164, weakly similar to 22.. 501 : 1283/493 (56%) TIPD protein-Homo sapiens (Human), 504 aa. . _. ___. _,. ___d_........ v A.. _. r __ _ s PFam analysis predicts that the NOV1 7a protein contains the domains shown in the Table 17F.

Table 17F. Domain Analysis of NOV17a Identities/ Pfam Domain NOV17a Match Region Similarities Expect Value for the Matched Region WD40 201.. 237 14/37 (38%) 0. 0003 30/37 (81%) WD40 287.. (l-Z.) 0. 0022 26/37 (70%) WD40 ; 368,, 403 ; 10/37 (27%) 0. 0068 33/37 (89%)

Example 18.

The NOVI 8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A.

Table 18A. NOV18 Sequence Analysis<BR> quence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 18B.

Table 18B. Comparison of NOV18a against NOV18b and NOV18c. NOV18a Residues/Identities/ atch Residues Similarities for the Matched Region r-» bs *_s rs t NOV I 8b 1 73 49/74 (66%) 35.. 108 58/74 (78%) | NOV I 8c 4 1 131 81/134 (60%) 1 1 134 97/134 (71%) Further analysis of the NOVI 8a protein yielded the following properties shown in Table 18C.

Table 18C. Protein Sequence Properties NOV18a Psort 0.4500 probability located in cytoplasm ; 0.3962 probability located in microbody 0 analysis : a (peroxisome) ; 0.1832 probability located in lysosome (lumen) ; 0. 1000 probability il located in mitochondrial matrix space I SignalP S No Known Signal Sequence Predicted analysis : A search of the NOV1 8a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D. t Table 18D. GENESEQ Results for NOV18a F- 3 l NOV18a Identities/ GENESEQ Protein/Organism/Length {Patent Residues/Similarities for Expect Identifier Date] Match the Matched Value | Residues Region f ABP5) 378 Human MDDTSEQJD NO 400-1.. 131 87/134 (64%) 3e-38 Homo sapiens, 199 aa. 17.. 150 100/134 (73%) l [W0200240715-A2, 23-MAY-2002] AAU29923 Novel human secreted protein #414- 1.. 131 81/134 (60%) 7e-35 Homo sapiens, 238 aa. 64 197 98/134 (72%) [W0200179449-A2 25-OCT-2001 ABG 16661 Novel human diagnostic protein 1.. 13 1 80/134 (59%) 0 3e-34 #16652-Homo sapiens, 313 aa. 159.. 292 96/134 (70%) [W0200175067-A2, I I-OCT-200 I] z a AAU29888 ! Novel human secreted protein 4379-1.. 131 82/135 (60%) i I e-33 'Homo sapiens, 261 aa. 86.. 220 98/135 (7] %) rt ! ; [W0200179449-A2, 25-OCT-2001] t AAU.) 122 Novel human secreted protein #3613 77/128 (60%) le-') 2 Homo sapiens, 177 aa. 8 135 94/128 (73%) § ! [W0200I79449-A2, 25-OCT-200)] ! In a BLAST search of public sequence databases, the NOV 8a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E.

Table 18E. Public BLASTP Results for NOV18a<BR> <BR> Table 18E. Public BLASTP Results for NOV18a NOV18a Identities/ Protein Residues/Similarities for Expect Accession Protein/Organism/Length N mber Value Number Residues Portion 3e-38 S01239 X ferritin light chain-rabbit, 175 aa. 1 131 87/134 (64%) X 3e-38 1.. 134 99/134 (72%) 6e-3 8 Q9JKP6, Ferritin-Cavia porcellus (Guinea 1.. 131 87/134 (64%) 6e-38 : pig), 175 aa. 1.. 134 101/134 (74%) FRRTL ferritin light chain-rat, 183 aa. 1.. 131 87/134 (64%) 8e-38 1.. 134 100/134 (73%) 154774 ; ferritin light chain-rat, 183 aa. 1.. 131 87/134 (64%) le-37 1.. 134 100/134 (73%) P094 1 Ferritin liaht chain (Ferritin L 2 131 86/133 (64%) He-37 ! subunit)-Oryctolagus cuniculus 1.. 33 98/133 (7-) %) (Rabbit), 174 aa. i t PFam analysis predicts that the NOVI 8a protein contains the domains shown in the Table 18F.

Table 18F. Domain Analysis of NOV18a Identities/ Pfam Domain NOV18a Match Region Similarities Expect Value for the Matched Region -t'7. ferritin 13,, 131 54/126 (43%) | 7e-35 i 488/126 (70%) 1 -L

Example 19.

The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.

Table 19A. NOV19 Sequence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 19B.

Table 19B. Comparison of NOV19a against NOV19b. NOV19a Residues/Identities/ Match Residues Similarities for the Matched Region |NOV19b 1 1216 1165/1219 (95%) 1.. 1219 1173/1219 (95%) Further analysis of the NOV 19a protein yielded the following properties shown in Table 19C.

Table 19C. Protein Sequence Properties NOV19a

Psort 0. 4500 probability located in cytoplasm ; 03000 probability located in microbody t analysis : (peroxisome); 0.1000 probability located in mitochondrial matrix space ; 0. 1000 probability located in lysosome (lumen) signale No Known Signal Sequence Predicted analysais : A search of the NOVI 9a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19D.

Table 19D. GENESEQ Results for NOV19a ''NOV19a Identities/ : GENESEQ Protein/Organism/Length ; Residues/Expect Similarities for the f Identifier lPatent #, Datel Match Matched Region Value Matched Region ! Residues jAAU75103 Leucille rich protein, L130-Homo s 1 1273 1273/1273 (100%) o. n sapiens, 1273 aa.'. 1 1273 1273/1273 (100%) [W0200198524-A2, 27-DEC-2001 t 0 ABB71881 Drosophila melanogaster., 40 1045 314/1035 (30%) e-129 polypeptide SEQ ID NO 42435-2 1027 512/1035 (49%) Drosophila melanogaster, 1275 aa. [W0200171042-A2, 27-SEP-2001 AAY95854 Autoantigen diagnostic of 516 700 179/185 (96%) 7e-95 endometriosis-Homo sapiens, 89 ! I.. 185 ! 80/185 (96%) aa. [W0200047739-A2, 17-AUG-2000] AA000059 Human polypeptide SEQ ID NO v 965.. 1124 137/160 (85%) le-69 13951-Homo sapiens, 164 aa. 1.. 160 146/160 (90%) [W0200164835-A2, 07-SEP-2001] L X ABB69797 Drosophila melanogaster 4.. 887 219/972 (22%) 6e-41 polypeptide SEQ ID NO 36183-'125.. 1062 405/972 (41 %) Drosophila melanogaster, 1072 aa. [W0200171042-A2, 27-SEP-2001 In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19E.

Table 19E. Public BLASTP Results for NOV19a

NOVX Residues/Expect Accession Protein/Organism/Length Similarities for the Number Residues Matched Portion j Residues P42704 130 kDa leucine-rich protein (LRP 1 1273 1273/1273 (100%) 0. 0 130) (GP130) (Leuchle-rich 1 1273 1273/1273 (100%) PPR-motif containing protein)- Homo sapiens (Human), ! 273 aa. j j S27954 heucine-rich protein-human, 1207 67.. 1273 1207/1207 (100%) 0. 0 jaa. 1.. 1207 207/1207 (100%) 'BAB93528 Leucine rich protein mLRP130-6 1273 955/1268 (75%) 0. 0 Mtis Mus musculus (Mouse), 1306aa. 40.. 1306 1100/1268 (86%) ! ~ -v s- Q96D84 Hypothetical 80. 0 kDa protein-572.. 1273 i 699/702 (99%) 0. 0 3 Homo sapiens (Human), 702 aa 1.. 702 700/702 (99%) 3 (fragment). H o Q9CRX4 31 10001 K 13Rik protein-Mus 561.. 1273 Y 542/713 (76%) 0. 0 j musculus (Mouse), 712 aa 1.. 712 627/713 (87%) 3 (fragmellt). (fra) 1172111.

PFam analysis predicts that the NOVI 9a protein contains the domains shown in the Table 19F. t Table 19F. Domain Analysis of NOV19a Identities/ Pfam Domain NOV19a Match Region Similarities Expect Value for the Matched Region PPR 77..)))) 3/35 (37%) 0. 0032 23/35 (66%) PPR 1112.. 146 9/35 (26%) 0. 00018 25/35 (71%) I PPR í G28 662 12/35 (34%) 1 0. 046 j 27, 35 (77%) PPR , 10/35 (29%) 10037 124/35 (69%) 1 * 24/35 (69%) Example 20.

The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.

Table 20A. NOV20 Sequence Analysis Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 20B.

Table 20B. Comparison of NOV20a against NOV20b and NOV20c. NOV20a Residues/Identities/ Protein Sequence Match Residues Similarities for the Matched Region NOV20b 1.. 1005 671/1020 (65%) 130.. 1068 710/1020 (68%) I NOV20c 1.. 1005 671/1020 (65%) 63.. 1001 710/1020 (68%) . . .. , s S

Further analysis of the NOV20a protein yielded the following properties shown in Table 20C.

Table 20C. Protein Sequence Properties NOV20a PSort 0.7600 probability located in nucleus; 0.3000 probability located in microbody | analysis : (peroxisome) ; 0.1000 probability located in mitochondrial matrix space; 0.1000 j probability tocated in) ysosome (tumen) SignalP E No Known Signal Sequence Predicted analysis : A search of the NOV20a protein against the GENESEQ database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20D.

, Table 20D. GENESEQ Results for NOV20a j nova 'GENESEQ Protein/Organism/Length Residues/ Expect Similarities for the i Identifier (Patent #, Date] Match Value Residues Matched Region Residues" AAU78283 Human apoptosis stimulating I.. 1005-'1 005/1005 (100%) 0. 0 protein 2 (APS-2)-Homo sapiens, 209.. 1213. 1005/1005 (100%) 1467 aa. [W0200212325-A2, 14-FEB-2002] ; {AAW93955 Human 53BP2 protein-Homo 1.. 1005 1'1005/1005 (100%) 0. 0 sapiens, 1005 aa. 1.. 1005 4 [W09915657-A2, 01-APR-1999] H L AAM78805 Human protein SEQIDNO 1467-1 1005 i479/1030 (46%) 0. 0 Homo sapiens, 1096 aa. 124.. 1096 1613/1030 (59%) [W0200157190-A2, l 09-AUG-200 1] AAU78282 j Human apoptosisstimutating L. ! 005 ! 478/) 030 (46%) 0. 0 3 protein I (APS-1)-llomo sapiens, 176 1142'611/1030 (58%) 4 1609 aa. [W02002 1 2325-A2,. I 14-FEB-2002] _ _. _. _____u__. __. __--__. _. T_ _ _ i. ____-_-. r__-__ AAM39292 Human polypeptide SEQ ID NO,, 1 1005 t 478/1030 (46%) 0. 0 2437-Homo sapiens, 1090 aa. 3 124 1090 4 611/1030 (58%) [W0200153312-A 1, 26-JUL-200 1] ,. _.. _... v_.. ... _... ... ..... ,.. u..

In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20E.

Table 20E. Public BLASTP Results for NOV20a

NOV20a Protein Identities/ Residues/ Expect | Accession Protein/Organism/Length Match Similarities for the 4 V IP t Match Value Number Matched Portion tS v >-S Q96KQ3 ASPP2 protein-Homo sapiens 1.. 1005 1005/1005 (100%) 0. 0 (Human), 1128 aa. 124.. 1128 1005/1005 (100%) i Q13625 Tumor suppressor p53-binding 1.. 1005 1005/1005 (100%) 0. 0 protein 2 (p53-binding protein 2) 1.. 1005 1005/1005 (100%) (53BP2) (Bcl2-binding protein) (Bbp)-Homo sapiens (Human), 1} 1005 aa. i AAH30894 Similar to tumor protein p53 258.. 1005 664/749 (88%) f 0. 0 binding protein, 2-Mus musculus 15.. 762 688/749 (91%) 1 (Mouse), 762 aa (fragment). ; 138607 p53-binding protein 2-human, 477.. 1005 529/529 (100%) 0. 0 529 aa (fragment). 1.. 529 529/529 (100%) ! Q96KQ4 ASPP1 protein (KIAA0771'1.. 1005 478/1030 (46%) i oPo protein)-Homo sapiens (Human), 124.. 1090 611/1030 (58%) 1090 axa.

PFam analysis predicts that the NOV20a protein contains the domains shown in the Table 20F.

Table 20F. Domain Analysis of NOV20a Identities/ Pfam Domain NOV20a Match Region Similarities Expect Value for the Matched Region 1 ank 835.. 867 16/33 (48%) l e-09 28/33 (85%) II ank 868 900 16/33 (48%) 5. 1 e-09 3 28l33 (85%) SH3 937.. 994 23/6) (38%)). 2e- ! 2 147/61 (77%)

Example B: Sequencing Methodology and Identification of NOVX Clones 1. GeneCallingTM Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al.,"Gene expression analysis by transcript profiling coupled to a gene database query"Nature Biotechnology 17: 198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments.

Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.

2. SeqCalling Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly

when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

3. PathCallingX isl Technology : The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The laboratory screening was performed using the methods summarized below: cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, CA) were then transferred from E. coli into a CuraGen Corporation proprietary yeast strain (disclosed in U. S. Patents 6. 057, 101 and 6, 083, 693, incorporated herein by reference in their entireties).

Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corporation proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly

represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N 106'and YULH (U. S.

Patents 6,057, 101 and 6, 083, 693).

4. RACE : Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.

5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species.

These primers were then employed in PCR amplification based on the following pool of human cDNAs : adrenal gland, bone marrow, brain-amygdala, brain-cerebellum, brain- hippocampus, brain-substantia nigra, brain-thalamus, brain-whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma-Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from

exon linking was cloned into the pCR2. 1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2. 1 vector.

The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBIastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2. 1 vector from Invitrogen to provide clones used for expression and screening purposes.

Example C. Quantitative expression analysis of clones in various cells and tissues The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISMS 7700 or an ABI PRISM 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions). Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), Al_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD. 01 (containing samples from

normal and diseased brains) and CNS neurodegeneration-panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2: 1 to 2.5 : 1 28s: 1 8s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, ß-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 pg of total RNA were performed in a volume of 20 1 and incubated for 60 minutes at 42°C. This reaction can be scaled up to 50 llg of total RNA in a final volume of 100 ul. sscDNA samples are then normalized to reference nucleic acids as described previously, using IX TaqMan (t Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (Tm) range = 58°-60°C, primer optimal Tm = 59°C, maximum primer difference = 2°C, probe does not have 5'G, probe Tm must be 1 0°C greater than primer Tm, amplicon size 75bp to 100bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5'and 3'ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900nM each, and probe, 200nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqManS) One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No.

4313803) following manufacturer's instructions. Reverse transcription was performed at 48°C for 30 minutes followed by amplification/PCR cycles as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1 X TaqManO Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

PCR amplification was performed as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were analyzed and processed as described previously.

Panels 1,1. 1,1. 2, and 1.3D The plates for Panels 1, 1. 1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney,

adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1. 1,1. 2 and 1.3D, the following abbreviations are used: ca. = carcinoma, * = established from metastasis, met = metastasis, s cell var = small cell variant, non-s = non-sm = non-small, squam = squamous, pl. eff= pl effusion = pleural effusion, glio = glioma, astro = astrocytoma, and neuro = neuroblastoma.

Genera ! screening pane ! vl. 4, v1. 5 and v1. 6 The plates for Panels 1.4, 1.5, and 1.6 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panels 1.4, 1. 5, and 1.6 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, 1.5, and 1.6 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, 1.5, and 1.6 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1,1. 1,1. 2, and 1.3D.

Panels 2D, 2.2, 2.3 and 2.4 The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have"matched margins"obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT"in the results below. The tumor tissue and the"matched margins"are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/ CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i. e. immediately proximal) to the zone of surgery (designated"NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc. ). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

HASS Panel v 1.0 The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls.

Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, MD) and were grown in the media and conditions

recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.

ARDAIS Panel v 1.0 The plates for ARDAIS panel v 1.0 generally include 2 control wells and 22 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human lung malignancies (lung adenocarcinoma or lung squamous cell carcinoma) and in cases where indicated many malignant samples have"matched margins"obtained from noncancerous lung tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i. e. immediately proximal) to the zone of surgery (designated"NAT", for normal adjacent tissue) in the results below. The tumor tissue and the"matched margins" are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). Unmatched malignant and non-malignant RNA samples from lungs were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.

Panel 3D, 3.1 and 3.2 The plates of Panel 3D, 3.1, and 3. 2 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D, 3. 1, 3. 2, 1, 1.1., 1. 2, 1. 3D, 1.4, 1.5, and 1.6 are of the most common cell lines used in the scientific literature.

Panels 4D, 4R, and 4. 1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4. 1 D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc. , Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-Sng/ml, TNF alpha at approximately 5-1 Ong/ml, IFN gamma at approximately 20-SOng/ml, IL-4 at approximately 5-lOng/ml, IL-9 at approximately 5-l Ong/ml, IL-13 at approximately 5-l Ong/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0. 1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), lOOpM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5. SxlO-5M (Gibco), and 1 OmM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20ng/ml PMA and 1-2plg/ml ionomycin, IL-12 at 5-lOng/ml, IFN gamma at 20-SOng/ml and IL-18 at 5-lOng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), I OOpM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol S. SxlO-5M (Gibco), and 1 OmM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5ug/ml.

Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1: 1 at a final

concentration of approximately 2Xl 06cellstml in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), I mM sodium pyruvate (Gibco), mercaptoethanol (5. 5x10-5M) (Gibco), and I OmM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions.

Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5. 5x10-5M (Gibco), and 10mM Hepes (Gibco), 50ng/ml GMCSF and 5ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100iM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5. 5x10-5M (Gibco), IOmM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately SOng/ml.

Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at I OOng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10µg/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), lOOuM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5. 5xlO-5M (Gibco), and 10mM Hepes (Gibco) and plated at 1 06cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with O. Slg/ml anti-CD28 (Pharmingen) and 3ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), I 00tM non essential amino acids (Gibco), ImM sodium pyruvate (Gibco), mercaptoethanol 5. SxlO-5M (Gibco), and l OmM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with

plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture.

The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol S. SxlO-5M (Gibco), and 1 OmM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at 106cells/ml in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5. sXlo-5M (Gibco), and lOmM Hepes (Gibco). To activate the cells, we used PWM at Spg/ml or anti-CD40 (Pharmingen) at approximately 10tg/mi and IL-4 at 5-lOng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours.

To prepare the primary and secondary Thl/Th2 and Trl cells, six-well Falcon plates were coated overnight with 10µg/ml anti-CD28 (Pharmingen) and 2pg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 105-10Obcells/ml in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), I mM sodium pyruvate (Gibco), mercaptoethanol 5. SxlO-5M (Gibco), 10mM Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (Sng/ml) and anti-IL4 (1 llg/ml) were used to direct to Th 1, while IL-4 (Sng/ml) and anti-IFN gamma (1 llg/ml) were used to direct to Th2 and IL-10 at Sng/ml was used to direct to Trl. After 4-5 days, the activated Th1, Th2 and Trl lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), I mM sodium pyruvate (Gibco), mercaptoethanol S. SxlO-'M (Gibco), 10mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Trl lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1µg/ml) to prevent apoptosis. After 4-5 days, the Thl, Th2 and Trl lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Thl and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Trl after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at SxlO5cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5x 1 05cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5. SxlO-5M (Gibco), I OmM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 1 Ong/ml and ionomycin at 1 llg/ml for 6 and 14 hours. Keratinocyte line CCD 106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol s. sXlo-5M (Gibco), and 10mM Hepes (Gibco). CCD 1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and Ing/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5ng/ml IL-4, 5ng/ml IL-9, 5ng/ml IL-13 and 25ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 1 07cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor.

The aqueous phase was removed and placed in a 1 sol Falcon Tube. An equal volume of isopropanol was added and left at-20°C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300p1 of RNase-free water and 35µl buffer (Promega) 5µl DTT, 7µl RNAsin and 8M1 DNase were added. The tube was incubated at 37°C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at-80°C.

AI comprehensive panel vl. 0 The plates for Al_comprehensive panel_vl. 0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital.

Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohn's disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used.

Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-lanti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_vl. 0 panel, the following abbreviations are used: Al = Autoimmunity Syn = Synovial Normal = No apparent disease Rep22/Rep20 = individual patients RA = Rheumatoid arthritis Backus = From Backus Hospital

OA = Osteoarthritis (SS) (BA) (MF) = Individual patients Adj = Adjacent tissue Match control = adjacent tissues - M = Male - F = Female COPD = Chronic obstructive pulmonary disease Panels 5D and SI The plates for Panel 5D and SI include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases.

Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study.

Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows: Patient 2: Diabetic Hispanic, overweight, not on insulin Patient 7-9: Nondiabetic Caucasian and obese (BMI>30) Patient 10: Diabetic Hispanic, overweight, on insulin Patient 11: Nondiabetic African American and overweight Patient 12: Diabetic Hispanic on insulin Adiocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U, which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al. , Multilineage Potential of Adult Human Mesenchymal Stem Cells

Science Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows: Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated Donor 2 and 3 AD: Adipose, Adipose Differentiated Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

Panel 51 contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 51.

In the labels employed to identify tissues in the 5D and SI panels, the following abbreviations are used: GO Adipose = Greater Omentum Adipose SK = Skeletal Muscle UT = Uterus PL = Placenta AD = Adipose Differentiated AM = Adipose Midway Differentiated U = Undifferentiated Stem Cells Panel CNSD. O1 The plates for Panel CNSD. O1 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at-80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and"Normal controls".

Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e. g. , Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used: PSP = Progressive supranuclear palsy Sub Nigra = Substantia nigra Glob Palladus= Globus palladus Temp Pole = Temporal pole Cing Gyr = Cingulate gyrus BA 4 = Brodman Area 4 Panel CNS_Neurodegeneration_Vl. O The plates for Panel CNS_Neurodegeneration_Vl. O include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at-80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from"Normal controls"who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like

pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease ; the occipital cortex is spared in AD and therefore acts as a"control"region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNSNeurodegenerationV1. 0 panel, the following abbreviations are used: AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy Control = Control brains; patient not demented, showing no neuropathology Control (Path) = Control brains; patient not demented but showing sever AD-like pathology SupTemporal Ctx = Superior Temporal Cortex Inf Temporal Ctx = Inferior Temporal Cortex A. NOV1 CG116579-02 : Intracellular protein-like protein.

Expression of gene CG116579-02 was assessed using the primer-probe set Ag6031, described in Table AA. Results of the RTQ-PCR runs are shown in Tables AB, AC, AD and AE.

Table AA. Probe Name Ag6031 SEQ Primers Sequence length Position lild No Forward 5'-gaccgcaggtgtcgtaaaag-3' ; 20 162 n , , _ __ _ _ Probe TET-51-agtagcccattttggataccgtcctcgc-31-TAMRA Reverse ; 5-aacgaccagactagcaacaggt-3'22 1258 169 g g'a Table AB. General screening panel v1.5 Rei. Ret. Exp. (%) ! Exp. (%) Tissue Name Ag6031, issue Name Ag6031, Run Run i228738344. 228738344 Adipose 1. 7 ; Renal ca. TK-10 il5. l Melanoma* Hs688 (A). T i6. 4 iBladder i4. 7 Melanoma* Hs688 (B). T'6. 9 Gastric ca. (liver met.) NCI-N87 ij 12. 6 Melanoma* M14 Jl4. 1 IGastric ca. KATO 111-100. 0 Melanoma* LO ? IMVI 21. 5 : Colon ca. SW-948 ; 10. 4 Melanoma* SK-MEL-S 4. 9 Colon ca. SW480, i3 7. 9 Squamous cell carcinoma SCC-4 16. 4 Colon ca. * (SW480 met) SW620, 26. 2 Testis !. ; 1 . JCo ! o"ca. HT29"") 24J Prostate ca. * (bone met) PC-3, jl O. 7 31Colon ca. HCT-I 16 i54. 0 Prostate Pool, j2. 0 Colon ca. CaCo-2 3j2 1. 0 .. _ . 4. 8. : Colon cancer tissue 115. 2 Placenta Ovarian p)'---- -. Ovarian ca. SK-OV-3"26. 6 Coion ca. SW-48 J7 Ovarian ca. VCAR-4 j) 7. 2 JCoionPoo) i2. 8 . __ _. ..... _ _. __ V _ Ovarian ca. OVCAR-5 Small Intestine Pool Ovarian ca. IGROV-1 111. 2 ;, Stomach Pool ! 0. 9 _ _, l______z ; : . ... _. __. _, ___."__ _. . _ _=. -.. . _ ___. ____ :,. : :. :. _... _... . __... __.. ___..,, _ qvanancOVCAR-8 J7. 7 jBone Marrow Pool Ovary i 1. 7-'. Fetal Heart 41. 1 _. : _ :-0. 4-_ Breast ca. MCF 7 . 8 0 Breast ca. MDA MB ^23. 1 rv YV. 24 7-_ TLymph Node Pool J.. _.. Y . ''g___ __. __. Breast ca. BT 549__.'. ^^_. ^... ^A. __.-y. Y 27. 4 : Fetal Skeletal Muscle-.-- {1 _3 _--" Breast ca. T47D 21. 8 : Skeletal Muscle Pool 3. 2 . __. W 3 Breast. MDA N 3 3 ca Breast Pool 2. 5 : Thymus Pool _. w _.. __^ w_. 5. 2 Trachea 4. 8 JCNS cancer (g) io/astro) U87-MG {9. 6' ,.. _... __.. . = Breast Pool 42. 5. Thymus Pool i5. 2 Lung (L6"CNS cancer (glio/astro) U87-MG A9. 6 Fetal Lung 1 1. 3 ; CNS cancer (neuro ; met) SK-N-AS 9. 3 Lungca. NC-I-N4I7 168" (Sancer (astro) SF-539')) T8 . _. :..... _.. _ _. _. T__.. ___. __. _. ........, __ Lung ca LX-I 15. 2 3CNS cancer (astro) SNB-75 t28. 9 Lung NCI-15. 2 CNS cancer (glio) SNB-l9'11. 0 Lungca. SHP-77]). 2 JCNS cancer (g) io) SF-295 08 Lung ca. A549 18. 4 Brain (Amygdala) Pool, 10. 0 LungcaNCIH526 9 jBrain (cerebe)) um)'2 Lu b ca. NCI-H526 9. 8 ; B (erebe) j ^ i ram c Ilum 9. 2 Lung ca. NC1-H23 1, 6. 3 Bram (fetal) 8. 8 Lungca. NCJ-H460) 7. 2 Brain (Hippocampus) Pooi5. 0 J |Lungca. HOP-62 09. 0 Cerebral Cortex Pooi 16 2 Luno ca. HOP-62 _____.... ... ____ . _ -- byal Cortex Pool v J- _y6. 2 Lung ca. NCI-H522 !)]. 3Brain (Substantianigra) Poo) J6. 3] Fr {0. 6 9Brain (Thalamus) Pool 3j39, 0 Fetal Liver 10. 0 Brain (whole) 9. 8 Live-^_ : a..-_ p.. _____________-. _..... P . 23 IS Kidney Pool 3. 3 Adrenal Gland 4. 6 Fetal Kidney 3. 4 APituitary gland Pool 3s 1. 6 Renal ca. 786-0 9. 9 Salivary Gland 2. 0 Renal ca A498 2. 4 3Thyroid (female) 312. 9 Renal 1. 2, 4 Thyroid Renal ca. U0-3 1 314. 0 XPancreas Pool 4 Table AC. Oncology cell line screening panel v3.1 Rel., Rel. . Exp. (%)'Exp. (%) Tissue Name Ag6031,. Tissue Name Ag6031, Run 1, 226203293 J 226203293 -..,,.,.-.,,,' CaSki Cervical epidermoid . Daoy Medulloblastoma/Cerebellum :'4. 9 ^- j34. 9 ! carcinoma (inetastasis) TE671 Medulloblastom/Cerebellum ; 7. 2 iES-2 Ovarian clear cell carcinoma 20. 7 D28') Med] Ramos/6hstimStimu) atedwith ! __ _ _ ___ Medulloblastoma/Cerebellum.'iPMA/ionomycin 6h PFSK-I Primitive"36 3. Ramos/14h stim_ Stimulated with $20 0 ; PMA/io y' Neuroectodermal/Cerebellum : PMA/ionomycin 14h' _ ; MEG-O1 Chronic myelogenous XF 498 CNS, a me okar oblast leukemia (megokaryoblast) SF-268CNS/gHobtastoma JI5. 9 JDaudiBurkitt's iymphoma 23. 5 : U266 B-cell -nua T98G Glioblastoi. 17. 4 47. 5 ,.-. 39. 0 ! CA46Burk) tt'stymphoma 0. 0 (metastasis) : s"j SK-N-SH_Neuroblastoma, 39 0', CA46 Burkitt's Iymphoma 0. 0 (metastasis). : SF-295 CNS/glioblastoma i6. 6 ; RL non-Hodgkin's B-cetl lymphoma 0. 0 _pre-B-cell lymphoma/leukemia 9. 1 Cerebe) ium : 3. 8 ! JurkatTce) iteukemia 25. 2 _.. _. :.. _ _. _. _....... :...... - ° :) 6. 8 ! rF- ! Erythro) eukem) a 20. 6 ca.'j- DMsTi4SmaH) ung cancer j jo'y"-""""'"'-y-78celfphom 'JLirkat T cell leukemia 125. 2 DMS-79 Small cell lung f22. 7 jU937 Histiocytic lymphoma 82. 9 cancer/lleuroendocrille ;'>-* ca. NCI-H 146 Small cell lung v ; cancer/neuroendocrine ; 5g. 6 ; KU-812 Myelogenous leukemia 9. 9 i, NCl-f-1526_Small cell Itnag 59 5. 769-P Clear cell renal ca., 10. 3 3cancer/1leuroelldocrine i ; ; _____... __. w.g. _____. _... ___. cancer/iieLirociidocrine cancer/neuroendocDne"j j - ° ; 35. 6 Caki-2 Clear cell renal ca. rv, 122 ( cancer/neuroendocrine _... _ , NCI-H82 Small cell lung li6. 0 iSW 839 Clear cell renal ca. 7. 3 cancer/neuroendocrine NCI-H 157 Squamous cell lung '25. 0 cancer (metastasis) NCI-H1 155 Large cell lung ; . 2 ; Hs766T_Pancreatic ca. (LN J"21. 6 cancer/neuroendocrine ! J jmetastasis) ! NCI-H 1299 Large cell lung' ! CAPAN-1 Pancreatic cancer/neuroendocrine : !' ! adenocarcinoma (iiver metastasis) ! Pancreatic carcinoma fr-tu-7-T7T- L ! SU86. 86 Pancreatic carcinoma NCI-H727 Lung carcinoid ; 44. 4 .-22. 7 ; j j ()) ver metastasis) NCI UMC-11 Lung carcinoid'39. 5'axPC-3 Pancreatic adenocarcinom 11. 5 - _, ; _. _. w- LX-1 Small cell lung cancer i'l 7. 0 ;'HPAC Pancreatic adenocaircinoma 116. 0 CFPAC-I Pancreatic ductal i -i., adenocarclnoma KM 2 Colon cancer '40. 1 n ! CFPAC-1 Pancreatic ductal - ; ; adenocarcinoma ' 'CFPAC-I Pancreatic rectal KM20L2 Colon cancer 16. 5 15. 7 ; ductal ca. NCI-H716 Colon cancer ; 36. 6 T24 Bladder ca. (transitional cell) y9. 9 SW-48 Colon adenocarcinoma 2 0. 9 Bladder ca. 17. 8 ! SW) n6Co) onadenocarcinoma ! l0. 9 HTii97Biadderca."J27. 4 , UM-UC-3 Bladder ca. (transitional 4 iUM-UC-3 Bladder ca. (transitional -I ; cell) 6 : Cell) .....', . j.... . jceii)....................... ..... .... L................. SW-480 Colon adenocarcmoma ; 20. 6 ; HT-1080 Fibrosarcoma _ 7 : 0 (NCI-SNU-5 Gastric ca. _,,......, , ; 24. 1 ; MG-63 Osteosarcoma (bone)...., 6. 6 tNCI-SNU-5 Gastric ca. 24. 1 MG-63_0steosarcoma (bone) 6 6 KATO III-Stomach i100. 0 Klva) S -Leiomyosarcoma KATO 111 Stomach'llOO. O :.-618. 0 ....... _.. _. _. _.. _. _.... __.. _ _. _... __....... _. _... ___. __... __.. _ :. __. __.... _..... .'SJRH30 R21abdomyosarcoma (met 6i ; (vulva) ' ;..... to bone marrow) E........ _... _ _..... _. _ __.......... _........ _. _.. _... _..... _..... __. _....... _.. .. :... NCi-SNU-i Gastric ca. ï9. 5 A43 1 Epidermoid ca. t76. 8 RF-] Gastric adenocarcinoma. 16. 7.. WM266-4 Melanoma {13. 5 .......... _ 6-MDA-MB-468 Breast MKN-45 Gastncca. : 30. ! !,.-7. 0 "adenocarcinoma MKN-45 Gastric ca. 630. 1 ; !.-47. 0 - ;. adenocarcmoma NCI-N87 Gastric ca. l 2 SSC-4 Tongue 11. 2 _. _. _,. .... _. _ ____. _ _ _. .. ; SSC-9 Tongue.. 3 _..... _ OVCAR 5 Ovaran ca. 3. 6 ;. 7 RL95-2 Uterine carcinoma i615. 4', SSC-15 Tongue 28. 7 MKN-45 Gastric ca.. 130. 1 7. 0 ; CAL 27-Squamous cell ca. of HelaS3 Cervical adenocarcinoma'8. 2 10. 4 " tongue itonQLle Table AD. Panel 4. 1D ........... Rel ; 1 46Rel. Ret. j Ret. Ep. (%) Exp. (%) Tissue Name Ag6031, Tissue Name Ag6031, Run Run 225428031 1225428031 _.. _... __ ___ s__vwv ;.-........ 4 _ ...... m_... __... _, ". Seconda Thl act 7. 3 HUVEC IL lbeta 3. 8 Secondary Th2 act 3. 9'HUVEC IFN gamma 2. 1 Secondary Trl act rS. I HUVEC TNF alpha + IFN gamma i'-3 Secondar_ Trl act 5. 1 _ HUVEC T'NF al ha + IFN amma 1. 3 Secondary Th I rest HUVEC TNF alpha + IL4 5. 9 Secondary Th2 rest 6. 6 HUVEC IL-I 1 i0. 7 Secondary Trl rest 16 7 aLung Microvascular EC none 45. 1 iSecondary. Trlrest,..,. ___...... __. __-..... 6.- __... . _ : l. Lung Microvascular EC none-^-. LungMicrovascularECTNFalpha Primary Th 1 act 2. 8, 1. 4 + IL-1 beta Primary Th2 act i6. 5 Microvascular Dermal EC none 11. 3 . i o e Microvascu) ar Dermai EC Pr. _. .. v__ _.. ___ _... _. Microvascular Dermal EC Bronchiar epithelium TNFalpha + E Primary Th I rest 2. 6 ILlbeta j0. 6 ils becta Primary Th2 rest j7. 3 Small airway epithelium none J5. 1 small airway epithelium TNFalpha 5 + IL-I beta ! ' CD45RA CD4 coronary artery SMC rest 5i 1. 3 5'Coronarv artery SMC TNFalDlla + i51 < =-~ '''IL-lbeta j CD8) ymphocyteact J6. 0 Astrocytesrest H. 6 5Secondary CD8 Iymphocyte rest 16. 5'iAstrocytes TNFalpha + IL-1 beta. 1. 1 ___. ... _.--' = . J hilre t... _. __... _. y_ . _. Secondary CD8 Iymphocyte act 35. 0. KU-812 (Basophil) rest .......... CD4 lymphocyte none 01. 6 ,. A/---4 '' jPMA/tonomyon JKU-812 (Basophil) - 11. 0 CCDI 106 (Keratinocytes) none 18. 3 Cn i i !'} (Keratinocytes) _.... __. __. ___ 3 qTNFalpha + IL-I beta 5 CHI 1 1* 1 ßLAK cells 1L-2 7 3 XLiver cirrhosis ïO. O LAK cel Is IL-2+1L-12 6. 4 jNCI-H292 none I. 3 _______. __. _. __. ______, _. __.... _... __-__g-____...-___ __. _-. _______ ______. _ __. _______. : __.. ____. ___.... __. ___.. __ LAK cells IL-2+1FN amma 4. 4 NCI-H292 IL-4 , 1. 3 _ LAK cells IL-2+ TL-18 10. 2 aNCI-H292 IL-9 04. 5 LAK cells IL-2+IFN gamma 4. 4 INCI-H292 IL-4 1-1. 3 LAK cells PMA/ionomycin 3. 1 NCI-H292 IL-13 2. 1 l _ :. __ : ___. ___ : ___ : ;. _ _=_____ :. ____ ; ___. _ _. __. ___________. NU Cells IL-2 rest 9. 1 a ^ 2 8 TwoWayMLR3day y"'""JHPAECnone"0. 7 _. __ __ _., .. . _ _ _ _ _. _ __ _.. _ __. __ . ., _... _-- :. ___.. _.... Two Way MLR 7 day 2 5 Tung fibroblast none 00. 8 -1 bet a 09 Two PWM l4. 4, LungfibroblastIL-4 01. 0 PBMC PHA-L 5. 9 lLung fibroblast IL-9 j4. 3 ! beta, PBMC iq. ILLin- fibroblast IL-9 Ramos (B cell) none 19. 9 1 Lung fibroblast IL-13 12. 1 ... ___. __..... ___.. _.. ____.... __.. _. __.. __ >. _. _. _... _. _.. _.. : _... _. : :. _.. _... ___ ___... _.. _.. __ R. amos (Bce) i) ionomycin 0-6 ! Lungfibrob) ast IFN gamma j2. 9 B lyi-npliocytes PWM 15. 6 ideri-nal fibroblast CCD 1070 5 Dermal fibroblast CCD1070 TNF B ymphocytesCD40LandtL-4 3. 3,, 7. 5 a) pha j 4 lDermal fibroblast CCDI 070 IL-I ! beta beta EOL-IdbcAMP rt , r-.... M on EOL-1 dbcAMP 5. 1'idermal fibroblast IFN gamma 3. 9 PMA/ionomycin Dendritic cells none 13.] jDermal fibroblast IL-4 2. 4 Dendritic cells LPS 1. 5; Dermai Fibroblasts rest 1. 7 Dendritic cells anti-CD40 11. 4 eutrophifsTNFa+LPS 0. 0 Monocytes rest ^ 0. 8t 1. 0 Monocytes LPS'Colon li. o Macrophages rest Lung Macrophages LPS i, Thymus 20. 0 JHUVEC none 3. 6 Kidney 4100. 0 UVEC starvedZI3iZZII !"" !" Table AE. Panel 5 Islet tRel. 1 iRel. ', Exp. (%) Tissue Name XAg603,. Tissue Name ! Ag6031, :, Run J253578283 ! J253578283 J97457Patient-02goadipose 24. 8 J94709Donor 2 AM-Aadipose 63. 7 i 97476 Patient-07sk skeletal 0. 0 9471 0 Donor 2 AM-B adipose ; 22. 4 muscle 97477 Patient-07ut utens 16. 4'9471 1 Donor 2 AM-C adipose 23. 5 _ __-.. __., _. _. _. .. __, ___. _______ ___ _. _..-___. _. . 97478Patient-07pip) acenta 29. 9 ! 94712Donor 2 AD-Aadipose i) l00. 0 99167 BayerPatient I il 1. 4 94713 Donor2 AD-B adipose, 58. 6 97482Patient-08ututerus 0. 0 94714Donor 2 AD-Cadipose j81. 2 94742 Donor 3 U-A_Mesenchymal 97483 Patient-08p1-placenta 0. 0 ; Stem Cells 62. 4 -'-} jStemCe)) s ! 97486_Patient-09sk_skeletal 40 0'. 94743_Donor 3 U-B_Mesenchymal'18 9 muscle Stem Cells 97487 Patient-09ut uterus 57. 8 J94730Donor3AM-Aadipose ] 6. 8 _ : z. _., ; _ ___ : ; _. =. ; ;. _4= 4 : ;. ___ ; = ; ;. v__. _ :. ___. ; = : =. _. ;."; ;. ; __ __ __ _. ___ __ ____ _~ _ ___ __ ______. :. _ : _. :. ______ _ ; _. ==. ; _____. _ : ______J : =. __ :. muscle iStem Cells 97492 Patient-lOut uterus 2. 0 1, 94732 Donor3AM-C adipose 111. 0 97493 Patient-lOpl_placenta i36. 9, 94733 Donor 3 AD-A adipose 421. 2 97495 Patient-llgo adipose 38. 7 594734 Donor3AD-B adipose. 19. 1 97495 Patient-11 sk skeletal ° _Placenta muscle-- - ^ .. __..-., ; :. . _u. 97497Patient- ! lututerus i38. 7 i77) 38LiverHepG2untreated j28. 9 r,-.-. o r. tn)) *-. ni ! 73556 Heart Cardiac stromaice !) s' 97498 Pat) ent-Hp) p) acenta 30.) ""'0. 0 Muscle ___...... _... ___.. __. _. _. __.. _... _. __.. _-_.. _-___-. _. _. ___.. _. ^ 97500 Patient-12go adipose i23. 7 48i735 Small Intestille i46. 0 i97501 Patient-12sk skeletal g V 72409 Kidney_Proximal Convolute Imuscle, 1 ubule l, 497502 Patient-12ut uterus 12. 8 82685 Small intesthle Duodenum'11. 2 Adrenal Adrenocortical 97503 Patient- ! 2p) piacenta d). 7 j.-"7. 2 adenoma 9472] Donor 2 U-Ln !- ; m r-j ucr-c 01 94721_Donor2 U-l66 0-72410 Kidney HRCE'. 82. 4 A Mesenchymal Stem Cells 140. 6 1 Kidney HRE 17. 1 B Mesenchymal Stem Cells 94723 Donor 2 U- 4_6 T : 73139 Uterus Uterine smooth 94723_Donor 2 U-147 6 731 39_uterus_Uterine smooth-13 7 ? B Mesenchymal Stem Cells -...... __. ____. __.... .-. __.. _. _____ :...-_-____. r_. . ___.-__r CMesenchymaI Stem Ce)) s 'jmusc) e ce) ! s

General_screening_panel_vl. 5 Summary: Ag6031 Highest expression of this gene is detected in gastric cancer KATO III cell line (CT=28.9). Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, and fetal liver. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene is expressed at moderate to low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Oncology_cell_line_screening_panel_v3. 1 Summary: Ag6031 Highest levels of expression of this gene is detected in gastric cancer KATO III cell line (CT=31). This gene shows a widespread expression in this panel. Moderate to low levels of expression of this gene is seen in number of cell lines derived from tongue, breast, prostate, melanoma, epidermoid, bone, bone-marrow, vulva, bladder, pancreatic, renal, gastric, colon, lung, and brain cancers. Moderate to low levels of expression of this gene is also seen in Wilm's tumor, histiocytic lymphom, T cell and B cell lymphoma/leukemia, and Burkitt's lymphom. Therefore, expression of this gene may be used as diagnostic marker to detect

the presence of all these cancers and also, therapeutic modulation of this gene or its protein product may be useful in the treatment of these cancers.

Panel 4. 1D Summary: Ag6031 Highest expression of this gene is detected in kidney (CT=29. 1). This gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_vl. S and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

Panel 5 Islet Summary: Ag6031 Highest expression of this gene is detected in differentiated adipose tissue (CT=32.5). Moderate to low levels of expression of this gene is also seen in placenta, uterus, small intestine and kidney samples. Please see panel 1.5 for further discussion on the utility of this gene.

B. NOV3 CG137623-01 : 2310038H17RIK protein-like protein (TmSP).

Expression of gene CG137623-01 was assessed using the primer-probe set Ag4919, described in Table BA. Results of the RTQ-PCR runs are shown in Tables BB, BC and BD.

Table BA. Probe Name Ae4919 Start SEQ ..". * flstart SEQ Position ID No Forward 20 1 ! 322 70 Probe ; TET-5'-gatgcggccatcgttctttccac-3'-TAMRA 23 i358 71 .. _. <-cagctcccatctccaggtat-3'20 1211 72 Table BB. CNS neurodeeeneration vl. O

; Rel. Rel. Exp (%) Exp. (%) Tissue Name jAg4919, issue Name Gag4919, ' : Run'Run '224997650 AD 1 Hippo 18. 4 Control (Path) 3 Temporal Ctx i9. 6 AD 2 Hippo 18. 6 Control (Path) 4 Temporal Ctx 19. 6 _.. _....-. ppo. T _....... a. _..... _... W.. _,. ; 12 2 _..... T... 3 ! D.. .. Dccipital Ctx,. w ...... .. .. __ 14. 4 ___.. AD 3 Hippo D I Occipital Ctx AD 4 Hippo, 4. 1 AD 2 Occipital Ctxyssing),.. ADSjiippo J73 AD 3 Occipita ! Ctx j ! 5. 0 _ :-__ _. _ __. Control 2 Hippo ! 28. 9 AD 5 Occipital Ctx Control 4 Hippo 15. 4 AD 6 Occipital Ctx 133. 4 Control Hippo... jl P. . L Z'J-.. Control (Path) 3 Hippo v6. 3 A Control 1 Occipital Ctx 43 AD 1 Tempera) Ctx J ! 4. 4 Contro) 2 Occipita) Ctx ! 62. 4 AD 2 Tempera) Ctxj) 5 Contro) 3 Occipita) Ctx} l). 2" AD 2 Temporal Ctx u '15. 6 my Control 3 Occipital Ctx ''. l 1. 2 AD 4 Temporal Ctx =14. 8 Control (Path) 1 Occipital Ctx ; 100. 0 _ JAD 5 Inf Tempera) Ctx <'82. 4 ontroHPath) Tbcp) ta) Ctx"5. 8 ,.. ral 82. 4 Contr I Path 2 cc rtal tx ; 5. 8 AD 5 Inf Tem o C o O C. P AD 5 SupTemporal Ctx 39. 5 Control (Path) 3 Occipital Ctx *5. 2 AD 6 Inf Temporal Ctx 4. 0 Control (Path) 4 Occipital Ctx ; 155 AD 6 Sup Temporal Ctx Control I Parietal Ctx 6. 1 Control 1 Temporal ; 4. 8"... Control 2 Parietay.. C. _-.-25.'7. ___... _.. _. __. __.. ___ Control 2 Temporal Ctx 42. 9 Control 3 Parietal Ctx i : 9. 0 tr I Temporal tx v12. 4 Control Path) I Parietal A64. 2 Control 4 Temporal Ctx ; 10. 2 Control (Path) 2 Parietal Ctx '30. 6 Control (Path) 1 Temporal Ctx. ; 44. 8Y Control (Path) 3 Parieta) Ctx 4.) Control (Path) 2'Temporal Ctx : 24 75 i3 8. 7 Table BC. General screening panel v1. 4 xi Rel. ; ; Rel. Exp. (%) ; Exp. (%) Tissue Name Ag4919, Tissue Name Ag4919, Run brun 222456686 222456686 Adipose 5. ! JRenatcaTK-iO j70. 7 Melanoma* Hs688 (A). T 8. 2-Bladder 12. 5 Melanoma* Hs688 (B). TU 6. 6 Gastricca. (liver met.) NCI-N87 #95. 9 [ie a-noina* M 14 37. 6 Gast'c ca. KATO I11 ; 81. 8 Melanoma* LOXIMVI 24. 0'Colon ca. SW-948 16. 6 Melanoma*SK-MEL-5 32. 1 ; Colonca. SW480 ; 89. 5 Squamous ce !) carcinoma SCC-4 12. 2 ; Colon ca. * (SW480 met) SW620 146. 7 , . 1--4 |Prostate ca. * (bone met) PC-3 132 3 Colon ca. HCT-1 16 76. 8 Prostate Pool 7. 0'Coion ca. CaCo-2 468. 3 {Placenta 3. 7'Colon cancer tissue 13. 7 Uterus Pool 14. 2. Colon ca. SW 1116 4 1 2. 3 Ovarian ca. OVCAR-3 20. 7, Colon ca. Colo-205 412. 5 28. 9 jOvarianca. SKOV-3 ! 58. 2 Coionca. SW-48 18. 7 Fvarian ca. OVCAR-4 I28. 9'Colon Pool j11. 8 IOvarian ca. OVCAR-S 450. 7, Small lntestine Pool, 18. 4 iOvarian ca. IGROV-1 25. 0 Stomach Pool ' J 4. 6 Stomach Pool Ovarian ca. OVCAR-8 5. 3 Bone Marrow Pool 43, 5 tOvary 98. 2 Fetal Heart 414. 6 _. _... __ i, _, ___, >__ _, ____,... _. _ _,, _. __"" 'ovary lbreast ca-MCF-7 44. 4, Heart Pool Breastca. MDA-MB-231 23. 7 ! LymphNodePooi10. 7 r °,.. _....... __.. _ Zu _....... _____d...... _..... ___. 'Breast ca. T47D 77. 9 aSkeletal Muscle Pool 14. 5 .. __ : : __.-. ___... __. . _. : __. : :. ___... _-. __.. __. _. _. _.... ___ : _. ___. __. . ..-. :.. : _J t ----------- Cool Breast Pool : Thymus 22. 2 Trachea 12. 0'. CNS cancer (glio/astro) U87-MG 1170. 2 JLung 4. 9 ! CNS cancer (giio/astro) U-)) 8-MGJ100. 0 JFetaiLung] 4.] CNS cancer (neuron-net) SK-N-AS 59. 5 _ :. _ : _ : _ : __.. , : : _ :. : :. :. : : : : : : _ : :. ___ : : _, _ : __-_. , Lunb ca. NCI N417 12. 3 CNS cancer (astro) SF 539 25. 7 ILung ca. LX-1 _ 5. 1... cancer (astro) SNB-75. 23. 5 ILungca. LX-1 51 4 lCNS cancer (astro) SNB-75 423. 5 iLung ca NCI-H146 13. 4 : CNS cancer (glio) SNB-I9 114. 9 , Lung ca. NCI-H] 46 I cancer (glio) SNB-19 1114. 9 : ___.. _. _. _. __ vBram (Amyd7. __ _... _. _. _. ..-----12. 5 aa Pool...,." :..... : _ . _ : ___. _ :... :,. . . _ Lung ca. NCI-H526 I 1. 7 Brain (cerebellum) 17. 8 79. 6 ! CNS cancer (glio) SF-295 ! Lung ca. NCI-H23_ _.......... ... ..... _... 0_..... _. __. _. _xBrain (fetal). _. _. _.. .... _6. Lungca. NCl-H460 45 7 Bram (HippocampuS) Pool 6. 4 {Lung caHOP62 ! L. Lc fL. ... IZ. . HOP 62 14. 1. 0 Lungca. NCI-H522 95. 9 JBrain (Substantianigra) Poo) 8. 8 s ßLung ca NCI-H522 95 9 Bl ain (Substantia nigra ? Pool 38. 8 Liver 0. 9 lBrain (Thalamus) Pool Qlls. s . T_ :-___. .. :. . _.... _........ _. .. _ , ____-_. . _.. _. _ Feta) Liver 15. 1 brain (whole) 6. 0 Liver ca. HepG2 543 ; Spinal Cord Pool 15. 6 Liver 0. 9. "Brain (Thalamus) Pool 19. 5 Kidlley Pool _s Be3_ Z Ad, reell. al ; >G ; ; l-an= ; dw As= ! s Kidney Pool 14. 3 aAdrenal Gland S. 5 Fetal Kidney 7. 9 Pituitary gland Pool 7. 9 |Renal ca. 786-0 39. 0 ! SaiivaryG ! and ! 3. 4 tRenal ca. A498 22. 8 ÄThyroid (female) 19. 2 Renal ca. ACHN 31. 4 ; Pancreatic ca. CAPAN2 40. 9 {penaica. UO-3) 23. 3 ; PancreasPoo) ! 23. 0 fRenal ca. U0-3 1 X23. 3 5JPancreas Pooi Table BD. Panel 4. 1D 'Rel. 1, Rel. 'iExp. () lEXp. (%) Tissue Name |Ag4919, Tissue Name SAg4919, ! Run', Run 86 8 i223458648 Secondary Th 1 act'29 1 HUVEC IL-1 beta i 14 5 Secondary Th2 act 329 1 HUVEC IFN gamma. 48 2 SecondaryTrl act 20. 0 HUVEC TNF alpha+ IFN gamma. 5. 4 Secondary Th l rest i4 6 sHUVEC TNF alpha + IL4 l 13. 6 - _. __. : : _ _.. _ :.. m. _. :.. :. T_ _ : __ : _ : . : u. : :. _u_.. =. _ __.. _ : : _ _ : : :. :.. v : cm-_. __- > : : _ : : :.. _ : ____ : w_ : :. _ : _ : >z_. ____vc : : _- :.. _u-_u-. _' Secondary TI2 rest a 12. 8 HUVEC IL-1 I ; 6. 4 Secondary Trl rest X5. 0 Lung Microvascular EC none 1, 21. 2 llung Microvascular EC TNFalpha PrtmaryThlact 29. 7. Y,,. ! 3. 8 ' + ! L- ! beta Primary Th2 act 1, 46. 7 Microvascular Dermal EC none 112. 8 Primar Th2'act. _ 46. 7 Mcrovascular Dermal EC none _. 8, 1 liMicrovascular Dermal EC PrimaryTrl act 59. 9 0. 12. 1 TNFalpha + IL-I beta . ti.. 11, Bronchia) epithe) iumTNFa ! pha+ . Prlmary Th1 rest 1 1. 1 IlLlbeta Pri i-nary Tli I rest Primary Th2 rest J5. 4 jSma)) airway epithelium none small airway epithelium TNFalplla Å 3 + IL-1 beta + ! L- ! beta ! Primary Tri rest 14. 7 rcnr ! L !'n CoronaryarterySMCTNFaipha+-. CD45R0 CD4 lymphocyte act 33. 0 IL-1 beta 2. 5 TL-) beta iCD8 lymphocyte act ; 28. 7 strocytes rest. i 0. 9 Secondary CD8 Iymphocyte rest qi40] ßAstrocytes TNFalpha + IL-1 beta'2. 1 __... Secondary CD8 lymphocyte act ; 16. 0 U-812 (Basophil) rest ;, 33. KU-812 (Basophil) ; 3 PMA/ionomycin Si 4 PMA/tonomycm i 2ry Th 1/Th2/Trl anti-CD95 12. 8 CCD 1106 (Keratinocytes) none 10. 9 Cul 1. z . a , e . W.. .. _.... __, . r ___. _. . _.. _, CCD 1106 (Keratinocytes) E TNFalpha + IL-1 beta LAeiis IL-2". 0Liver cirrhosis 315 9 LAKce)) s ! Lj2+ ! L-] 2 19. 8"lNCI-H292none'28. 5 LAK cells 1L 2+IFN gamma ! 7. ! NCI-H292IL-4 J4Z. 3 LAKcellslL-2+1L-18 14. 7 gNCI-H2921L-9 444. 1 LAKcellsPMA/ionomycin 3518. 2 NCI-H292IL-13 411. 9 ! NKCe) tsIL-2rest ] 5. 3 NCI-H292IFN gamma 9. 8 iNK Cells IL-2 rest 315. 3 NCI-H292 IFN gamma j19. 8 NKC.... _. _ _.. _.... __..... _. _-.... ___... _. _. _... _... _.... _. . . _., _ :. _...... : _...... :. :. _.. _____... ____.. _ Two Way MLR day i 19. 6 IHPAEC none. 14. 0 TwoWayMLR5day \. ! 33. 2HPAECTNFa) pha+IL-) beta 46. 1 Two Way Ml, R 7 day 411. 8 35Lung fibroblast none j12. 3 ___ ______. __.. _... _. ____ __. __.. __. _ _ _. ______ Luog fibrobfast'1'NF alpha +.. IL_ ____j 5 J3 _ ibeta v broblast IL-4 i, 7 5 PBMC PHA-L. 146. 3 Lung fibroblast IL-9'15-2 Ramos (B cell) none'82. 9 Lung fibroblast IL-13 ; 6. 3 Ramos (B cell) ionomycin 00. 0 Lung fibroblast IFN gamma 15. 0 _-_ 1 :) 5. 1 Dermal fibroblast CCD1070 rest. 5. 8 Dermal fibroblast CCD 1070 TNF 1, ., Dermal fibroblast CCD1070 TNF J B Iymphocytes CD40L and IL-4 140. 6 alpha 415. 4 alpha . Dermal fibroblast CCD1070 IL-1 X4 5 EOL-1 dbcAMP 423 8 1, , beta. 4 EOL-1 dbcAMP e9. 2 iDermal fibroblastlFN gamma iS. 7 _. _ __-,--- Dendritic cells none i, 29. 9 aDermal fibroblast IL-4'14. 4 PMA/) onomyon ! Dendritic cells LPS 8. 7 Dermal Fibroblasts rest j5. 3 i26. °....... _-... __. _ ,. _ _ Dendritic cells anti-CD40 212 9 Neutrophils TNFa+LPS 117. 7 Monocytes rest 126. 4 Neutrophils rest Monocytes LPS 12. 2 Colon i4. 7 Dendritic ce) ! santi-CD40 12. 9 JNeutrophDs TNFa+LPS 7. 7 Monocytesrest 6. 4 Neutrophiisrest p. 6 MonocytesLPS h2. 2 Colon 7 Macrophages rest 1'30. 4 Lung' ! 7. 4 Macrophages LPS ts. o Thymus, 30, 4 {HUVEC none ] 2. 7 Kidney, 4t 13. 8 arved _

CNS neurodegeneration vl. O Summary: Ag4919 This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals.

However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

Genera ! screening pane ! vl. 4 Summary: Ag4919 Highest expression of this gene is detected in a brain cancer U-1 1 8-MG cell line (CT=31. 2). Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at low levels in pancreas thyroid, pituitary gland, skeletal muscle, fetal heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may

prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene is expressed at low levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Panel 4. 1D Summary: Ag4919 Highest expression of this gene is detected in ionomycin treated Ramos B cells (CT=32. 6). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by thymus.

This widespread expression pattern suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

C. NOV4 CG137687-01 : Cyclin (5730405I09RIK Homolog).

Expression of gene CG137687-01 was assessed using the primer-probe set Ag4926, described in Table CA. Results of the RTQ-PCR runs are shown in Tables CB, CC and CD.

Table CA. Probe Name Ag4926 c. ! r Start SET Primers Sequences No '° Position ! ID No Forward 5'-gctccttagcagatgacaacaa-3' : 22 843 73 _. . _.... _ _.. _ ..... _...... .. _......... _...... Probe TET-5'-cctgaattttctatttgctcctcttagca-3'-TAMRA', 29 865', 74 _. _. ___. _ : : :1-agcctct ggt : : _.. : :. :. y___ :. :..... :. ___W_..... ______.. _.. _....... _. _..,. __. __... _. _. __. __.. _......... _.,.... __... ___. _... :. _... _.. :.. _.. _.... ______... _.. _ : ;.. _. _. _......,. : " :. : ___.... __.. __ Reverse 5'-agcctctaggttctgtgctctt-3'22 898 ; 75 Table CB. CNS neurodegeneration v1.0

Rel. ! Exp. (%) lExp. (%) Tissue Name Ag4926, issue Name Ag4926, 'Run v224735007 i224735007 AD 1 Hippo Control (Path) 3 Temporal Ctx AD 2 Hippo Control (Path) 4 Temporal Ctx 32. 3 AD 3 Hippo 7 0 lAD I Occipital Ctx g18 4 AD 4 Occipital Ctx (Missing) 10 _. AD 5 Hippo'62. 0 AD 3 Occipital Ctx ', 8. 0 AD 6 Hippo-'. 56. 3 AD 4 Occipital Ctx g3 1. 0 AD 6 Hippo 56. 3 AD 4 Occipital Ctx I. o ". ,. v. . .... , ......,., 6, _ga... , p . :.- 2 6. _. _. __, :. : _. ,..... : __ iControl 4 Hippo, 16 8 AD 6 Occipital Ctx i26. 2 I . _ __. : : _ : :... __... _.. _.. _ AD I Temporal Ctx, 23. 2 Control 2 Occipital Ctx 134. 6 = H AD 2 Temporal Ctx 24. 7 Control 3 Occipital Ctx 417. 3 AD 3 Tempera) Ctx ! 7. 5 Contro) 4 Occipital Ctx-, 9. 0 mporal Ctx AD S Inf Temporal Ctx. 72. 7 Control (Path) 2 Occipital Ctx a __.......... _.. _..-_.-.-_ AD S Sup Temporal Ctx, 50. 0 Control (Path) 3 Occipital Ctx ! 5. 4 AD 6 Inf Temporal Ctx. 70. 2 Control (Path) 4 Occipital Ctx 12. 7 AD 6 Sup Temporal Ctx. 74. 7 Control 1 Parietal Ctx c12 0 Control 1 Temporal Ctx 10 4 ßControl 2 Parietal Ctx ; 12. 0 Control 2 Temporal Ctx'. 38. 2 lControl 3 Parietal Ctx', 16. 4 Control 2 Temporal Ctx : 38. 2 Control 3 Parietal Ctx 182 4 Co ol 3 T po. () lControl 3 Temporal Ctx. 11 0 Control (Path) 2 Parietal Ctx 28 3 3Control (Path) I Temporal Ctx. 75 8 Control (Path) 3 Parietal Ctx Ctx 75. 8 Control (Path) 3 Parietal Ctx, 31. 9 _. __.. wrw d.

Table CC. General screening panel v1. 5 Rez. Exp. (%) iExp. (%) Tissue Name Ag4926, issue Name 3, Ag4926, Run'Run 228839252 t j228839252 Adipose 30. 1 ll'Reiial ca. TK-10 187. 7 Adipose 30. 1 renal ca. TK-IO =X87. 7 Melanoma* Hs688 (A). T 32. 5 3Bladder s28. 1 Me) Hs688 (B). T 35. 6 Gastric ca. (liver met.) NCI-N87 70. 7 Melanoma* M14 33 9 Gastric ca KATO 111 XMelanoma* LÖXIMVI 436. 6'iColon ca. SW-948 J11. 2 iMelanoma* SK-MEL-5 47. 6 iColon ca. SW480 172. 2 Squamous ce) i carcinoma SCC-4 28.) ! Co) on ca. * (SW480 met) SW620 J2). 3 Testis Pool 18 8. Colon ca HT29 110. 8,, Prostate ca. * (bone met) PC 3"33. 7 ; Colon ca HCT-116 43. 2 Prostate Pool ! 7V "100. 0 Placenta 4. 8 Coioncancertissue j ! 6. 8 pUterus Pool 14. 5 43Colon ca. SW I 1 16 3. 7 Ovarian ca. OVCAR-3 36 Coion ca Coio-205 j"" 0 riva Ovarian OVCAR-445. 4 CoionPoo) !] 7. 8 _., w tOvarian ca. OVCAR-S a74. 7-Small lntestine Pool 19. 0 Evarian ca. IGROV-1 13. 4 iStomach Pool 438. 8 Ovarian ca. OVCAR-8 3. 5 one Marrow Pool ! 0. 2 jOvary 9. 1 jpetai Heart ! n. d Breast ca. MCF-7 31. 9 iHeart Pool 58. 1 jiBreastca. MDA-MB-23 ! i35. 4 JLymphodePooi J19. 9 Breastca BT 549 125. 7. Fetal Skeletal Muscle 7 4 Breast ca. T47D T49. 2'. Skeletal Muscle Pool 17. 9 ... _ Breast Poo) H. 1 ThymusPoot 9. 3 (Breast ca. MDA-N 14. 7. Breast .... . _.. ... ...... 1.,... 1. _.... _'Thymus Poo-y. _,.. ,... .,. _ ;.. _.......... _ : JTrachea16. 4 CNS cancer (glio/astro) U87-MG |50. 0 Ffrachea iLung 4. 9. CNS cancer (glio/astro) U-1 1 8-MG 179. 6 L_zzza=_ Fetal LUng 34. 2'CNS cancer (neuro ; met) SK-N-AS j3 1. 4 Lung ca. NCI-N417 T3. 5 sCNS cancer (astro) SF-539, 19. 1 Lung ca. LX-1 ji 8. 3 vCNS cancer (astro) SNB-75 34. 6 _.. __-_. __ __ __.......... _.. _..... ___. _ . _ ; _. __. _.. :.. Lung ca SHP-77 41. 8 jCNS cancer (glio) SF-295 J56 6 Lungca. A549 i63. 3 Brain (Amygda) a) Pooi ! 10. 3 ÌLungca NCI-H526, 1j6. 7.. Brain (cerebellum) 10. 6 ........ Lung ca. NCI-H460 itS7 8, Brahl (Hippocampus ? Pool 8 7 l g"... ...... ! iLung ca. HOP-62 15. 2'Cerebral Cortex Pool 13. 6 Lun ca. 52. 5 ' ; Brain Substantia nigra) Pool 10. 2 'Lung ca. NCI-H522 Liver 2. 5 ='Brain (Thalamus) Pool 15. 5 Fetal Liver 30. 6 Brain (whole)j20. 6 _. « _... _..... _. _ _ _. _. _ ........ . !........ _. . _. _. e _. _ _..... __, Liver ca. HepG2 48. 0 iSpinal Cord Pool jl2. 2 {Kidney Pool] 21. 6 iAdrenal Gland ij9. 9 Feta) Kidney 17. 9 jPituitary giand Poo) 2. 5 Renai Kidney ipituitary gland Pool Renal ca. A498 21. 6 ; Thyroid (female) 18. 8 Rena) ca. ACH 65. 5 Pancreatic caCAPAN2} 37. 9 Renal ca. UO-3 1 1j48. 0 Pancreas Pool'j l 8. 3 Table CD. Panel 4. 1D g rv Rel. 23, Rel. Ep. (%) JExp. (%) Tissue Name Ag4926, Tissue Name 3Ag4926, Run 1'Run 223598854 1 T223598854 Secondary Th) act] 2. 9HUVECIL-ibeta"T65°5 "" . _ lSecondaryTh2 act 13. 8, 1HUVEC iFN gamma 367. 8 Secondary Trl act 11. 5 HUVEC TNF alpha + IFN amma'48. 6T v Secondary Th I rest 4. 5. 4 3HUVEC TNF alpha + IL4 c403 Secondary'Fl12 rest I-IUVEC IL-I I i36. 9 Secondary Trl rest 6. 2 Lung Microvascular EC none, 84. 7 ) . _ _.. _... _.... v.,. Pr<maryTh) act 9. 3 . j. 1.. 48. 0 -' j j+IL-lbcta j Primary, Th2=act. , 20. 6 _ Microvascular, Dermal EC., none 52., 9 ary Th I act 9. 3 ;, 48. 0 ill+ IL-I beta ip, rrii-mmary,, T, h2 act 20. 6, I, Mi. crovascular Dermal EC none 152. 9 lar Dermal EC ' TNFatpha+IL-lbeta j y : 1L l beta ; Pr<maryTh) rest 5. 0 , it- 4. 0 -'. iIUbeta j IL-I beta _ r____.. __. ___. _ . _ __, _.. _....... _... ...... ...... _. _ ; ____ _....... _... __ _ __ 'Small airway epithelium TNFalpha' Primary Trl rest 10. 0 =, 26. 1 . .......... _....... __ _... _.... _. _. _. _........ _.... x _IL-1 beta ___... __. __ ; _.. _ _.. ___ _ _ ___. Primary Trl rest | 10. 0 Jsmall airway epithelium TNFalpha S26 1 ' ! + ! L- ! beta CD45R0 CD4 Iymphocyte act 414. 4 3Coronary artery SMC rest i26. 6 IL-1 beta, A v^a. _...... : CD8 ! ymphocyteact 6. ! Astrocytesrest it 7. 8 Secondary CD8 Iymphocyte rest 8. 6, 3Astrocytes TNFaipha + IL-lbeta. 17. 9 :....... _ : _ :..... _. _.... _......... :....... :.. _. : : :. : : _......... _.. :,......... _. _... Secondary CD8 iymphocyte act 3. 3 JKU-8j2 (Basophi)) rest i l 1. 5 CD4 iymphocyte none'6. 7 A/''i-0 PMA/ionomycm ; 2ry Thl/Th2/Trl anti-CD95 g. l CCD1106 (Keratinocytes) none 37. 6 CHI 1 CCD1106 (Keratinocytes) ! i ells rest 26. 8 49. 7 a + IL 1 beta .. _. . _. __ _. LAK cells IL-2 9. 1 Liver cirrhosis 6. 7 LAK cells IL-2+IL-12 @5. 7 jNCI-H292 none 17. 7 LAK cells IL-2+IFN gamma 10. 9_ INCI-H292 IL-4 57. 0 LAK cells 1L-2+ IL-18 112. 2 JNCI-H292 IL-9 357. 4 LAK cells PMA/ionomycin 32. 8 7NCI-H292 lL-13 52. 5 NK Cells IL-2 rest l l. O NCI-H292 IFN gamllla 27. 2 Two Way MLR 3 day 116. 3,} IPAEC none 162. 0 Two Way MLR 5 day 414 3 tcHPAEC TNF aipha + 1 beta 3100. 0 Two Way MLR 7 day 46. 7 JLung fibrobiast none ) 7. 4 __,., ,.. . _.. __.. ____. _. _ __ _-_ _____ __. ___. _... ______. _.... _______w _____. sLung fibroblast 1'NF alpha + IL-I PBMC rest 36 7 ; 313. 4 4 =, beta PBMC PWM ilung fibroblast IL-4 21. 8 PBMC PHA-L 10 Lung fibroblast IL-9 38. 4 Ramos (Beet)) none J29. 7 JLungfibrobiastJLSi ; 9...... Ramos (B ce) i) ionomycin 29. 3 ! Lung fibrobiast IFN gamma j 31. 0 B iymphocytes PWM"J Oermai nbrob ! atCCD1070 rest J 23. 7 B ly p yt pWM oblast CCD1070 rest 23. 7 B) ymphocytesCD40Land ! L-4 H. 7 25. 3 'a) pha j 'Dermal fibroblast CCD1070 IL-I B dbcAMP) 5. 0 21. 8 alpha EOL-1 dbcAMP 1115. 0 idermal fibroblast CCD1070 IL-1 21. 8 ', beta EOL-I dbcAMP Dendritic cells none 40. 3 ; Dermal fibroblast IL-4 78. 5 _.. : _____.. _____.., ___.. : ___ : : __. _, _. -. _.-... :. ___. : : _______ : : _.... : __.... __ : :... ______ : : __ : . : _ : : _-_ :. ___. :. : :.. :. __.. :. __ EOL-I dbcAMP 315. 0 fDermal fibroblastCCD1070 IL-I 21 8 q 3beta EOL-I dbcAMP 6 9. Dermal fibroblast IFN gamma |28. 5 PMA/ionomycin Dendritic cet) s LPS 43. 5 Derma) Fibrob) asts rest 21. 3 .. _..... Dendritic cells anti-CD40'41. 5 eutrophils TNFA+LPS 6. 9 __&_ ; v= ; m w s : __ ~w__ w _ ~ w*_m w___ _'e_w'~'~m_7= ___ Monocytesrest 22 1 tNeutrophilsrest 12. 2 _ __ a_ | u O'_ ww Monocytes LPS 446. 3 lColon 0. 0 Macrophages rest 336_6 iLung 20. 4 _-....... _....... i :.-..."_... ......... : __-.... _____. _. _. :..... _.... Macrophages LPS 30. 6 aThymus 24. 1 HUVEC none J61-6 HUVEC none.'43. 5 qKidney 461. 6 HUVEC starved J5). 6

CNS neurodegeneration v1. 0 Summary: Ag4926 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1. 5 for discussion of utility of this gene in the central nervous system.

General_screening_panel_vl. 5 Summary: Ag4926 Highest expression of this gene is seen in a colon cancer cell line (CT=26.7). This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

Among tissues with metabolic function, this gene is expressed at moderate levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that dysregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex.

Therefore, therapeutic modulation of the expression or function of this gene may be useful

in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

In addition, this gene is expressed at much higher levels in fetal lung and liver tissue (CTs=28.5) when compared to expression in the adult counterparts (CTs=32.5). Thus, expression of this gene may be used to differentiate between the fetal and adult source of these tissues.

Panel 4. 1D Summary: Ag4926 Highest expression of this gene is seen in HPAECst treated with TNF-a/ILl-b. This gene is also expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease.

These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in Generalscreeningpanelvl. 5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

D. NOV5 CG143198-01 : Nuclear protein-like protein.

Expression of gene CG143198-01 was assessed using the primer-probe set Ag7138, described in Table DA. Results of the RTQ-PCR runs are shown in Tables DB and DC.

Table DA. Probe Name Ag7138 Start 14 SEQ Primers fsequences < ; Position : ID No Forward ; 55'-caagactctgaagcagcagg-3'20 1 73 _ _ _.. TET-51-ttcgaaatttagatgctcagtatgaaatg-3'-TAMRA I I everse 5'-gtgtgggtttgtgatcttgc-3'i2o 1231, 78 Table DB. CNS neurodegeneration vl. O

!'Rel. Rel. Exp. (%) ! Exp. (%) Tissue Name Ag7138, tissue Name Ag7138, Run ! Run icontrol (Path 1AD 2 Hippo i24. 1 Control (Path) 4 Temporal Ctx 125. 0 IAD 3 Hippo'9. 5-, AD I Occipital Ctx 18. 3 AD 3 Hippo J9 : ; AD] QccipitaiCtx ! ! 8. 3 gAD 3 Hippo.'9. 5''AD 1 Occipital Ctx 18. 3 AD 4 Hippo'*"''"'""10. 6<AD26ccitarCtx (Missing) 0. 0 tfAD 5 Hippo 197, 9, AD3 Occipital Ctx 2, 8. 8 tAD 6 Hippo 1349. 7 if AD 4 Occipital Ctx l l. O 'Control 2 Occipital Ctx 147. 6 Control 4 Hippo. 11. 8 fAD 6 Occipital Ctx 34. 4 JCpntro) 4 Hippo""HI. 8 P.. J iAD I Tei-nporal Ctx i24. 7 lAD I Temporal Ctx'. 24. 7-fControl 2 Occipitai Ctx 27. 4 P t 5 'Control 4 Occipital Ctx 'fAD 3 Temporal Ctx'', 10. 1 Control 4 Occipital Ctx »'7. 8 __.. __ . . __. _..... _. _... __. _..- jAD 5 Inf Temporal Ctx ; 100. 0, ; Control. (Path) 2 Occipital Ctx 13. 4 ! AD 5 S. lp Temporal Ctx 355. 1 IControl (Path) 3 Occipital Ctx 43. 9 AD 6 Inf Temporal Ctx. 54. 7 sControl (Path) 4 Occipital Ctx'15. 4 s gh 'AD 6 SLIP Tei-nporal Ctx. 1'52. 5"Control I Parietal Ctx 17. 3 lcontrol I Temporal Ctx 6. 7 Control 2 Parietal Ctx g56. 3 ! Control 2 Temporal Ctx"25. 0. ; Control 3 Parietal Ctx 13. 3 , Control 3 Temporal Ctx,, gl6. 5 Control (Path) I Parietal Ctx i53. 2 jControl 3 Temporal Ctx 9. 5 fControl (Path) 2 Parietal Ctx f, 22. 2 iControl (Path) 1 Temporal Ctx Is45. 7 Control (Path) 3 Parietal Ctx j7. 2 'Control (Path) 1 Temporal VCtx v45. 7 : Control (Path) 3 Parietal Ct : c ; i7. 2 Contro) (Path) 2 Temporal Ctx : : 31. 9-'Control (Path) 4 Parietal C Table DC. Panel 4. 1D Rel. Rel. Rel. Rel. Exp. () Exp. (%) Tissue Name Ag7138, Tissue Name Ag7138, Run Run 283838272 4283838272 Secondary Th l act 55. 9 HUVEC IL-I beta 30. 4 Secondary Th2 act 100. 0 lHUVEC 1FN gamma 027. 5 Secondary Trl act 40. 1. HUVEC TNF alpha + IFN gamma ; 11. 7 rSecondary Th 1 rest 16. 0 tiHUVEC TNF alpha + IL4 1 1. 3 Secondary Th2 rest 8. 4 HUVEC IL-11 10. 4 Wndary Trl rest 7. 6 Lung Microvascular EC nolle 138. 7 Lung Microvascular EC TNFalpha 19 Primary Th 1 act 11. 3 i+IL-lbeta ' " ! +IL-beta j Primary Th2 act 453. 6 i, M icrovascuìaF Dermal ËC none 16. 2 ! Microvascular Dermal EC Primary Trl act 137. 1'9. 7 'TNFalpha + IL-I beta A lBronchial epithelium TNFalpha + 3 Primary Th I rest JA6 9. 5 ; IL I beta airway p thelum none Primary Th2 rest J4. 1 Small airway epithelium none ii6. 1 6. 1 t sSmal l airway epithelium TNFalpha 4 '+ IL-1 beta A l+ IL-lbeta Coronary artery SMC rest'A} 12. 9 Lr. T. L Lnn JCoronaryarterySMCTNFa) pha+ L- jCD45R0 CD4 lymphocyte act 49. 0 ; 173 ''' L- ! beta ! CD8) ymphocyteact 17. 6 JAstrocytesrest 11. 6 secondary CD8 Iymphocyte rest. 18. 2 JAstrocytes TNFalpha + IL-lbeta, iS. 6 Secondary CDS tymphocyte act . 5 jK. U-8) 2 (Basophi)) rest 27. 4 IKU-812 (Basophil) - _,--.. _ 3KU-812 (Basophil) ^ CD4 lymphocyte none 17. 3 1'13 8. 2 1 PMA/ionomycin Aw 2ryThl/Th2/Trl_anti-CD95 i10. 7 CCD1106 (Keratinocytes) none i, 26. 1 4-CCD1 106 (Keratinocytes) . < CCDI 106 (Keratinocytes) I ; LAK cells rest 13. 5 19. 8 TNFalpha + IL-1 beta iLAK celis IL-2 i20. 9 iLiver cirrhosis il3. 6 LAKceHs'fL-2+iL-] 2"""-"' I"'''''''8''''" LAK ce) ls IL-2+IL-12 2. 8'NCI-H292 none 30. 8 JLAKceiistL-2+IFN gamma U0. 5 NCJ-H292IL-4 p0. 6 LAK cells IL-2+ IL-18 , 7. 5 INCI-H292 IL-9 446. 0 pLAK cells PMA/ionomycin 51. 8 iNCI-H292 IL-13 iii45. 4 45. 7. rv NCI-H292 IFN gamma 24. 7 NK Cells IL-2 rest 145. 7 ! NCI-H292 IFN gamma 124. 7 , A _ = _ _,, _,, _ ___, __ : : ; :, =, _ :. : :. _ : : : :. :. ;. : _. ____. ___ : : : : ;. _= ; _ ;.,.,, =_. =.-'.-_ _'.' . a Two Way MLR S day » ; 15. 0 AHPAEC TNF alpha + IL-1 beta tu27, 7 lTwo Way MLR 7 day 12. 3'Lung fibroblast none ; 22. 4 AL Lung fibroblast TANF alpha + IL-I f I P B M C re st Å S. 6 Å ? ? | y 5 ? 1 beta, PBMC Way i13. 9,, Lung fibroblast IL-4 t12. 2 . _ _... : :. _ _.... _. PBMC PHA-L i22. 2 Lung fibroblast IL-9 Å 14. 0 . ILLIlIg fibroblast TNF alpha + IL-I tRamos (B cell) none til2. 2 ALUllg fibroblast IL-13 _ 13. 6 Ramos (B cell) ionomycin X, 40. 9 tLung fibroblast IFN gamma 132 5 . ___.. _. __.. __.. B Iymphocytes PWM 25. 0 IpermaJ HbroNast CCDI070 rest XA37 1 Dermal fibroblast CCD1070 TNF B ! ymphocytesCD40LandtL-4 44. !,. 63. 3 . .. ......-. Z,...... .... . L--- , ADermal fibroblast CCD1070 IL-I'A beta EOL-I dbcAMP 153. 2 iAbeta, 28. 5 EOL-1 dbcAMP'53. 2'28. 5 PMA/iollomvc i 11 s, AA Dendritic cells nolle A15, 0 jDermal fibroblast IL-4 S jDendritic ce)) s LPS 8. 5} Derma ! Fibrob) asts rest 20. 4 RDendl-itic cells anti-CD40 l6. 5 Neutrophils TNFa+LPS 6. 3 wMonocytes rest l8. 0 _Neutrophils rest test'22. 5 Monocytes LPS i38. 2 Colon 14. 0 , Macrophages rest 8. 7 Lung 2. 1 Macrop_. __g... . _. ___ :.-_... :,. _ :.. __. _.... ____ _... __. _. __hymus : : ___-. --_--...... _ _ .. 9 _.. ____ :.. __, __. _.. Macro ha es LPS 102 Th mus. 8 HUVEC none 28. 5 HUVEC starved a31. 4 3 __., ... _... _,. _. _..... , ,.. , 4... .. _.. ....,.. y.. .

CNS neurodegeneration v1. 0 Summary: Ag7138 This panel shows expression of this gene at moderate levels in the brain in an independent group of individuals. This gene appears to be slightly upregulated in the temporal cortex of Alzheimer's disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.

Panel 4. 1D Summary: Ag7138 Highest expression of this gene is seen in chronically activated Th2 cells (CT=30.4). This gene is also expressed at moderate to low levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

E. NOV8 CG145988-01 : Phosphatidylethanolamine-binding protein-like protein.

Expression of gene CG145988-01 was assessed using the primer-probe set Ag5948, described in Table EA.

Table EA. Probe Name As5948 start Primers Sequence'Length "jPosttton JD No Forward 5'-atgcgggtgaacctcagac-3'=19 145 ; 79 Probe TET-5'-tggagccttcaggaagt : ggacgaa-3'-TAMRA j24 ) 78'80 Probe , aggtgtagagtttcccta-31 F. NOV9 CG146452-01 : LRR domain containing protein.

Expression of gene CG 146452-01 was assessed using the primer-probe set Ag7055, described in Table FA. Results of the RTQ-PCR runs are shown in Table FB.

Table FA. Probe Name As7055 11 Start isEQ ,.-Start<. __ ; SEQ Pnmers Sequence Length. Tr j ° Posttton ID No _ _ _ __.... ____. _ _. _.. _. g. g_ _. _... _3 :. __.... _ °82 Probe tactccaagcgcttcgccgtcttc-3'-TAMRA Reverse 5 -ccttcatgctgcacctcat-3' ; 19 595 ; 84 tReverse 5 s-ccttcatgctgcacctcat-3', 19 595,, 84 Table FB. General screening panel v1. 6 Rel. S Rel. Exp. (%) ! Exp. (%) Tissue Name Ag7055, issue Name lAg7055, Run, JRun 282273880 1282273880 _.. _. e 0. 3 : Reiial ca. TK-10 4 Melanoma* Hs688 (B). T 5. 3 : Gastric ca. (liver met.) NCI-N87 29. 7 Melanoma* M14 8. 1. Gastric ca. KATO 111 227. 2 Me) anoma*LOXIMVI. O'TCo) onca. SW-948 J) 4. 7 Melanoma LOXIMVI 0. 7.. 7 Melanoma SK-MEL-5 1. 1 ; Colon ca. SW480 32. 5. Squamous cell carcinoma SCC-4 12. 1 Colon ca. * (SW480met) SW620 7. 1 Testis Pool--_.. _... ... . _. l..........- : _----Colon ca. HT29y... _, yrw : .. _ __t4, ., _14. 5.... _. - TestisPooi).) ! Co ! onca. HT29 h4. 5 Prostate ca. * (bone met) PC-3 5. 9 vColon ca. HCT-116 ; 47. 6 Prostate Pool 3. 0 Colon ca. CaCo-2 j 16. 3 Placenta 113 9, Colon cancertissue 0] 2. 6 Uterus Poo.. 0. 4_-_____-Colon ca. S W 1116-_^_.. __.. ___... __.. ______ 153-.. ... _ _ _... _. _. ___... _. _.. yColon ca. Colo-2p5......... _.. Ovarian ca. OVCAR-3 22. 5,'Colon ca. Colo-205 48. 4 Ovarian ca. SK-OV-3 45. 7 Colon ca. SW-48, 11. 0 Ovarian ca. OVCAR-4 22. 8. Colon Pool i1. 5 Ovarian ca. OVCAR-5 33. 2, _'Small Intestine Pool t1. 7 Ovarian ca. IGROV-1 33. 0 Stomach Pool, 2. 3 Ovarian ca. OVCAR-8 053. 2 iBone Marrow Pool t0 4 Ovary L3Fetaj Heart"0. 5 Ovarian ca. 32. 8) HeartPoo) 0. 4 fBreast ca. MDA-MB-23 1 31. 6, Lymph Node Pool', 1. 9 Breast ca. MCF-7 32. 8 Heart Pool 0. 4 Breastyca. MDA-MB-231 _. .. _.. _. 31. 6 _-___. _jymp Node Poo-_-. ___. ______. _.......... __,.. __. _.. . ... 9. _. __. _. _.. __. _ Breast ca. BT 549 1 Fetal Skeletal Muscle 11. 1 Breast ca. T47D 8., Skeletal Muscle Pool, 0. 0 't, Breast ca MDA-N 1, 11. 3, Spleen Pool, 0. 0 X Breast Pool, 1. 8 Thymus Pool, 4. 4 {Trachea r7 o, CNS cancer (giioiastro) U87-MG t100. 0 J z w Lung cancer (glio/astro) U-1 18-MG 10. 2 Fetal Lung 3. 1 iCNS cancer (neuro ; met) SK-N-AS 2. 0 _.. ___. ________. _."L_. _-_ ___, _. T-____. _____... _ Lung ca. NCI-N417 1. 4 lCNS cancer (astro) SF-539 17. 6 Lung ca. LX-1 11. 2 CNS cancer (astro) SNB-75 40. 9 Lung ca. NCI-H 146 1. 8 iCNS cancer (glio) SF-295 : :. ___.. _____. ____. __ : __. : : _.... . __ _______- _.. : :"_. __ ___. _.. g CNS cancer lo) Lung ca.-z44 11. 5 Brain (Amygdala) Pool Lungca NCI-H526 S cerebellum) vAL { Lung ca. NCI-H23 20. 9 ! Brain (fetal) i0, 0 1 __ _ _. _ t. _. _. _, ., . _. ..- Lung ca. HOP-62 6.] Cerebrai Cortex Poo) 1o. 6 Lung ca. HOP-62 6. 1 ECerebral Cortex. Pool, _____ 0,. 6,., , Lung ca. NCI-H522 10. 4'Brain (Substantia nigra) Pool 0. 0 -.. w F ' Thalamus Pov A 2 Fetal Liver 4_7 v aBrain (whole) 0_2 Fetal Liver 4. 7 lbrain (wliole) 0. 2 Liver ca. HepG2 11 4 S inal Cord P°°l _....... <1° 7------'--- y Adrenal Gland ___. r . 5. , _.-____. _ : _-. JFeta) Kidney 2.) jPituitarygtandPoo) 1. 7 Fetal Kidney 2. 1'ipituitary glaiid Pool 11. 7 XRenal ca. A498 120. 3. Thyroid (female), L3. 0 nal ca. 786-0 213 ; Salivary Gland ; 9. 2 _.. _. _. _ Renal ca. A498 , 1 203 Thyroid (female) 3. 0 21. 3 Salivary Gland _ __'' - 24 ; Pancreas Pool Renal, ca. UO 31''

General_screening_panel_vl. 6 Summary: Ag7055 Highest expression of this gene is seen in a brain cancer cell line (CT=30). This gene is widely expressed in the cancer cell lines on this panel, with moderate to low expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of cancer.

Among tissues with metabolic function, this gene is expressed at low but significant levels adrenal gland, pancreas, thyroid, and fetal liver. This expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that dysregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

G. NOV10 CG146731-01 : Membrane Binding protein-like protein.

Expression of gene CG 146731-01 was assessed using the primer-probe set Ag6046, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB and GC.

Table GA. Probe Name Ag6046

Start SEQ Primers Sequence Length Forward Position, ID No i_..... _ __.., _, _. . _ ____. _w__. _ _. _... -. _ _..., _-.... __ _ _. _. _. _... __. _.. _. . ___a__...... |Probe STET-5'-gatcctgaacccctgtgtgca > 186 IReverse 51-gaagtggttttcctccaagg-31 Table GB. General screening panel v1. 5 Rel.'Rel. Exp. (%) Tissue Name Ag6046, issue Name SAg6046, Run Run 228783203 4228783203 Adipose 9. 4 RnacaTK-10"-""---- Adipose 9 4 Renal ca. TK-1O 010 9 Melanoma* Hs688 (A). T 0. 0 Bladder 136. 1 Melanoma* Hs688 (B). T 0. 1 Gastric ca. (liver NCI-N87 445. 1 H w t--- Melanoma* M 14 j0. 0 Gastric ca. KATO 111 19. 2 jMe) anoma*'LOXIMVI""'" o""""""""'" Melanoma* LOXIMVI^ m 0_ 1 _ ^ ^^ _ N, _ Colon ca. KATO III Melanoma* SK-MEL 5 0 0 Colon ca SW480 ; 0 7 flsquamous cell carcinoma SCC-4 2. 3 lColon ca. * (SW480 rnet) SW620 Jl. o cris l>Cau _ _ 13. 7 gColon ca HT29, i29. 5 g Testis Pool 3 7 Colon ca. HT29 129. 5 _....-_... _. _.. _... _ Prostate Pool 417. 0 lColon ca. CaCo-2 139. 0 _...... _.. _____.. __* Prostate Pooi) 7. 0 Cobnca. CaCo-2 ! 39. 0 __....... _ _. .,.. __ ...... _ _.. __ .. _ ___. _.. _. . _. _ uterus Pool 18. 7 jColon ca. SW1116 1° ° Placenta 51. 1 Colon cancer tissue 293 0 Ovarian ca. OVCAR-3-L Co) on ca. Coio-205 - _ . _. _ : ovarian ca. SK-OV-3 03 Colon ca. SW 48 31 9 Ovarian ca. OVCAR-4 2. 4 Colon Pool w t15. 8 Ovarianca OVCAR-S 016. 7 iSmalllntestinePool 11. 4 Ovarian ca. OVCAR-4 2. 4 Colon Pool : 3, 15. 8 Ovanan ca. IGROV- 0. 4 Stomach Poo ! 13. 0" Ovarian ca. OVCAR-8 0. 6 Bone Marrow Pool 7. 6 . __, . . , " _........ _.. Ovary 4. 8 lFetal Heart 1. 0 Breast ca. MCF-7 47. 3 Heart Pool ; 8. 8 Breast ca. MDA-MB-231 4. 6 Lymph Node Pool 15. 7 Breast ca. BT 549 1. 1 Fetal Skeletal Muscle I. 3 iBreastca T47D j10. 7 lSkeletalMusclePool 017. 6 Breast ca. MDA-N Wi. o Spleen Pool 1. 1 {Breast Pool 48. 3 3Thymus Pool 017. 0 ITråcllea-~= =~ ! si-ls Trachea 5).) CNS cancer (giio/astro) U87-MG 0. ! Lung].) CNS cancer (g) io/astro) U- ! 18-MG 0. 6 'Fetal Lung 0. 5 CNS cancer (neuro ; met) SK-N-AS 0. 0 _.. _.. . w _.. _ . _ _ _ .. . _ J ILung ca. LX-i t5. 6 {CNS cancer (astro) SF-539 0. 0 'Lung ca. LX-1 5. 6 4 CNS cancer (astro) SNB-75 0. 2 L_ _. _ _ . 100 CNS g)- SNB-.. _. Lun ^ CI-H146 m. 0 N cancer lio SNB-19 1. S Lung ca. SHP-77 3J CNS cancer (glio) SF-295 0. 3 Lung ca. A549 0. 1 Brain (Amygda) a) Poo) 0. 3 Lung ca. NCI-H526 8. 5 Brain (cerebellum) 0. 7 Lung ca. NCI-H23 1. 7 Brain (fetal) ; 0. 5 Lungca. NCI-H460 3. 5 .. ...--. . Lung ca. HOP-62 0. 2 Cerebra) Cortex Pool X, 0. 2 (Substantia nigra) Pool : 0. 2 Lung ca. NCI-H522 0. 0 Liver 2. 7 Brain (Thalamus) Pool. 0. 3 ! Fetal Liver 10. Bramwho) e) . 4 LivercaHepG*2' !. 2 Spinal Cord Pool 0. 3 Kidney Pool 23. 0 Adrenal Gland 3. 8 Foetal Kidney 36. 1 Pituitary gland Pool Renal ca. 786-0 0. 0 Salivary Gland Renal ca. A498 Thyroid (female) Renal ca. ACHN 0. 2 Pancreat) cc'APAN2-- Renal ca. UO-31 0. 3 Pancreas Pool J25. 5 Table GC. Panel 4. 1D ! Rel. e 1. jEp. (%) ! Exp. (%) Tissue Name jAg60467', Tissue Name {Ag6046, Run Run ,, Run 1, Run l225160585 12-25160585 Secondary Th1 act io. 0 HUVEC IL-I beta Secondary Th2 act 0. 0 XHUVEC TFN gamma 10. 2 _. _.. _..... _ _.. __... _ _.... _. _ _ Secondary Trl act'0. 0 diHUVEC TNF alpha + IFN gamma in. 0 y mma zu xi Secondary Th 1 rest iO. 7 IHUVEC TNF alpha + IL4 i, o. o j y Th 0. 7 _, E 3 Secondary Th2 rest. 3 EC IL 11 1. 6 Secondary Trl rest 0. 0 Lung Microvascular EC none 1. 4 __. ___m _.. . _,., , jLung Microvascular EC TNFalpha y Primary Trl act 40. 0 40. 0 '+IL-] beta Primary Th I rest 10. 0 Bronchial epithelium TNFalpha + 4. 6 Primary Th2 act 0. 0 Microvascular Dermal EC none 0. 0 } lMicrovascular Dermal EC 'o. o I Primary Trl rest 1 2. 2 ' TNFatpha+IL-lbeta j PrimaryThl rest 0. 0 |ILlbeta 4. 6 Primary Th2 rest T0. 0 lSmall airway epithelium none 6. 0 ' : jILIbeta Primary Trl rest r0. 0 q+ IL-lbeta 2. 2 . ri.. n Smai) airway epithe) ium TNFa) pha-- PrtmaryTrlrest jO. O,,,.'' 2. 2 corona Y P Yt ,-..-..,-r. ,,-. .,,.. L.'CoronaryarterySMCTNFa) pha+,. ; ; IL-1 beta CD8 lymphocyte act 0. 0 lAstrocytes rest 0. 0 {, Secondary CD8 Iymphocyte rest 10. 0 §^Astrocytes TNFalpha + IL-1 beta qO O Secondary CD8 Iymphocyte act} 0. 0 i, KU-812 (Basophil) rest 335. 8 .,.""'",,' ! KU8) 2 (Basophi)) CD4 p. UA/ionomycin. 0 'PMA/lonomycin mi) j - 0. 0 iCCDI 106 (Keratinocytes) none 0. 5 LAK cells rest,,,-T-7 TNFalpha (IcLraltbnocytes) |2. 6 TNFaipha+tL-ibeta JLAKceHsJL-2 6. 0 jLiver cirrhosis i j6"' jLAK cells IL 2 0. 0 Lmer cirrhosis 15. 6 LAK cells IL-2+IL-12 0. 3. NCI-H292 none ^0. 13. 9 _... _...... :. _. :. : _, _., _...... ____ ___. : ___. _ : :.. _ _ :..... _____..... _. _... __ __. _. _.. __. __... :.. ____>.... : : __ : :. : :. : _ : __.. __. _. ___ LAK cells IL-2+IFN gamma 0. 0 'NCI-H292 IL-4 9. 6 L 18 . 8 NCI H292 IL-1-8. 6 LAK cells PMA/ionomycin 41. 4'; NCI-H292 IL-13 8. 6 __ NK Cells IL-2 rest 0. 0 IFN gamma 14. 9 Two Way MLR 3 day i0 jHPAEC none"'0. 3 |TWO Way MLR 5 day 1. 0 jHPAEC TNF alpha + IL-1 beta : 0. 2 Two Way MLR 7 day 0. 9', ! Lung fibroblast none l iLung fibroblast TNF alpha + IL-1 PBMC rest 0. 0 beta fPBMC PWM 0. 3 iLung fibroblast IL-4 2. 1 iPBMC PHA-L'0. 3 Lunb fibroblast IL-9 2. 0 iLLiiia fibroblast 12. 0 PBMC PHA-L '0 fB) ymphocytesPWM O. O Tpermai fibrobiast CCDI070 rest 0 f'Dermal fibroblast CCD1070 TNF B) ymphocytesCD40Land ! L-4 iO. O,, jO. O ''' ! jatpha EOL-1 dbcAMP lbeta 30. 2 L-1 dbcAMP w : iww°.., y. _.. _. ___. :..... _. _........ -.,..,..) 0. 0 ! Derma) fibrob) astiFN gamma]. 4 zu j) tDendritic cells none 30. 4. 3, Dermal fibroblast IL-4 i'0. 3 _ _ _ __ _--_. _ Dendritic cells LPS 0. 0 lDermal Fibroblasts rest 1. 3 Dendritic cells anti-CD40 3, 0. 0 lNeutrophils TNFa+LPS 0. 3 Monocytesrest 0. 0 Neutrophi) srest iO. 8 Monocytes rest 0. 0 Neutrophils rest 0. 8 Monocytes LPS 10. 5 3, Colon 312. 8 Macrophagesrest JO. 6 33Lung. 311 l Macrophages rest 0. 6 ! Lung 1. _ _. _...... _.. _....... _.. HUVEC none 0. 6 ikidiiey 100. 0 HUVEC starved 0

General_screening_panel_v1. 5 Summary: Ag6046 Highest expression of this gene is seen in a lung cancer cell line (CT=28. 7). Moderate levels of expression are also seen in ovarian and breast cancer cell lines relative to the expression in the normal tissue samples. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, heart, skeletal muscle, and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that dysregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene is expressed at much higher levels in heart and skeletal muscle (CTs=31-32) when compared to expression in their fetal counterpart (CTs=35).

Conversely, expression of this gene is much higher in fetal lung tissue (CT=32) when compared to expression in the adult counterpart (CT=35). Thus, expression of this gene may be used to differentiate between the fetal and adult sources of these tissues. In addition, the relative overexpression of this gene in fetal lung tissue suggests that the protein product may enhance lung growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung related diseases.

Panel 4. 1D Summary: Ag6046 Highest expression of this gene is seen in the kidney (CT=30), with low to moderate expression seen in LPS treated monocytes, untreated small airway epithelium, TNF-a/ILl-b treated bronchial epithelium, liver cirrhosis, treated and untreated samples from the KU-812 basophil cell line and the NCI-1-1292 mucoepidermoid cell line, and normal colon, lung and thymus. Thus, expression of this gene could be used to differentiate the kidney derived sample from other samples on this panel and as a marker of kidney tissue. In addition, therapeutic targeting of the expression or function of this gene may modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.

H. NOV12 CG147246-01 : Actin-Binding Protein Frabin-Alpha-like protein.

Expression of gene CG147246-01 was assessed using the primer-probe set Ag6047, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB, HC and HD.

Table HA. Probe Name Ag6047 .... I 1 : 1 . Position IID No ., a 1 n c o o Forward 5'-tcggaacacttcagcacaa-3 19 f. 1305 88 Probe TET-5'-ccttttcttattcaacaacatgttgctg-3'-TAMRA 28 : 1332__. '89 Reverse 5'-ctggatttgggcacacagta-3'20 a1360 9090 Table HB. CNS neurodegeneration vl. O _.., Rel _-_______ ____. _. ___.. .. ____- Re I '. Rel. 3 jRel. 1 Rel.] Rel. 'Exp. Tissue Name vAg6047 {issueName 3Ag6047, Run lRun J225249597 J225249597 _<_<___. __ : ___ pp____=__ _.. _... __ : :, _..... _........ -16. 8-_-__ Cont-.. __ (_____ : _ :. _-. p _. _. _... __ ontrol (Path) 3 Temporal Ctx AD 2 Hippo 16. 8 c 1. 3 AD 3 Hippo I 1. 7 AD I Occipital Ctx 428. 1 AD 3 H o tal C AD 3 Hippo 11. 7 AD 4 Hippo 1 H. 7 AD I Occipital Ctx (Missing) d10. 0 AD4Hippo"I)]. 7 AD 2 Occip) ta ! Ctx (M'ssing) JO. O AD 5 hippo j59. 9 AD36ccipitarCtx' AD 6 Hippo i73. 7 AD40ccipita ! Ctx LO AD 6 Hippo AD 4 Occipital Ctx i3 1. 0 ControlT2 Hippo_. _.. ___. ______. :.. v, : 3. :. 7.--....-.-AD, S Occipitai C-..... __. . y.. 46,. 7.""., _. _ AD 6 Hippo 73. 7 4AD 4 Occipital Ctx 131. 0 jControl (Path) 3 Hippo 1 1. 1 Control 1 Occiptal Ctx 6 7 AD) Tempera) Ctx ! 25. 7 CotTtroi 20ccipita) Ctx 334. 9 : _,- :.. _.. __.. __ :. :. _ : : x. : _ : _ _ _____ ; _ __ __ __ ____ _ __ _ __ ____ ~ ~ ___w_ _ _Y_ _ _ ___ __ _ _ ____ JAD 2 Tempera) Ctx ! 38. 4 Contro) 30ccipitaiCtx J) 9. 6 AD 3 Temporal _-Control 4 OccipitalCtx _-. , AD 3 Temporal Ctx''9. 0 Control 4 Occipital Ctx. 1 14. 8 AD 2 Temporal Ctx Control 3 Occipital Ctx 19. 6 AD 4 Temporal Ctx. 28. 1 Control (Path) 1 Occipital Ctx-Tloo. o AD 5 Inf Temporal Ctx Control (Path) 2 Occipital Ctx 113. 0 AD 5 SupTemporal Ctx 30. 4 Control (Path) 3 Occipital Ctx 15. 5 AD 6 Inf Temporal Ctx ; 6 1. 1'18. 6 AD 6 Sup Tempera ! Ctx ! 24. 3"JControNParietaiCtx 2.] Control ; Temporal Ctx. 7. 8 icontrol 2 Parietal Ctx 5. 1 Control 2 Temporal Ctx'27. 9 JControl 3 Parietal Ctx 412. 1 Contro) 3 Tempera) Ctx""M"8Contro) (Path) 1 Parieta ! Ctx J63. 3 Control I Temporal Ctx. 7. 8 lControl 2 Parietal Ctx 135. 1 60-1'2 Temporal Ct'7*. 9 Control (Path) 1 Temporal Ctx 14. 8 lcontrol (Path) I Parietal Ctx 11. 2 Control 3 Temporal Ctx, 14. 8 Control (Path) I Parietal Ctx ! 63. 3 Control 4 Temporal Ctx 114. 8 Control (Path) 2 Parietal Ctx 29. 9 Control (Path) I Temporal Ctx', 44. 1 Control (Path) 3 Parietal Ctx 1 1. 2 Control (Path) 2 Temporal Ctx 5. 2 Control (Path) 4 Parietal Ctx 47. 0

Table HC. General screening panel v1. 5 XRel. i IRel. lEXP-(%) J jExp. (%) Tissue Name Ag6047,. issue Name Ag6047, Run.. tRun 228783233 4228783233 Adipose 449. 7'. Renal ca. TK-IO 131. 2 Melanoma* Hs688 (A). T 72. 4', Bladder í71. 2 Meianoma Hs688 (Bf"""iS"JGastric ca. (liver met) NCI-N87 100. 0 Me) M 14 114. 9 : Gastric ca. KATO III 63. 7 Me) anoma* LpXIMVJ J08". JCoion ca. SW948 J9.] [. Me) anoma*SKMEL5'J63. 3 Squamous cell carcinoma SCC-4 3. 7 ! Colon ca. * (SW480 met) SW620 414. 4 Testis Pool 36. 6 Testis Colon ca. HT29 124. 1 Prostate ca. * (bone met) PC-3 3. 3 Colon ca. HCT-1 6" 20. 6 Prostate Pool 27. 7 icolon ca. CaCo-2 50. 7 Placenta Placenta 7'Colon cancer tissue 52. 9 Uterus Pool !"---JCotoncsLSWni6) . 5 Ovarian ca. JCo'oncaCofo-2p5... . 6 Ovarian ca. SK-OV-3 80. 7 Colon ca. SW-48 --- Ovarian ca. OVCAR-4 )]. 3 iCotonPoo)]] 4. 0 ---------- Ovarian ca. OIVCAR,-51 29. 5 iSmall Intestine Pool Ovarian ca. IGROV-I 26. 8 Stomach Pool 115. 1 Ovarian ca. OVCAR-8 4. 0 4Bone Marrow Pool . 18. 0 Ovary 23. 3'"JFetai Heart------j- 14. 4 Breast ca. MCF-7.) 4. 4 ! HeartPooi 0. 7" Breast ca. MDA-MB-23] 7. 5"* iLymphNodelpool2 Breast ca. BT 549"JCL2 Feta) Skektat Muscie 24. 0 Breast ca. T47D : : Skeletal Muscle Pool 166*9 kB Breast ca. MDA-N 10. 8 SpieenPoo)'*'""TTi Breast Pool 14. 6 JThymusPooi 3. 0 Trachea 24. 7.'CNS cancer (glio/astro) U87-MG 40. 0 Lung j 18. 9 sCNS cancer (glio/astro) U87-MG 10. 0 Lung 73. 2 jCNS cancer (neuro ; met) SK.-N-ASi'] 0. 4 ---------------- LungcLX---jy-'. -.-..-..-....-...... Lungca. NC !-H ! 46 23. 7 CNS cancer (astro) SNB-i9'" 442. 0 Lung ca. LX-1 28. 7' : CNS cancer (astro) SNB-75 115. 0 Lung ca.-i41-1 : 4 Lung ca"SHP-77"'T'"'"" ! CNSancer7gHo) SF-295-jy Lungca. A549 9. 5 ! ! Brain (Amygda) a) Poo) 28. 7 Lunga.'NCllH526""j"---"'jgjj--- == Lung ca. NCI-H526 9. 9 ; Bra'ln (cerebellum) 19. 9 Lung ca. NCI-H23 07. 2. Brain (fetal) f65. 5 Lungca. NCI-H460 25. 7 Brain (Hippocampus) Pool 32. 3 Lung ca. HOP-62 17. 7' ; Cerebral Cortex Pool 35. 4 Lung ca. NCI-H522 t14. 3 JBrain (Substantia nigra) Poo7 25. 0 Liver.... iBrain (Tha) amus) Poo)"-- ver 7. 2 Feta) Liver]). 4 Brain (whoie) 7. 2 Liver ca. HepG2 116. 7 Spinal Cord Pool 26. 4 Kidney Pool 117. 6' ; Adrenal Gland Fetal Kidney ipitultary gland Pool 114. 2 Renal ca. 786-0 140. 1 4, Salivary Gland Rena) ca. A498 7. 8 (Thyroid (female) 46. 4 3Renal ca. ACHN 149. 0 Pancreatic ca. CAPAN2 50. 0 J ca. U r, y WL __ v m RenaLca. UO J29. 9""r"°PJ I] Table HD. Panel 4. 1D Rel. w Rel. Et)- (%) Exp. (%) Tissue Name Ag6047, Tissue Name Ag6047, Run Run 225160587 225160587 isecoiidary Th I act 0. 0 ii-luVEC IL-l beta 363 Secondary Th2 act 0. 4'AFIUVEC IFN gamma 26. 4 Secondary Trl act ; 0. 4 HUVEC TNF alpha + IFN gamma 11 7 ) SecondaryTh'] rest JTo"JVECFphaJ24.] {Secondary Th2rest'"'". -..-..--j..---. -- iSecondaryTrirest JO. O jLungMicrovascutarECnone ! 26. ! Lung Microvascular EC TNFalpha ; Primary Th 1 act, 0. 0, 5 5 '} + ! L- ! beta Primary Th2 act} 0. 0 Microvascuiar Derma) EC none ! 22. 1 ! Microvascular Dermal EC ct io. o 1 2. 9 'j ! TNFa) pha+ ! L-) beta Primary Trl act i0. 0 pcrovascular Dermal EC PrimaryThl rest 0. 0'Bronchialepithelium'INFalpha+_. 20. 3 'Primary Th I rest : 10. 0 120. 3 ,"Primary Th2 rest 10. 2 jSmaii airway epithelium none y ; 12. 2 small airway epithelium TNFalpha, 23. 5 ; Primary Trl rest i0. 6 ; + IL-1 beta ; ,. =CD45RA CD4 lymphocyte act 1. 7 aCoronary artery SMC rest 5. 0 ___Inary artery SMC. rest CD45ROCD4iymphocyteact, 0. 4 T tt ! iL*tbeta CD8) ymphocyteact 0. 6 ! Astrocytesrest 5. 0 lymphocyte act 0. 6 Astrocytes rest i5. 0 ,......,. __.... : __...... ___... :. : _. _.... _.. _... __. _.. __..... __..... : _.. __. ___.. _.. _.. y. __. _. : _ :. : : _..... _......... _.. _.... _... _. _ : __... _. _.. :.... :.... .. : __ : ___.. _....... _. _. _ _ __.... _. _..... :... _ {Secondary CDS tymphocyte act h. 9 jKU-8t2 (Basophi)) rest J5. 3 _. __..... _. _. KU_812 (Basoph, p-.. «. KU-812 (Bas opliil) PMA/ionomycin } 2ryTh)/Th2/Tr ! anti-CD95., ir,...'""""""" !-"" 1CH I 1 E CCD1106 (Keratinocytes) CCD] 106 (Keratiiiocytes,' none 1180 LAK cells IL-2 0. 0 Liveracirrhosis i26. 4 LAr, cells rest 27. 4 3. 5 TNFal pha + IL-I beta LAK cells IL-2 0. 0 Liver cirrliosis LAK cells IL-2+IL-12 10. 2 NCI-H292 none LAK cells 1L-2+ FN gamma 0. 8 NCI-H292 IL-4. 3 LAK cells 1L-2+ IL-18 0. 0 NCI-H292 IL-9_ _ 25. 3 LAK cells PMA/ionomycin 13. 3 NCI-H292 IL-13 22. 5 NKCetfs ! L-2rest . NC !-H292) FN gamma'5. 9 jfwoWayMLR3day 3. 0 HPAECnone j) 2. 8 Two Way MLR 5 day J9J HPAEC TNF'a) pha + Hbetaj8 jTwoWayMLR7day 2. 1 Lung fibrobiast none j] 3. 2 . _-____. _. ___ _. _. -ILun-fibi-oblastTNFalplia+] L-1 PBMC rest 10. 1 : 9. 3 . beta i PWM 0. 0 Lung fibroblast IL-4'18. 1 PBMCPHA-L . PBMC PHA-L * 1. 4 lLung fibroblast IL-9 q 14. 9 Ramos (B cell) none 125. 5 Lung fibroblast IL-13 5. 2 Ramos (B cell) íonomycin t26. 1 {Lung fibroblast IFN gamma 110. 2 |B Iymphocytes PWM 40. 2 3Dermal fibroblast CCD1070 rest 6. 3 Y P Yt _ fibro_ V _.... a X Dermal fibroblast CCD 1070 TNF alpha Dermal fibroblast CCD 1070 IL-I EOL-) dbcAMP 0. 9. 7. 9 beta 4 beta EOL-I dbcAMP J0. 2'tDermal fibroblast IFN gamma t7. 1 PMA/ionomycin Dendritic cells none Dermal fibroblast IL-4 7. 6 F7. 6 Dendritic cells LPS 47. 5 tDermal Fibroblasts rest i7. 7 Dendritic cells anti-CD40 454. 7 jNeutrophils TNFa+LPS S100. 0 Monocytesrest 59. 0 Neutrophi) srest p8. 7 10... 4 Colo Monocytes LPS-410. 4 Colon 412. 6 Macrophages rest 75. 3 Lung 419. 9 Macrophages rest. 3 ung ligg _ __. _.. __. y_.. __ _. _ _. HUVEC none i24. 3 qKidney J33. 7 L HUVECtarved""""6. 3 '''""'---y--j 46. 3 z

CNS neurodegeneration v1. 0 Summary: Ag6047 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile confirms the expression of this gene at moderate levels in the brain. Please see Panel 1.5 for discussion of utility of this gene in the central nervous system.

Genera ! screeningpanetvl. 5 Summary: Ag6047 Highest expression of this gene is seen in a gastric cancer cell line (CT=27.4). This gene is widely expressed in this panel, with moderate expression seen in brain, colon, gastric, lung, breast, ovarian, and melanoma cancer cell lines. This expression profile suggests a role for this gene product in cell survival and proliferation. Modulation of this gene product may be useful in the treatment of these cancers.

Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic function and that dysregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

This gene is also expressed at moderate levels in the CNS, including the hippocampus, thalamus, substantia nigra, amygdala, cerebellum and cerebral cortex.

Therefore, therapeutic modulation of the expression or function of this gene may be useful

in the treatment of neurologic disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

Panel 4. 1D Summary: Ag6047 Highest expression of this gene is seen in TNFa/LPS treated neutrophils (CT=28.4). Moderate levels of expression are also seen in many cell types, including LAK cells, monocytes, macrophages, dendritic cells, keratinocytes, lung epithelium, lung and skin endothelium, lung and dermal fibroblasts, HPAECs, HUVECs, and treated and untreated samples from the NCI-H292 mucoepidermoid cell line. The neutrophil expression is reduced in resting neutrophils, suggesting that the protein encoded by this gene is produced by activated neutrophils but not by resting neutrophils. Thus, expression of this gene could be used to differentiate between resting and activated neutrophils. In addition, modulation of the expression or function of this gene may be useful in the treatment of symptoms in patients with Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis.

I. NOV13 CG147651-01 : Actin Related Protein 2/3 Complex protein-like protein.

Expression of gene CG147651-01 was assessed using the primer-probe set Ag5949, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB and IC.

Table IA. Probe Name Ag5949 __ Q |Primers rSequence L th jStart-SEQ i.... _...... _........ v _....... _. _.. ;....... ' !"Position ID No 120 91 Probe TET-5'-cat : gggagccagcgagt : gaaagct :-3'-TAMRA 24) 69 L'92 _.......... _......... Reverse 5'-tgatatgtccattg< : gctcact : gag-3' ! 25 99 ! 93 Reverse 5'-tgatatgtccattgtgctcactgag-3'25 l] 99 d93 Table IB. CNS neurodegeneration v1. 0 Rel. l Rel. jExp. (%) l Exp. (%) Tissue Name jAgS949, i, issue Name Ag5949, 3Run, Run Run i247854400 247854400 ........ |AD 2 Hippo. l20. 3. Control (Path) 4 Telllporal Ctx 40. 0 p 'pp ,'.,. ; 20. 3 ; Control (Path) 4 Temporal CtY.. 0. 0 AD 2 Hi o ßAD 4 Hippo io. o jAD 2 Occipital Ctx (Missing) ai0. 0 1AD 5 hippo i43. 5 ; AD 3 Occipital Ctx J, 0. 0 [AD 6 Hippo45 JAD40ccipitaCtx U3. 2 rAD 6 Hippo 145 4, AD 4 Occipital Ctx ... , 45. 4. . .. ___.. _w'. 2 Control 2 Hippo AD 5 Occipital Ctx 0. 0 0 Control 4 Hippo 13. 6 iAD 6 Occipital Ctx S 15. 5 Contro) 4 Hippo j ! -.''' j " Control (Path) 3 Hippo i0. 0 iControl I Occipital Ctx 30 0 AD 1 Temporal Ctx 424. 5 jlEControl 2 Occipital Ctx j25. 3 AD 2 Temporal Ctx, 0 Control 3 Occipital Ctx 0 0 AD 3 Temporal Ctx 12. 9 _'Control 4 Occipital Ctx AD 4 Temporal Ctx. 9. 1 Control (Path) I Occipital Ctx 138. 2 _.... _... _......... _ ; -,.. _, _. _..... _-.... _ AD 5 Inf Temporal Ctx J 100. 0 : Control (Path) 2 Occipital Ctx 0. 0 AD 5 SupTemporal Ctx i42. 3 (Path) 3 Occipital Ctx d0. 0 AD6InfTempora) Ctx jO. O iContro) (Path) 4 Occipita) Ctx ! 43. 5 " AD 6 Inf Temporal Ctx ;,,. 0.. ; ntrol,., Path 4 Occi ital Ctx . 5 AD 6 Sup Temporal Ctx 63. 3 33Control I Parietal Ctx-s0. 0 Control 1 Temporal Ctx 0. 0,, Control 2 Parietal Ctx j 13. 8 ............. _. _......... ^ ; i Control 3 Temporal Ctx 0. 0 y () ietal Ctac 403 Control 4 Temporal Ctx : 0. 0 __----____. _. _. _______.. __.. ____. _-______ _ __... _.. _. _, "-__.. _,. __ 0. 0 Control (Path) I Temporal Ctx 17. 4'Control (Path) 3 Parietal Ctx 30. 0 _. _... _ ~=_,... _. _.,,. _.,,........ __... _ ___....,, t Control (Path) 2 Temporal Ctx. 45. 4 iControl (Path) 4 Parietal Ctx 115. 1 Table IC. Panel 4. 1D 3Rel. X 3Rel. Ep. (%) Exp. (%) Tissue Name rAg5949, 3Tissue Name Ag5949, rRun 3 SRun 850160 i247850160 .....--------- SecondaryThI act 30. 0 jHUVEC IL-Ibeta 30. 0 Secondary T112 act o. o 1HUVEC IFN gamma ...... :. T _ _. Secondary Th2 HUVEC IFN gamma ", . _. ary. . ________.. _........ :, yHUVEC TNF alpha + IFN gamma _ _____. _.. _.. .. _.. _____ . 0 . 0 Secon"...... _... _.. Trl act v. u ____ .. T'^. T _-______. ___ -__ YJY _.. Secondary Th I rest 10. 0 HUVEC TNF alpha + IL4 0. 0 1+ IL-I beta Secondary Th2 rest HUVEC =,, ;, O., _.... _.,............. =..,. _ =, =,,...''"=,, ; _. : ; _ ; ;. _ _ _,. _ _...... _............ _ _ _.. Secondary Th2 rest 0. 0 XUVEC IL-I I t42. 0 __t wt Secondary Trl rest 10. 0 Lung Microvascular EC none 96. 6 Primary Thl act lO. 0 ILung Mbecrovascular EC T'NFalpha _... __. 1. 4-r Dermal EC . 3 Microvascular Dermal EC 0 ' ! +IL-) beta j Microvascular Dermal EC Primary Trl act 0. 0 0. 0 TNFalpha + IL-I beta ,, _ -' TNFa ! phaj-IL- ! beta Primary Th I rest 0. 0 Bronchial epithelium TNFalpha'+ Primary Th) rest 0. 0,.,.' 0. 0 ILlbeta beta 3 3Small airway epithelium TNFalpha 3 Primary^Trl rest 0. 0 Small airway epithelium TNFalpha a, 0 i + IL-1 beta.. _....... . -' i+IL-ibeta CD45RA CD4 Iymphocyte act 0. 0 Coronary artery SMC rest 63. 3 CD45RA CD4 lymphocyte act 0. 0 ! Coronary artery SMC rest j iCoronary artery SMC TNFalpha + CD45RO CD4 lymphocyte act 10. 0 1 24. 1 IIL-I beta 8 1 m hoc e act . 0 SecondaryCD8Iymphocyterest 0. 0 3iAstrocytesTNFalpha+lL-lbeta 0. 0 . __. _. _. : ____ Y-_ _. ___, ____. ________. __. Secondary CD8 lymphocyte act 0. 0 tKU-812 (Basophil) rest 0. 0 1, KU-812 (Basophil) CD4 lymphocyte none. 0. 0 0. 0 iPMA/ionomycin _ ; _a_-. _ _. _. _ 2ryThl/Th2/Trl_anti-CD95. 0 |CCDll06 (Keratinocytes) none 100. 0 C11 CCD1106 (Keratinocytes) LAK cells rest 0. 0's 29. 3 jTNFatpha+IL-lbeta . I I I..---I , LAK cells IL-2. 10. 0 ii'Liver cirrhosis'o. o _.,"",,,,..........., _ W _ _ _"_ 1 _ = _ c e IIs IL-2+IL-1 2 IN Cl-H 2 9 2n o ne 0. 0 LAKceHsIL-2+IFN gamma ! 0. 0 NC !-H292 ! L-4 17. 7 LAKcellsIL-2+1L-18 l0. 0 ANCI-H2921L-9 416. 6 __... _. _ _... :... _..,. ___.... _ :. _.. ___.. ___ : ... :....... __... H292 IL __ FLAK cells PMA/ionomycin. 0. 0 ! NCI-H292 IL-13 38. 7 liK Eeiis IL-2 rest. 0. 0 ! NCI-H292 IFN gamma. 0 ITwo Way MLR 3 day 0. 0 I ! HPAEC none. 0. 0 1 Y Y ___w. Y Y ...... -. _....... Y.. _.... _ _.... _ _ _.. _. .. _ _ _-0 HPAE p 77. 9 lTwo Way MLR 5 day 10. 0 aHPAEC TNF alpha + IL-I beta 177. 9 ... _.. Two Way MLR 7 day J0. 0 4. Lung fibroblast none t23. 8 , beta ! PBMC o.. p betag.. broblast TNF alpha + IL-1 0. 0 . _.-. __...... _____... ____.. _.. __... __.... _...... __.. __. _. _____..... _.... __r.... __________..... ..".. ___. __". _____.... _. _... ________. _. __,. _ {. PBMC PWM j0. 0 Lullg fibroblast IL-4 l0 0 ! PBMC PWM __-_. ___, . .... _..,... _...,. _ _. . _-_--.. . _ e. __. _ ,. S I - 0. 0 Lun fibroblast IL-9 24. 5 PBM PHA E C Ramos (B cell) none 0. 0'Lung fibroblast IL-13 0. 0 _. __..- : =...., ",. , .,. _. _, Ramos (Bce))) ionomycin 0. 0 iLungftbrob) ast ! FN gamma 74. 2 fi. iDermal fibroblast CCD1070 TNF fibroblast CCD1070 TNF v _-____..,. IB ymphocytesCD40LandIL-4 0. 0 !,, 27. 9 yawl ha 4alpha EOL-] dbcAMP 0. 0,.. 0. 0 r _. __ lbeta SEOL-I dbcAMP l0. 0. Dermal fibroblast IFN gamma 112. 2 PMA/ionomycin ; 0"_ __=, _ 0 0 s ; _ L __ : =.. _.. _ =. _ __. = L. : L aww ____w__ nY : _ ___ Dendritic cells none 40. 0 flDermal fibroblast IL-4 41. 2 Dendritic cells LPS 0. 0 idermal Fibroblasts rest 0. 0 rmal Dendritic cells anti-CD40 20. 0 tNeutrophils TNFa+LPS 0. 0 Monocytes rest 0. 0 lNeutrophils rest 0. 0 Monocytes LPS 0. 0 ßColon 0. 0 Macrophagesrest 0. 0 jLung 0. 0 , _,. __. .. _. _ _. R .. . __ , _ ..,.. s... a. _.--. HUVEC none y 35. 6 HUVEC4starved yy : 27. 9, . _ . y."y rcy., , .., .. . « x.. . .. _.... _.... _....... 14UVEC starved'127. 9

CNS neurodegeneration v1. 0 Summary: Ag5949 This panel does not show differential expression of this gene in Alzheimer's disease. However, this profile shows this gene to be expressed at low levels in the brain. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurological disorders,

such as Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, stroke and epilepsy.

Panel 4. 1D Summary: Ag5949 Expression in this panel is restricted to untreated lung microvascular endothelial cells, IFN gamma treated lung fibroblasts, untreated keratinocytes, untreated coronary artery smooth muscle cells, and TNF-a/IL1-b treated HPAECs. Thus, this gene product may be involved in inflammatory conditions of the lung, including asthma, allergy, emphysema, and COPD.

J. NOV14 CG149303-01 : Hepatocellular Carcinoma Autoantigen-Like protein.

Expression of gene CG 149303-01 was assessed using the primer-probe set Ag5631, described in Table JA. Results of the RTQ-PCR runs are shown in Tables JB, JC and JD.

Table JA. Probe Name Ag5631 _. _. _.. _. ___. _... _. .. __.. wy. _.. . ..... .. .. .. .. . a_. ... , my, n........ r.. _. _.. _.. __... ....... _. ........ _x.. x.... ..... ",. w. a : : : startu'SEQ 'Pnmers Sequence iLensth .... i-,.- : s ÏForward 45'-tgccagtgctgagatagagatt-3'422 [1006 94 .-_.. ______ -. _ » Probe TET-5'-attttcaaaggcctcacgcagcttct-3-TAMRA 26 1032 J95 JReverse 5'-ccgaagt : gggt : attaacagt : ca-3' j22 ! l065 : 96 Table JB. CNS neurodegeneration v1. 0 ! y ; Rel. Rel. Exp (%) Exp (%) Tissue Name: Ag5631,'issue Name Ag5631, Run Run 5246956912 246956912 Ad Hippo 17. 5., Control (Path) 3 Temporal Ctx 6. 7 Control (Path) 4 Temporal Ctx JAD 4 Hippo i. AD 2 Occipital Ctx (Missi2gL t D 5 Hippo ; 31. 0 'AD^3TOccipital Ctxyv 0. 0 f ! AD 5 Hippo 1AD 6 Hippo ; 37. 6... ..... _.... _.. _. .. _. _ _. _.. ! ptal Ctx _. _... _ lControl 2 Hippo.. _. ^... T. _ __. _. __ _____--fi62 AD S Occipital Ctx 27-.--.. __ _ _ : rad ., ... _ ! Control (Patli) Hippo 0. 0 ; Control I Occipital Ctx 12. 9 ! AD I Temporal Ctx i26. 2 2 Occipital Ctx 1'63. 7 RAD 2 Temporal Ctx i40. 9'. Control 3 Occipital Ctx ; 186. 5 jAD 3 Temporal Ctx 7. 0'pital Ctx ^. 6 ! AD 4 Tempora) Ctx b). 6 JContro) (Path)) Occipita) Ctx 42. 0 RAD 5 Inf Temporal Ctx 149. 7' ; Control (Path) 2 Occipital Ctx 31. 6 AD 5 Sup Temporal Ctx 25. 0 J : Control (Path) 3 Occipital Ctx 10. 0 jAD 6 lnf Temporal Ctx ; 463 Control (Path) 4 Occipital Ctx 18. 7 HSup Temporal Ctx, 88. 3 Control I Parietal Ctx 8 Control. 1 Temporal Ctx ;] 5. 3 control 2 Parietal Ctx 35. 6 Control 2 Temporal Ctx 134. 6'. Control 3 Control 3 Temporal tx jcontrol (Path) I Parietal Control 3 Temporal Ctx i29. 7 i4 a O, Control (Path) 1 Temporal Ctx 4'66. 9 iControl (Path) 3 Parietal Ctx ^ 0. 0 Control (Path) I Temporal Ctx. 66. 9_. Control (Path) 3 Parietal Ctx. 0 0 Control (Path) 2 Temporal Ctx I. 8 'Control (Path) 4 Parietal Ctx 69.

Table JC. General screening panel v1. 5 ReL""Rei. Exp. (%) lExp. (%) Tissue Name Ag5631, issue Name Ag5631, Run IRun 3|245240923 i245240923 Adipose 36. 9 Renal ca. TK- s4. 6 Bladder 38. 7 I. Melan. oma* Hs688 (A). T ,,,,,. __ _. _ ___. _ =_,......,.,,,.,,.,., __. _, _.... Melanoma* Hs688 (B). T. 4 |Gastric ca. (liver met.) NCI-N87 l8. 6 Melanoma* M 4 20. 2 Gastric ca. KATO 111. 316. 6 _. _____. _ __ _ _... _ _ _ _. _ _ _ _. _.. _. _ _ __ _ _ _ __ n__ -4 iMelanoma* LOXIMVI 57. 0 ajColon ca. SW-948.'46. 3 IMelanoma* SK-MEL-5 88. 9 3colon ca. SW480 3 7 Squamous cell carcinoma SCC-4 116 7 3Colon ca. * (SW480 met) SW620 MTestis Pool S _ IrColon ca. HT29 34o 6 3Prostate ca. * (bone met) PC-3 119. 2 SColon ca. HCT-I 16.'19. 5 Prostate Pool s58. 6 Colon ca. CaCo-2 416. 0 Prostate Pool 58. 6 Colon ca. CaCo-2 y16. 0 Placenta 38. 2 |Colon cancer tissue'29. 9 __ : ______ :., :. __.... .... _ Uterus Pool 31 1. 4 Colon ca. SW 1 1 16. 3j l 0. 9 _ _-_..-_........ .. _........ __ __ : _. ____, _ _ Ovarian ca. OVCAR-3 8.) Colon ca. Coio-205 . 7 Ovarian ca. SK-OV-3 63. 3 Colon ca. SW-48 39. 9 Ovarian ca. SK-OV-') _163..') iColon ca.. §W-48'19. 9 _.. _. _ : _... _ : __... _ : _ _... _.... _. _. _. :.. __.... _.. Ovarian ca. OVCAR-4 11. 7 Colon Pool 377 9 Ovarian ca. OVCAR-5} 3. 4 Small Intestine Pool i81 2 Ovarian ca. IGROV- ! 100. 0 Stomach Pool 18. 6 Ovarian ca. OVCAR_8-. 'T T-47. 0-... __-< Bone Marrow Pool.... yl_.] _-__... Ovary 20. 3 Feta) Heart''76'"'""' Breast ca. MCF-7 6. 9 Heart Pool 22. 1 Breast ca. MDA-MB-231 14. 1 Lymph Node Pool 1 1. l Breast ca. BT 549 _. _.. _.. __. _. _......... _... _... _.. _... et __.. _.. .... __ : :-_. ____. _. ______, "_. _... _ : _. __. :.. ____.. ;. __. _. __.. _.. _. _. _ _ X _ awr Breast ca. T47D ~ Skeletal Muscle Pool 428. 9 reastca. MDA-N 3i70. 7 |Spleen Pool 175. 8 31 reast Pool 42 6 Thymus Pool #0. 0 Breast Poo) 2. 6 yR'-'sJPooi 0. 0 B reast Poo l-__.. ___.... ___.... _ _. __. _. __... _.. _. __.. _ _. ___. __.. m.. _ ! ? ? u s Poo l _,.,-y_ ^., T. y. _-. .. _ Lung i46 D 1CNS cancer (glio/astro) U-118-MG «'10. 4 : ».. _., . : __.... _ __....... _... _. _. __.. __.. __. e_... _... _.,. ___...... __.. _.. _. _. __........ ___........ _.. __.. _.......... __. _. ___. _. _. ___.. _.... __. _. _ _.. _. _ _. __.... __ :.. __. _ _... Lung 46. 3 CNS cancer (glio/astro) U-1 18-MG : 10. 4 ! Feta) Lung 8. 7 JCNS cancer (neuro ; met) _ N AS tS67 8 3Lin1gcci NCI-N437 188 CNS cancer (astro) SF-539 -- ILLliig Lungca. LX-1 15. 6 ICNS cancer (astro) SNB-75 21. 9 Lungca. NCI-H146 114. 6 XCNScancer (glio) SNB-I9 49. 0 Lungca. SHP-77 j3. 3 lCNS cancer (glio) _SF-295_... _... _ :.. __.. ___. _... 8. 9,.. 9 {Lungca. A549 6. 3 Brain (Amygdala) Pool i66. 9 Lung ca. A549 6^3 _Brain (Amygdala) Pool 366. 9 Lungca. A549 6. 3 Brain (Amygdata) Foot 66. 9 Lung ca. NCI-H526 2. 2 Brain (cerebellum)'32. 1 Lung ca. NCl-H23 6. 2 Brain (fetal) j23. 3 Lung ca. NCI-H460 7. 0 Brain (Hippocampus) Pool g 12. 3 Lung ca. HOP-62 6. 8 Cerebral Cortex Pool 465. 5 Lungca. NCI-H522 50 Brain (Substantianigra) Poo) 5. 2 Liver 4 Brain (Thatamus) Poo) 4. 5 Fetal Lmer n X. _. __ Fetal Liver 17. 6 Brain (whole) 310. 4 . = _................................, =_ _......... =. _ _ _,................................. _ Liverca. HepG2 11 l 5 pSpinal Cord Pool ; 5. 9 : _. :. :.. :... :.. _....... : _... _.. _..... _____.. ___...... _.. __.... __. _... __. ;.. _, :....., _ : : : :. : : : :. _.. _ :, <__. : _. _. _., :.. __. __ : _. : : : :. :.. _ : _ Renal ca. 786-0 20. 9 Salivary Gland 37. 1 f ------------- 3Renal ca. 786-0 420. 9 Salivary Gland 437. 1 Renal ca. A498 J20. 4 Thyroid (female) ¢ 1. 8 Renal ca. ACHN 2. 7 Pancreatic ca. CAPAN2 64. 2 ; Rena ( ca. UO-3 I 4. 3 Pancreas Poot'7. 7 __.. : F..... :..... _, :. __.,.

Table JD. Panel 4. 1D rez. : ex. (%) Tissue Name Ag5631, tissue Name jAg5631, Brun ! Run j 246490837 J246490837 Secondary Th) act 24. 7 jHUVECIL-lbeta' ! 8. 3""*" Secondary Th2act'' Secondary fr) act"5'HUVEC TNF aipha + ! FN gamma 7. 5 SecondaryTh'rrestJOO"HUVEC'TtprmJO -... _. _. . , __........ __ _..... _ . __......... __.L. .... _ Secondary TrI rest ! o. O LungMicrovascuiarECnone : 46. 0 0. 0 Secondar Th2 rest 0. 0 _........ PnmaryThtact 0. 0, mL !-4 -', +IL-lbeta j Primary Th2 act 34. 6 Microvascu ! ar Derma) EC none p. O + IL-I beta Primary Th act L-0. 0 Lung Microvascular EC TNFalpha _4 I rii-nary Th2 act 26. 6 T. t. m) L O'O imicrovasctilar Dermal Ex TNFalpha + IL-1 beta . .. t.. nn BronchiatepitheiiumTNFa) pha+,,, PnmaryThIrest 0. 0,,,. ') 4. 5 -' LIbeta Primary Th2 rest 0. 0 small airway epithelium none 112. 6 ! Si-nall airnvay epithelium TNFalpha lprimary Trl rest 3. 4... 23. 2 ! +IL- ! beta IL-I beta L-'rcnrt oo'Coronary artery SMCTNFatpha+, ,, CD45R0 CD4 lymphocyte act'88. 3 ; IL-1 beta CD8iymphocyteact ; 0. 0 Astrocytesrest JO. O jSeeondaryCDS iymphocyterest ] 6. 0 AstrocytesTNFaipha+ ! L-) beta j]. 2 Secondary CD8 lymphocyte act iO. OKU-812 (Basophi)) rest31. 4 j'JKU8 ! 2 (Basophit)". : m CD4iymphocytenone : 0. 0 LA,'603 '.. jPMA/) onomyc) n 2ry Thi/Tli2/Trl-anti-CD95-iPMA/ionomycin I ,.'-9. 8 CCD]) 06 (Keratmocytes) none) 2. l <n if i j ....,, !, CCD ! ! 06 (Keratinocytes).----. LAKcettsrest 12. 6-,-.,.',.,, U5. 0 ! TNFaipha+ ! L-) beta j LAKceifsIL-2 2. 8 Livercirrhosis 4. 8 . .. "'j"""""" 6. 9"""" iNCI-H292 IL 18. 2 LA. K. c. elis IL-2+IFN gamma 4. 0-4 LAKceHs) L-2+tL- ! 8 ! 3. 4 ! NC !-H292 ! L-9 35. !""" LAKceiisPMA/ionomycin] 24. 0" {NCi-H292IL- ! 3 n. 8 NKCe !) sIL-2rest --- ipN gamma] Q. 5 Two Way MLRYay7. 9 JHPAEC none J7. 9 T7 TwoWayMLR5ay'"J jHPAECTNFatpha+IL-fbet ! l8. 7 Two Way MLR 7 day ] 53 Lung fibrob) ast [none p2. 2 ---] Lung fibroblast TNF alplia + IL-1 PBMC rest 10. 0 16. 7 l'becta PBMC PM .. . . .. ... .. .. ...-...... . ....... , IPBMC PFIA-L 7. 4 ILuiig fibroblast IL-9 1. 8 Ramos (Beet !) none} 3. 0 LungbrobtastfL-) 3 J4. 5 Ramos (B cell) ioiioi-n 22. 8 Ramos (B ce))) ionomycin ! 22. 8 ! Lung fibrobiast) FN gamma 8. 4 BtymphocytesPWM )). 8 Deri-nal fibroblast CCD 1070 rest 129. 5 , Dermal fibroblast CCD 1070 TNF BiymphocytesCD40L and ! L-4 ! 54. 0 ion. o alpha Dermal fibroblast CCD] 070 IL-1 '''j jatpha ibeta EOL'AMP) 29'5JDermanHa E' ! s-9 bermaifbrob ! ast ! FN gamma 4. 9 jPMA/tonomycm J ° Dendritic ce) ts none 2. 6 Dermal fibroblast IL-4 57. 4 Deiidritic cells LPS 10. 0 Dermal Fibroblasts rest 12. 7 Dendritic cef) s anti-CD40 0. 0 NeutrophHs TNPa+LPS ! -2 Monocytes rest. 6 Neutrophils rest 149. 0 Monocytes LPS ! 52. !........... Co'on jfO. O Yt 5. 2. 1 Coloil Macrophagesrest 5. 1 Lung 0. 0 ! MacrophagesLPS ! 3. 7 Thyms HUVEC none. 19 'y.""J23" HUVECstarved j] jU) HmT"" I J

CNS_neurodegeneration_v1.0 Summary : Ag5631 Low expression of this gene is seen in temporal cortex of a control patient (CT=34. 7). Therefore, therapeutic modulation of this gene may be useful in treatment of neurological disorders.

General_screening_panel_v1. 5 Summary : Ag5631 Highest expression of this gene is detected in ovarian cancer IGROV-1 cell line (CT=32. 8). Moderate to low levels of

expression of this gene is also seen in number of cancer cell lines derived from pancreatic, colon, ovarian, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, colon, ovarian, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at moderate to low levels in adipose, adrenal gland, skeletal muscle, fetal heart, and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene is expressed at low levels in amygdala, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Panel 4. 1D Summary: Ag5631 Highest expression of this gene is detected in TNF alpha treated dermal fibroblasts (CT=33. 3). Low levels of expression of this gene is also seen in IL-4 activated dermal fibroblasts, resting neutrophils, basophils, lung microvascular endothelial cells, LPS activated monocytes, CD40L and IL-4 activated B lymphocytes, resting IL-2 treated NK cells, activated primary and secondary Th2 cells and activated memory T cells (CD45RO CD4 lymphocyte). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

K. NOV15 CG149312-01 : Hematopoietic stem/progenitor cells protein MDS029-Like protein.

Expression of gene CG149312-01 was assessed using the primer-probe set Ag5846, described in Table KA.

Table KA. Probe Name Ag5846 M imers ilength Position'ID No torvard 45'-atgggtCtcacacaaaacaca-3 i2] 0260 7 , 21 iProbe rTET-5-tgtcccacgttgactccagtctcttc-3'-TAMRA << pReverse 335'-ctccagtctcttcgttgtgttt-3'522 3274 ;, 99 .. w. k. _ _ _.... __.... ___, _y ,. _.. . __. ____x.. __.. _. __.,. _.... _,..... ____. _...... _. _ __ J. :. __ L __ _ _ _. _. _ _ X_, _.,., _ _

L. NOV16 CG150951-02: TRAP-delta protein-like protein.

Expression of gene CG150951-02 was assessed using the primer-probe set Ag6940, described in Table LA. Results of the RTQ-PCR runs are shown in Table LB. Please note that this sequence represents a full-length physical clone.

Table LA. Probe Name Ag6940 ""art SEQ ! tart SEQ Primers l xLength ! Primers Length Position ID No Forward j5'-gagatctccctgacat : gcaa-3' 2013) 5 jYoO Probe XTET-5'-ctccaggacacctggaccctgttc-3'-TAMRA 24 3335 1101 | '39 9J J Reverse 5-ctcgtcgaagaatctaacctcatag-3 25 389 1] 02 g Table LB. General screening panel v1. 6 Rel. lRel. I Exp. (%) jeep. (%) Tissue Name Ag6940, issue Name Run Run 278700428 l278700428 .......... _. 2 ; 278700428 Adipose 0. 0 {Renal ca. TK-10, 2. 6 Melanoma* Hs688 (A). T 1. 5 Bladder Melanoma* anoma*Hs688 (A). T !. 5 Btadder ; 3.) Melanoma* M14 6. 3 Gastric ca. KATO III i29. 9 _ w. __.... _. Melanoma* LOXIMVI 9. 7 _ _ t c 7 Meianoma* SK-MEL-5'"0. 8 Co) on ca. SW480 133. 4" 7 Melanoma* SK-MEL-5 t0. 8 Colon ca. SW480"33. 4 Colon ca. * Testis Pool.... V... 0. 0 C°lon ca. HT29 ; 6. 2 Prostate ca. * (bone met) PC-3 7. 0 Colon ca. HT29 16. 2 Prostate Poo) 0. 0 Co) onca. CaCo-2"""------'- Prostate Pool 0. 0 Colon ca. CaCo-2 8. 1 Prõståte ca Uterus Pool y ry2. 9olon ca SW1116 0. 8 y Prostate Pool 0. 0 XColon ca. CaCo-2, 8. 1 Placenta 0. 0 Colon cancer tissue 0. 0 0. 0 t olon 30. 0 Uterus Pool 42. 9 lColon ca. SW1116 3, 0. 8 Ovarian ca. OVCAR-3 10. 6 ZColon ca. Colo-205 7, 0. 0 Ovarian ca. SK-OV-3 9. 7 Colon ca. SW-48 30 0 Ovarian ca. OVCAR-4 7. 3 Colon Pool j0. 0 Ovarian ca. OVCAR-5 0. 0 Small Intestine Pool, 0. 0 Ovarian ca. IGROV-1 6. 6 _tStomach Pool, 7, 0. 0 Ovarian ca. OVCAR-8 0. 0 Bone Marrow Pool, 2. 0 _. ^_ : _, : ___. __-.-. ; ___-_. _. __.. _. _ __ Ovary 0. 0 Fetal Heart I0. 0 _ __ _ _ _. _ ! _. __. _ _. _. _ E.,.. v _ 2___ 6 _., _ ______. @7.. _. _ Breast ca. MCF-7 i14. 1 Heart Pool jO. O , Breast ca. MDA-MB-23 1 8 2 Lymph Node Pool, 1 2 i _w_ 2 Breast ca. BT 549 Fetal Skeleta I Muscle 10. 0 Breast ca. T47D 10. 0 SSkeletal Muscle Pool 4, 2. 1 0 S s ; Breast ca. MDA-N 14. 4 Spleen Pool j0. 0 Breast Pool 0. 0 Thymus Pool 4. 0 Trachea 0. 0 CNS cancer (glio/astro) U87-MG 18. 2 Lung 0. 0 CNS cancer (glio/astro) U-118-MG 8. 4 _ r _ _ er. ..,..... . Fetal Lung 0. 0 CNS cancer (neuro ; met) SK-N-AS 0. 0 Lungca. NCI-N417 1jl9 5 CNS cancer (astro) SF-539 t 8. 3 Lung ca. LX-1 0. 0 CNS cancer (astro) SNB-75 5") _... . _g.... ... _...... __... _, : _......... _..... __... _.... :....... ... (g..)... _-... :. Lung ca NCI-H146 9. 9 CNS cancer (glio) SNB-19 3. 0 Lung ca. SHP-77'Mj5CNS cancer (giio) SF-295 0. 0" Lung ca. SHP-77 | 14. 6 CNS cancer (glio) SF-295 00. 0 g Lung ca A549 Brain (Amygdala) Pool a0. 0 Lung ca. NCI-H526 6. 8 Brain (cerebellum) i0 0 Lung ca. NCI-H526 6. 8 Brain (cerebellum) 0. 0 , J... Lungca. NC !-H460 0. 0 Brain (Hippocampus) Poo)"JO. O Lungca. HOP-62 0. 0 Cerebral Cortex Pool 00. 0 Lung ca. NCI-H522 0. 0 Brain (Substantia nigra) Pool. 10. 0 Lungca CI-H522 ryBrain (Substantianig) 0. 0 Liver 0. 0 Brain (Thalamus) Pool 0. 0 lFetal Liver ljO. 0 TBrain (whole) 0. 0 Liver ca. HepG2 iio 0 Spinal Cord Pool 10. 0 Liver. ca.. HepG2_.... _....... _...... __........ ....... iSp ! nal Cord Pool _.......... _..... Fetal Liver 0. 0 Brain (whole) 0. 0 Fetal Kidney d0. 8 Pituitary gland Pool 0. 0 Fetal Kidney ",--IO. 8. 1',, PitLlitary gland Pool 0. 0 Renal ca. 786-0 4. 2 Salivary Gland 0. 0 Renal ca. (female) ~ _. y 4 3 Rena. l. ca. ACHN... _. _.. «... __. __..... _. 1"y _ Pancreatic ca. YCAPAN2__. _. . _... _....... __. . Sv. ...... ! Renal ca. UO-31 1. 2 Pancreas Pool 1. 6 _

General screening_panel vl. 6 Summary: Ag6940 Highest expression of this gene is detected in squamous cell carcinoma SCC-4 cell line (CT=32). In addition, moderate to low levels of expression of this gene is seen mainly in number of cancer cell lines derived from lung, gastric, colon and brain cancers. Therefore, expression of this gene may be used as diagnostic marker to detect the presence of squamous cell carcinoma, lung, gastric, colon, and brain cancer. Furthermore, therapeutic modulation of this gene or its protein product may be useful in the treatment of these cancers.

M. NOV20 CG59323-02 and CG59323-03: TP53BP2: tumor protein p53-binding protein (ASSP)-like protein.

Expression of gene CG59323-02 and CG59323-03 was assessed using the primer-probe set Ag6327, described in Table MA. Results of the RTQ-PCR runs are shown in Tables MB, MC, MD and ME.

Table MA. Probe Name Ag6327

Start 7SEQ ID Position No j ° Position No Forward 151-atgaggttgatgacccaagc-31 Probe TET-5'-tgcccaatgatgaaggcatcacg-3'-TAMRA 23] 2918 {104 1 -. _ __ _.--_______ _ . _ _ __. __ Reverse 5'- acacacagcattgtgaagagc-3'21 2941 IOS Table MB. CNS neurodegeneration v1. 0 Rel. Exp-(%) Exp. (%) ! Tissue Name ! issue Name Ag6327, t Run Run 59045579 259045579 AD 1 Hippo j)). 7 tContro) (Path) 3 Tempera) Ctx J53. 6 AD 2 Hppo 88. 9,-_. ___.. _. _. _. _ ( ______p _. _. _. __ 23-__T__-_ icontrol (Path AD 3 Hippo 4 Temporal Ctx 23. 2 9.... _. AD 4 Hippo 25. 9 AD 2 Occipital Ctx (Missing) 20. 0 59 D O c C AD 4 Hi o 3 lAD 5 hippo. 35. 8 AD 3 Occipital Ctx 16. 0 JAD6Hippo"1480 JAD40ccipitaiCtx 48. 3 : _.. _. : _.... : _ Control 2 C 24 , 6 O prta1 Ctx_... _..... 17. 9.--°. : ____.. _. _ 4 Hi o cc- fControl 2 Hippo 19. 9, AD 5 Occipital Ctx 4424. 5 = pp 9 _ _.. _.. _ Oc_ipit. _. _... __.. _ _ _ _. _. lControl 4 Hippo. 17. 7 AD 6 Occipital Ctx 17. 9 J I Occipital Ctx , Control (Patli) 3 Hippo ' ! AD I Temporal Ctx :, Control 2 Occipital Ctx AD 2 Temporal Ctx-. 100. 0 iControl 3 Occipital Ctx jl8. 0 IAD 3 Temporal Ctx 5. 4 Control 4 Occipital Ctx 8. 6 fAD 4 Temporal Ctx-65. 5. Control (Path) 1 Occipital Ctx 443. 2 AD 5 Inf Temporal Ctx 44. 4 Control (Path) 2 Occipital Ctx'6 1AD 5 SupTemporal Ctx-38. 4 Control (Path) 3 Occipital Ctx S35. 4 q6. 6 AD 6 Inf Temporal Ctx iS5. 5, Control (Path) 4 Occipital Ctx 8. 0 AD 6 Sup Temporal Ctx 64. 2. Control I Parietal Ctx j 10. 8 t _ _. _ ..... . _ _... _ . _ Control I Temporal Ctx 12. 9 ; Control 2 Parietal Ctx 39. 8 Control 2 Temporal Ctx 427. 4'|Control 3 Parietal Ctx 12. 4 _ __. __. _ _. _ __. __ __. __.. __. _. ___. ___ _ _ _ _ _ _ _... ___. _... ___... _____.... ___ _.. ___.. _ ____,.. __. __.. _ __ Control 3 Temporal Ctx 18. 6 ^Control (Path) 1 Parietal Ctx 35. 1 Control 4 Temporal Ctx 10 9 ; Control (Path) 2 Parietal Ctx 12. 4 Control (Path) 1 Temporal Ctx 18. 6, iControl (Path) 3 Parietal Ctx t43. 5 Control (Path) 2 Temporal Ctx Control (Path) 3 Parietal Ctx 43. 5 iso_____ _ w_Wz__ _ Table MC. General screening panel v1. 5 . Rel., Rel. Exp. (%) Exp. (%) Tissue Name Ag6327, issue Name Ag6327, Run Run j 259139893 259139893 [Adipose"7"Rena) ca. TK- ! 0 0 Me) anoma* Hs688 (A). T 12. 1 Bladder 14. 1 Gastricca. (liveri-net'l Me ! anoma* Hs688 (B). T] 0Gastric ca. (''ver met.) NCI-N87 ) 29. 9 Me) anoma*Mf4 43. 2 Gastricca. KATOII ! J45. 4'"""' fmelanoma* f Melaiioi-na* M 14 43. 2'igastric ca. KATO 111 45. 4 ] Me) anomaLbX ! MV ! 24 JCp'pn ca SW-948'J 2. 9 l2p4 } Me) anoma* SK-MEL-5) 7. 2 ! Colon ca. SW480 ! 9. 9 7. 2 ! Squamousce) i carcinoma SCC-4 1l8. 4 ! Cofonca. * (SW480met) SW620 ! l6. 0 TestisPoo)"iToCo) onca. HT29 5" 5. 6 Prostate' (bone met) PC-3 j 21 JCofon'ca HCTT) 6" ! 9. zu rostate Pool 6. 6'iion ca. CaCo-2 111. 1 ! placenta 12. 5 coton cancer tissure 9. 4 Uterus Pool 5. 3 Co ! ! onca. SW) l) 6 3. 2 ovarian ca. OVCAR-3 8. 8 Cotonca. Co) o-205 ! 3. 2 Ovariaca7SK-OV-3 25. 3 iicolon ca. SW-48 5. 0 i-O, v, ari*a-*n--ca. OVCAR-4 i,. Colon Pool 18. 8 ovarian ca. OVCAR-5 23. 2 : ! Small Intestine Pool 7. 1 Ovarien ca. IGROV !] 4 ? 7 JiStomach Poo} ?. 7 Ovarian ca. OVCAR-8 ; 0. 6 JBone Marrow Poo) i3. 6 Ovary ) 2. 7""Feta) Heart 88"*" , breast ca. MCF-7 0. 9 jHeart Pooi 'T breast ca. MDA-MB-231 16. 4 Nymph Node Poil 8. 4 ! Breastca. BT549 ! 40. i JFetaJ Ske) eta) Muscie J4. 9 Breast ca. T47D 6. 8jsketeta ! Muscie Pooi ft8. 7 Breast ca. MDA-N 5fJSpHeenPoo) "} 7. 0 lbi-east Pool 11. 3 Pool 118. 2 ! CNS cancer ( trachea"8. 8 ! CNS cancer (g) io/astro) U 87-mu JLung 2. 5 i ! CNS cancer (gi io/astro) U-I 18-MG 7. 7 jFeta ! Lung 69. 7 CNS cancer (negro ; met) SK-N-AS 136. 6 ungca. NU4r73. 7 JCNS cancer (astro)'SF-539""8' Luna ca. LX-1 . . . . .......... .-...... .... ....-.., jcj' Lungca. NC !-H] 46 48J CNScancer (g) io) SNB-t9 i ! 4. 8 Lungca7SHP-77'''24""ancer' (gho)'SF"32 '13 3. 2 Lung ca. A549] 38 Bram (Amygda) aPop) . 8 '113. 8 , Lung ca. NCI-H526 ! 3. 8 Strain (cerebe)) um) 50. 0 ... ...., .. . . """''11 114. 8 JLung ca. NC !-H460 18. 9} Brain (Hippocampus) Poil 114. 8 {Lung ca. HOP-62 26. 8 Cerebra) Cortex Pool 21. 5 Lill-ca. NCI-1522 2 Lungca. NC)-H522 28. 9 JBrain (Substantianigra) Poo)) 5 ? 7""""" liver 0. 6 ; Brain (Thalamus) Pool dd. ! Fetal Liver 25. 0 Brain (who) e) 25. 3 'spinal Cord Poil 13. 4 , Liver ca. HepG2 8. 4 Kidney Poo) 5. 0 adrenal Gland zu Fetal Kidney 27. 7 Pituitary g) and Poo) zu Renal ca. 786-0 ! 54. 7} Sa) ivaryG) and ! 2.) : Renal ca. A498 jj9.) JThyroid (fema) e)] 3J 19 Renal ca. ACHN 20. 3 Pancreatic ca. CAPAN2 19. 2 } Renal ca. U0-3L 135. 4 Pancreas Pool l 1 fo Table MD. Panel 4. 1D iRel. Rel. Ex. (%) Tissue Name i'Ag6327,', Tissue Name Ag6327, Run Run 259181431 259181431 iSeco. ndar. y. T, hl.,. ac, t,,- ill. 7 ! Secondary Th2 act 20. 6 HUVEC IFS gamma 8. 7 ..econ.. ry _t 3. 1 C TNF alpha + IF.-. ^g mma'1. 6 Seconda Trl act- . :-",. __ rV .. N a--.-_ __ Secondary Th 1 rest"... _... __.. _ O ___ _... _... : HUV y- p _-_. _ . -. _ . __ __ ;.. 'Secondar Th2 rest 0. 2 'Secondary Tri rest 410. 0 Microvascular EC none 9. 5 __... __. SLung Microvascular EC TNFalpha - PrimaryThIact 0. 1 2. 9 I L-I beta ... . a ; primary Th2 act 14. 6. !'Microvascular Dermal EC none 0. 8 Microvascular Dennal EC 'Primary Trl act l 1. 0 3. 5 i" ! TNFa) pha+ ! L-lbeta '-.-, - :'Bronchiaiepithe) iumTNFa) pha+ !. Pr) maryTh) rest, 0. 3 i.,,. ! 4. 8 ;. ! L ! beta fPrimary Thl rest 0. 3 yBronchial epithelium TNFalpha + ; 0. 3 4. 8 , Prit-nary Tii I rest i i Th2 rest 0. 5 ne P L. , ! -, iSmai) airway eDitheiiumTNFaIpha _.... _ _ ; :. _. _ : ; CD45RA CD4 lymphocyte act a 6. 4 Coronary artery SMC rest 6. 0 i..-,..-.,, n'Coronary artery SMCTNFa) pha+ .. ! CD45ROCD4) ymphocyteact H9. 8,,,.'10. 0 j j j JL-tbeta ! i'''" ,, .... . _... ... .... . _ __. _.. __ __., Secondary CD8 ! ymphocyte rest j8. 0 jAstrocytesTNFa) pha+ ! L-Ibeta jtl. 4 Ut KU-812 (Basophil) CD4 lymphocyte none 0. 4 40. 9 PMA/ionomycin _.... _. _ ____. ......... ___. _..-_ _.. _ _ _ .,. _ _ _ _ 2ry Th 1/Th2/Trl anti-CD95 "-0. 6 CCD ! I06 (Keratmocytes) none 5. 9 ! ! LAK cells rest 10. 9 CCDI 106 (Keratinocytes) LAKce)) srest) 0. 9 T, r..... 1. . 9 ITNFalplia + IL-I beta LAK cells IL-2'i2. 1, Liver cirrhosis 4. 5 LAK cells IL-2+IFN gamma 3. 9 NCI-H292 IL-4 7. 1 LAK cells IL-2+ IL-18 . 4 rNCI-H292 IL-9 11. 0 LAK cells PMA/iononycin _ sl _--_.. ____.. ____. ____ (NCI-H292 IL-13 -.. _. -. ___. _. 13, 1.....,... iNK Cells IL-2 rest 6. 0 iNCI-FI292 IFN gamma 15 5 ,-Two Way MLR 3 day IHPAEC none. 120, ITwo Way MLR 5 day 0 4 HPAEC TNF alpha + 1L-1 beta 10. 6 Two Way MLR 7 day p. O Lungfibrobtastnone 7. 7 Lung fibroblast TNF alpha + I beta PBMC PWM 13. 7 Lung fibroblast IL-4 1 ! 4. 8 PBMC PHA-L"g fibroblast IL-9' ; 8. 3 PBMC PHA-L} 2. i jLung Dbrob) astIL-9 ! 8. 3 Ramos (B cell none. 3 Lun fibroblast IL- Ramos (B cell) ionomycin 7. 7 ^ Lung fibroblast IFN gamma ^ 9. 0 .. .. _ . _ g _ y.., p 7 C'e S i B) ymphocytesPWM 9*"DermatfibrobiastCCD) 070 rest 19. 5 ;'Dermal fibroblast CCD1070 TNF B lymphocytes CD40L and 1L-4 9. 6 # : 19. 2 alpha Dermal fibroblast CCD1070 1L-1 EOL-1 dbcAMP 10. 4 s14. 8 peta i .. T __.. __.-_. _... _. _.. _...... 3.... 1, 1. 2 idermal fibroblast IFN gamma PMA/tonomyon i ! ;.--..--...... Dendritic cells LPS 4. 5 Dermal Fibroblasts rest 3. 7 Dendritic cells LPS 4. 5 Monocytesrest 0. 5)'Neutrophiisrest 3. 3 _ ..... Y.. . Coion-....., : .. ___. _.. _. . J0. 6_y_. _ __ Macrophagesrest 5. ! ! Lung : 0. 7 MacrophagesLPS j3. 8 ! Thymus JO. 9 ______.. _..... __.... _. _.. _.. _.. _... ____.'.. _. ____.. ___. ... none _. __-5. 6,..... _ : _. : : :...... : :. : _.. _- : Kidney.... _.. __.... _... _. ________ : _. :..... _.. _ :....... :. :. ___. __.... _ ;. 1 H U V EC, HUVEC starved ... _ _..... _.. __.. _____... _. j 6. 5 YV _, i_.. __. ___-__ : .-. _ _..-. _ : ___. _.. _........ _ : _____ _..... _ : _..........

Table ME. Panel CNS 1. 1 Rel. ; : Rel.. ____ Exp. (%) j JExp. (%) Tissue Name : Ag6327, Run : 259229795 41259229795 CingGyrDepression2 ). 6"TBAI7PSP2 ! 6. 3 CingGyr Depression JIO. O JBA) 7PSP 25. 0 Cing ^Gyr PSP2 _.. l5. 2 ^. _ aBA 17 Huntington's2"'"""'"'J87" CingGyr PSP U9. 3 BA ! 7Huntington's2" Cing Gyr Huntington's2 40. 9 ! BAi7Parkinson's2 1. 0 Cing Gyr Parkinson's2 ; ; I9. 9 : BA17 Alzheimer's2'1. 7' » Cing G r _.inson.... .. . _'642, BAl7 Control2,.... 13. 1 Coing Gyr Aizheimer's2 j4. 5 BA ! 7Contro) 24. 0 Cing Gyr Alzheimer's 26. 1 BA9 Depression2 Depression 6. 0 , ; ; BA9 PSP2 Z :------- p. _. _..... __ ___ p_, ______- _. __.. _.. _. _... . _. _.-- ^44. . _. __. _____ 0. 7 TempPo) eDepression2 9. 9 ! BA9PSP--y-- Tem e D Temp Pole PSP2 3. 5 rBA9 Huntington's2 ; 7. 6 Temp Pole PSP BA9 Huntington's") 6. 6 Temp_. Pole H. untington's ____ ; BA9 Parkinson's2 28. 7 Temp Po) e Parkinson's2 J-0 JBA9 Park'nson's 54. 0 TempPoteParkinson's 41. 5 jBA9A) zheimer's2 5. ! TempPo) eAizheimer's2 5. 8 iBA9A) zheimer's ! 5. 6 Temp Poie A) zhe) mer's . 2 JBA9 Contro) 2 """ ! 29. 3 Temp Pole Contro12 i29. 7'tBA9 Control 8. 3 Temp Pole t I. 0-... _. _... jGlob Palladus Depression 7. 1 YU 3BA7 PSP2 T 20. 4 , Glob Palladus PSP2 iBA7 PSP. 47. 0 iglob Palladus PSP 16. 5 BA7 HLintington's2-T36. 9 JG) ob PaHadu7parkinson's2 0. 7 jBA7Huntington's ! 36. ! lob Palladus Parkinson's ! BA7 Parkinson's2 111. 3 : Glob Palladus Alzlieimer's2"BA7 Parkinson's'25 3 Glob Palladus Control2 : 18. 1"BA7 Contro12 i9. 0 xGlob Palladus Control J t 17. 7,. _.... __... _ BA7 Control ____. __-____.. _. _. __.. 16. 0-____. ____ Sub Nigra Depression2 5. 5 BA4Depression2 ! 4. 7 SubNigra Depression s7. 1 BA4 Depression ) 5. 2 Sub Nigra PSP2 j2. 6 ! ! BA4PSP2 n9 ra PSP2 iSub Nigra Huntington's J39. 8 jBA4Huntington's2 5. 2 __. : : : __. :. _. _ _.. _.... __.. __ _ __________. :.. __.. _. __ _ :. : _ __. ;.. _. . :.. _ : : _ :. : ___ :..-.. _-_.- :. _... ! SubNigraParkinson's2 j4 !. 5 ! BA4Huntington's U9. 5 Sub Nigra Parkinson's2'BA4 Huntington's 119. 5 gra Contro 9 6 ; BA4 Parkinson's 58. Sub N'12 'BA4 Parkinson's 7 De resson2 _...... BA4 Control2 _... _. _ _.. _...... _. 1BA 17 Depressio112. 110. 2 rl'BA4 Control2 3'10. 8 , ,. w... .. .-r....... . . A4.... _., _ _ . 7

CNS neurodegeneration vl. O Summary : Ag6327 This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals.

This gene is found to be slightly upregulated in the temporal cortex of Alzheimer's disease patients. Therefore, therapeutic modulation of the expression or function of this gene may decrease neuronal death and be of use in the treatment of this disease.

General screening-panel vl. 5 Summary : Ag6327 Highest expression of this gene is detected in a renal cancer TK-10 cell line (CT=28. 9). Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric. colon, lung, liver, renal, breast ; ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung,

liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.

Among tissues with metabolic or endocrine function, this gene is expressed at moderate to low levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

Interestingly, this gene is expressed at much higher levels in fetal (CTs=29-31) when compared to adult lung and liver (CT=34-36). This observation suggests that expression of this gene can be used to distinguish fetal from adult lung and liver. In addition, the relative overexpression of this gene in fetal tissue suggests that the protein product may enhance lung and liver growth or development in the fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of lung and liver related diseases.

Panel 4. 1D Summary: Ag6327 Highest expression of this gene is detected in PMA/ionomycin treated LAK cells (CT=27.8). Lower levels of expression of this gene is also seen in resting and cytokine treated LAK cells. These cells are involved in tumor immunology and cell clearance of virally and bacterial infected cells as well as tumors.

Therefore, modulation of the function of the protein encoded by this gene through the application of a small molecule drug or antibody may alter the functions of these cells and lead to improvement of symptoms associated with these conditions.

Moderate to low levels of this gene is also seen in activated polarized, memory and naive T cells, IL-2 treated NK cells, two way MLR, activated PBMC cells, Ramos B cells, B lymphocytes, eosinophils, dendritic cells, activated monocytes, macrophages, endothelial cells, bronchial and small airway epithelium, mucoepidermoid cells, astrocytes, basophils, keratinocytes, lung and dermal fibroblasts, neutrophils and normal tissues represented by lung, thymus and kidney. Therefore, therapeutic modulation of this gene product may

ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

Panel CNS-1. 1 Summary: This panel confirms the expression of this gene at low levels in the brains of an independent group of individuals. Please see Panel 1. 5 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

Example D: Identification of Single Nucleotide Polymorphisms in NOVX nucleic acid sequences Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a"cSNP"to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and

protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraToolsTM program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265,2000).

Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

NOV2 CG126119-02 SNP data: CG126119-02 has 2 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG126119-02 variant differ as shown in Table DJ.

Table DJ. cSNP and Coding Variants for CG126119-02. Variant Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380802 99 T C 30 Ala Ala 133 80813 140 A C 44 Asp Ala NOV3 CG137623-01 SNP data CG137623-01 has 2 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG137623-01 variant differ as shown in Table DB.

Table DB. cSNP and Coding Variants for CG137623-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380806 407 T C 64 Leu Pro 13380805 588 T C 124 Thr Thr

NOV5 CG143198-01 SNP data: CG 143198-01 has 2 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG143198-01 variant differ as shown in Table DC.

Table DC. cSNP and Coding Variants for CG143198-01. Variant Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified cl111. 5225 209 G T 70 Gly Val cgl 11. 5224 212 G T 71 Arg Ile

NOV6 CG144756-01 SNP data: CG144756-01 has 1 SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG144756-01 variant differ as shown in Table DD.

Table DD. cSNP and Coding Variants for CG144756-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380801 480 C T 153 Leu Leu NOV7 CG145473-01 SNP data: CG 145473-01 has 2 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG 145473-01 variant differ as shown in Table DE.

Table DE. cSNP and Coding Variants for CG145473-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified c100. 13 459 T C 131 Met Thr 13380809 781 C T 238 Ser Ser

NOV9 CG146452-01 SNP data: CG 146452-01 has 3 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG146452-01 variant differ as shown in Table DF.

Table DF. cSNP and Coding Variants for CG146452-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13377204 52 A G 0 13377208 334 T A 93 Ser Thr 13377209 385 C T HO Leu Leu

NOV11 CG147048-01 SNP data: CG147048-01 has 6 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG147048-01 variant differ as shown in Table DG.

Table DG.cSNP and Coding Variants for CG147048-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 133 80827 40 A G 14 Thr Ala 133 80828 45 T C 15 Cys Cys 13380829 379 C T 127 His Tyr 13380830 406 C G 136 His Asp 13380831 484 G A 162 Gly Arg 13380832 1151 T C 384 Phe Ser

NOV12 CG147246-01 SNP data: CG147246-01 has 1 SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG147246-01 variant differ as shown in Table DH. able DH. cSNP and Coding Variants for CG147246-01. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380833 435 C T 145 Asp Asp NOV16 CG150951-01 SNP data CG150951-01 has 1 SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG150951-01 variant differ as shown in Table DA.

Table DA. cSNP and Coding Variants for CG150951-01. Nucleotides Amino Acids Variant Position lnitial Modified Position Initial Modified 133 81070 454 A G 98 Glu Gly NOV20 CG59323-02 SNP data: CG59323-02 has 2 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs: and, respectively. The nucleotide sequence of the CG59323-02 variant differ as shown in Table DI.

Table DI. cSNP and Coding Variants for CG59323-02. Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380818 2843 A G 758 Asp Gly 13380819 2996 A G 809 Glu Gly

Example E: Protein Interactions in the DAPK3 (zip kinase) Signaling Pathway Novel associations between Death Associated Protein Kinase 3 ("DAPK3") proteins and DAPK3 interacting polypeptides ("DAPK-IP"), and the nucleic acids that encode them, are described, as are various diseases or pathologies associated with DAPK3 and DAPK-IP protein complexes ("DAPK: DAPK-IP"). The DAPK-IP proteins, polypeptides and their cognate nucleic acids were identified by Curagen Corporation in certain cases. The DAPK-IP and any variants thereof, are suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed DAPK: DAPK-IP protein complexes in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

DAPK3 is a serine/threonine kinase, designated ZIP kinase, that mediates apoptosis.

ZIP kinase contains a leucine zipper structure at its C-terminus, and a kinase domain at its N-terminus. ZIP kinase physically binds to ATF4, a member of the activating transcription factor/cyclic AMP-responsive element-binding protein (ATF/CREB) family, through interaction between their leucine zippers. The leucine zipper domain is necessary for the homodimerization of ZIP kinase as well as for the activation of kinase. An immunostaining study showed that ZIP kinase localizes in the nuclei. Overexpression of intact ZIP kinase (but not catalytically inactive kinase mutants) led to the morphological changes of apoptosis in NIH 3T3 cells, suggesting that the cell death-inducing activity of ZIP kinase depends on its intrinsic kinase activity. Interestingly, the catalytic domain of ZIP kinase is closely related to that of death-associated protein kinase (DAP kinase), which is a mediator of apoptosis induced by gamma interferon. Therefore, both ZIP and DAP kinases represent a novel kinase family, which mediates apoptosis through their catalytic activities. PMID: 9488481 The ZIPK gene was mapped to 19qui3. 3 by fluorescence in situ hybridization and by polymerase chain reaction-based analyses with both a human/rodent monochromosomal hybrid cell panel and a radiation hybrid mapping panel.

ATF4 (CREB2) is a stress-inducible gene. The bZIP domain of ATF4 forms a heterodimer with the bZIP domain of C/EBP beta that binds the cAMP response element, but not CCAAT box DNA, with high affinity. The basic region of ATF4 has a higher alpha-helical propensity than that of C/EBP beta. The degree of ordering of the basic region and the fork and the dimerization properties of the leucine zipper combine to distinguish

the structurally similar bZIP domains of ATF4 and C/EBP beta with respect to DNA target sequence. PMID: 11018027 CCAAT/enhancer binding protein-delta ("CEBPD") is important in the transcriptional activation and regulation of genes involved in immune and inflammatory responses. It may also play an important role in the regulation of the several genes associated with activation and/or differentiation of macrophages.

Gaddl53, also known as chop, encodes a member of the CCAAT/enhancer-binding protein (C/EBP) transcription factor family and is transcriptionally activated by cellular stress signals. GADD153 inhibits the DNA-binding activity of CEBPD by forming heterodimers that cannot bind DNA. Dysregulation of GADD 153 is seen in a form of myxoid liposarcoma. Arsenite treatment of rat pheochromocytoma PC 12 cells results in the biphasic induction of Gadd 153 mRNA expression, controlled in part through binding of C/EBPbeta and two uncharacterized protein complexes to the C/EBP-ATF (activating transcription factor) composite site in the Gaddl53 promoter.

Components of these additional complexes are two ATF/CREB (cAMP- responsive-element-binding protein) transcription factors having differential binding activities dependent upon the time of arsenite exposure. During arsenite treatment of PC 12 cells, enhanced binding of ATF4 to the C/EBP-ATF site at 2 h was observed as Gadd 153 mRNA levels increased, and enhanced binding of ATF3 complexes at 6 h was observed as Gaddl53 expression declined. ATF4 activates, while ATF3 represses, Gaddl53 promoter activity through the C/EBP-ATF site. ATF3 also repressed ATF4-mediated transactivation and arsenite-induced activation of the Gad 153 promoter. Results suggest that numerous members of the ATF/CREB family are involved in the cellular stress response, and that regulation of stress-induced biphasic Gaddl53 expression in PC 12 cells involves the ordered, sequential binding of multiple transcription factor complexes to the C/EBP-ATF composite site. PMID: 10085237 CHOP/gaddl53 is a transcription factor induced by cellular stresses such as UV light, genotoxic agents, and protein misfolding in the endoplasmic reticulum. These stresses induce CHOP expression, and at the same time cause cellular apoptosis. CHOP can directly induce apoptosis. A GFP-tagged CHOP vector, ectopically overexpressed in several cell types (3T3 fibroblasts, keratinocytes, and HeLa cells), caused apoptosis as defined by morphology, DNA fragmentation, and FACS analysis. Apoptosis was quantified using a rapid fluorescence assay that measures the signal from cells collected in culture

supernatants. Simultaneous overexpression of CHOP and p38 significantly augmented apoptosis. However, although p38 kinase clearly modulated the activity of full-length CHOP, it was not absolutely required. Deletion mapping experiments showed that the bZIP region of CHOP stimulates apoptosis to nearly the same extent as wild-type CHOP. Thus, while the amino-terminal region of CHOP serves an important modulatory role (i. e., regulation by p38), the underlying apoptosis-inducing activity of CHOP resides within the bZIP region of the molecule. PMID: 11426938 Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. However, viroid genomes contain no open reading frames, whereas HDV RNA encodes a single protein, hepatitis delta antigen (HDAg), which is required for viral replication. A cellular gene whose product interacts with HDAg has been identified, and this interaction was found to affect viral genomic replication in intact cells. DNA sequence analysis revealed that this protein, termed delta-interacting protein A (DIPA), is a cellular homolog of HDAg. These observations demonstrated that a host gene product can modulate HDV replication and suggested that HDV evolved from a primitive viroid-like RNA through capture of a cellular transcript.

PMID: 8810253 The CEBPD inducible protein has an immunoglobulin ("Ig") domain as determined by Pfam analysis, and is predicted to be cytoplasmic. Ig domains are important mediators of protein-protein interactions. The interaction of CEBPD with ATF4 could indicate a role in ATF4-dependent transcription in response to cellular stress or cell proliferation.

In pancreatic acinar cells, the HOX-like factor PDX I acts as part of a trimeric complex with two TALE class homeodomain factors, PBX I b and MEIS2b. The complex binds to overlapping half-sites for PDX1 and PBX. The trimeric complex activates transcription in cells to a level about an order of magnitude greater than PDXI alone. The N-terminal PDX1 activation domain is required for detectable transcriptional activity of the complex, even though PDX1 truncations bearing only the PDX I C-terminal homeodomain, and pentapeptide motifs can still participate in forming the trimeric complex. The conserved N-terminal PBC-B domain of PBX, as well as its homeodomain, is required for both complex formation and transcriptional activity. Only the N-terminal region of MEIS2, including the conserved MEIS domains, is required for formation of a trimer on DNA and transcriptional activity: the MEIS homeodomain is dispensable. The activity of the pancreas-specific ELA I enhancer requires the cooperation of the trimer-binding element

and a nearby element that binds the pancreatic transcription factor PTF 1. The Pyx 1.

PBXlb. MEIS2b complex cooperates with the PTF1 basic helix-loop-helix complex to activate an ELA I mini-enhancer in HeLa cells. This cooperation requires all three homeoprotein subunits, including the PDX I activation domain. PMID: 11279116 Tumor endothelial factor I (TEMI ; ENDOSIALIN) is a la-type plasma membrane protein with extracellular EGF and sushi domains. TEMI is expressed by tumor blood vessel endothelium. Human tumor endothelial marker I/endosialin (TEMI/endosialin) was recently identified as a novel tumor endothelial cell surface marker potentially involved in angiogenesis, although no specific function for this novel gene has been assigned so far. It was reported to be expressed in tumor endothelium but not in normal endothelium with the exception of perhaps the corpus luteum. The mouse Tem I/endosialin homolog was identified and its promoter region was characterized. Its expression pattern in murine and human tissues and murine cell lines in vitro has been extensively characterized.

The single copy gene that was mapped to the chromosome 19, is intronless and encodes a 92 kDa protein that has 77.5% overall homology to the human protein. This gene is ubiquitously expressed in normal human and mouse somatic tissues and during development, and its expression at the mRNA level is density dependent and upregulated in serum starved cells. In vitro, its expression is limited to cells of embryonic, endothelial and preadipocyte origin suggesting that the wide distribution of its expression in vivo is due to the presence of vascular endothelial cells in all the tissues. The ubiquitous expression in vivo is in contrast to previously reported expression limited to corpus luteum, and highly angiogenic tissues such as tumors and wound tissue. PMID: 11489895 Discovery Method: DAPK-IPs were identified using PathCalling Technology (CuraGen Corporation). The sequence were derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were sequenced. In silico prediction was based on sequences available in Curagen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The laboratory screening was performed using the methods summarized below: cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states

from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, CA) were then transferred from E. coli into a CuraGen Corporation proprietary yeast strain (disclosed in U. S. Patents 6,057, 101 and 6, 083, 693, incorporated herein by reference in their entireties).

Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corporation proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.

Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106'and YULH (U. S.

Patents 6,057, 101 and 6,083, 693).

Description of the Interaction: Death Associated Protein Kinases are very important in the propagation of the apoptotic signal due to the binding of Interferon gamma (INFg) to its receptor. These kinases constitute a novel family of protein kinases whose catalytic activity plays a critical

role in cell survival. In these Yeast-2-Hybrid experiments, the aa403-453 region of DAPK3 was used to screen for interacting proteins. The C-terminus of DAPK3 contains the leucine zipper motif that is critical for protein-protein interactions.

Sites of DAPK : DAPK-IP protein-protein interactions were mapped. Through its phosphorylating activity and leucine zipper protein-protein interaction motif, the DAPK3 interacted with ATF4 (aa5-, 14-, 71-, 77-, 80-351). ATF4 (aa2-, 7-, 66-, 71-351) interacted with CEBPD (aa211-281). The DAPK3/ATF4 interaction could modulate the CEBPD/ATF4 interaction with protein and/or DNA targets or modulate CEBPD- interactions with other proteins and/or DNA binding sites to regulate expression of various target genes.

One target gene could be the CEBP-induced protein, whose function in cell survival is not entirely clear, but seems to indicate a possible feedback mechanism with CEBPD affecting its activity. The domains used in this interaction were; CEBPD (aa211-281), and CEBP-inducible protein (aa42-453). This is also observed in the interaction with GADD 153, which is a transcription co-regulator that binds to CEBPD and prevents it from binding DNA on the promoters of target genes. The domains that gave the interaction are CEBPD (aa211-281), and GADD153 (aa40-, 43-, 51-169). Gaddl53 expression is increased due to growth arrest and DNA-damage and promotes apoptosis.

TEMI is a type la plasma membrane protein with extracellular EGF and sushi domains. These domains are important in transducing cell signaling events such as in growth, differentiation, and apoptosis. The C-terminus of TEMI was used in the Yeast-2-Hybrid screen. This domain likely contains motifs important for transducing cellular signals. TEMI is expressed by tumor blood vessel endothelium and could be receptor, the endogenous ligand is as of yet unknown. The interaction of CEBPD with TEMI could indicate a signaling step in binding of TEMI to its ligand. The domains that gave this interaction were; CEBPD (aa211-281), and TEMI (aa686-757). CEBPD is particularly interesting because of its importance in inflammatory signaling cascades. The interaction of DAPK3 with the homeobox protein, MEIS2, may function to alter its activity and modulate the expression of genes during development or house-keeping type genes in the adult. Additionally, the interaction of the DIPA protein, which has been shown to interact with viral phosphoprotein Hepatitis Delta Antigen (HDA), with CEBPD could indicate an interaction necessary for the disruption of the INFg apoptotic signal allowing

for increased viral replication. The domains that gave the interaction were; CEBPD (aa211-281), and DIPA (aa31-, 52-202).

The identified DAPK3 protein interactions and their corresponding biological pathways are shown in Table Fl.

Table F 1 : Diagram of Protein Interactions and/or Biological Pathway : The nucleotide and polypeptide sequences of the identified DAPK-IPs are provided in Table F2.

Table F2. Nucleic Acid and Amino Acid Sequence Analysis of Interacting Proteins

Example F: TRAF5 Interactions Novel associations of TRAF5 proteins and TRAF5 interacting proteins (TRAF-IP), and the nucleic acids that encode them, are described, as are various diseases or pathologies associated with TRAF5 and TRAF-IP protein complexes (TRAF5 : TRAF-IP).

The TRAF-IP proteins, polypeptides and their cognate nucleic acids were identified by Curagen Corporation in certain cases. The TRAF5 : TRAF-IP protein complexes, and any variants thereof, are suitable as targets for an antibody therapeutic and targets for small molecule drugs. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed TRAF5 : TRAF-IP protein complexes in various screens to identify such therapeutic antibodies and/or therapeutic small molecules.

Discovery Method: TRAF-IPs were identified using PathCalling Tm Technology (CuraGen Corporation).

The sequences was derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were sequenced. In silico prediction was based on sequences available in Curagen Corporation's proprietary sequence databases or in the public human

sequence databases, and provided either the full length DNA sequence, or some portion thereof.

The laboratory screening was performed using the methods described in Example E.

Description of the Interaction: Lymphotoxin beta receptor (LTßR), a member of the TNF-receptor superfamily is required for the development and organization of the lymphoid tissue. Besides its role in the immune system, it is also required for the development of diabetes in nonobese diabetic mice. It is expressed in a variety of normal and transformed cells but absent in T and B lymphocytes. In vitro it can induce growth stimulation of fibroblasts and is associated with a variety of inflammatory disorders. LTpR induces signaling via its interaction with TRAF proteins, TRAF2, 3 and 5. It activates NFkB signaling via the activation of NFkB inducing kinase.

A primary function of TRAF5 is protection of cells against cell death via activation of NFkB. One of the two TRAF5 proteins described in the interaction (TRAF5 SV) is a novel splice variant that lacks amino acid residues 232-263 present in the TRAF5 protein available from the public data base. The other TRAF5 (novel TRAF5) described in the interaction has extra 11 amino acids inserted between residues 125-126 of the public gene.

In the PathCalling interaction, full-length TRAF5 SV and residues 280-569 of the novel TRAF5 were used.

As shown in Table Fl, both of the TRAF5 protein constructs interacted with LTpR receptor as expected. This interaction is likely via their TRAF domains. In addition, both the TRAF5 protein constructs interacted with the human ubiquitinating enzyme (AAT62352), which is highly homologous to the ubiquitin-like protein SUMO-1 conjugating enzyme. This is a novel interaction as no other TRAF protein has been shown to interact with this enzyme. The interaction is significant because it is known from the literature that TRAF6 is multi-ubiquitinated via Ubcl3-Uevl A. Such ubiquitination does not target TRAF6 for degradation via the proteasomal pathway and is essential for TRAF6-dependent signaling. Based on the interaction between TRAF5 and the ubiquitinating enzyme, it can be hypothesized that TRAF5 is modified via an ubiquitin-like protein and this modification is important in TRAF5-mediated signaling.

A second interesting interactor of the novel TRAF5 protein is with the Activatory receptor protein (CG124499-01), which belongs to the Immunoglobulin-superfamily of receptors and homologous to the PILRa protein. These receptors bind to their inhibitory

counterpart on the cell surface like PILRa binds PlLRß and counteract each others activities. Interaction of TRAF5 with the activating receptor suggests a novel mechanism of signaling from these family of receptors. Another interactor of TRAF5 is a protein that binds activated STAT3 (PIAS3) and is a negative regulator of JAK/STAT signaling similar to the SOCS proteins. Sequestration of PIAS3 is therefore a likely mechanism of activating the JAK/STAT pathway. The activatory receptor (CG124499-01) may influence JAK/STAT pathway by removing PIAS3 from STAT3 protein utilizing TRAF5. In a broader perspective, TRAF proteins may play an interesting role in receptor cross-talk between different cell surface receptors.

Uses of the Compositions of the Invention: The interactors of TRAF5 and their relevance to TRAF5 and in general to TRAF signaling provides opportunities to develop tools against various pathologic situations in which signaling through TRAF proteins are involved, and against the receptors that regulate the signaling pathways. Therefore, the TRAF5 : TRAF-IP complexes of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These tools include identification of TRAF5-TRAF-IP associations for a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein is to be assessed. Potential therapeutic applications for the TRAF5 : TRAF-IP complexes are the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: cancer; inflammation and autoimmune disorders including Crohn's disease, IBD, allergies, rheumatoid and osteoarthritis, inflammatory skin disorders, allergies, blood disorders; colon cancer, leukemia AIDS; metabolic disorders including diabetes and obesity; pancreatic disorders including pancreatic insufficiency and cancer; and prostate disorders including prostate cancer and other diseases, disorders and conditions of the like. These materials are further useful in the generation of antibodies that bind immunospecifically to the substances of the

invention for use in therapeutic or diagnostic methods. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

The identified DAPK3 protein interactions and their corresponding biological pathways are shown in Table Fl.

Table Fl. Diagram of Protein Interactions and/or Biological Pathway : Novel splice variant (Curagen gene calling) Human ubiqutinating enzyme Lymphotoxin beta receptor (TNF receptor superfamily). ' : LTE LTfi_ v _... ; Fi r fT 1 9-n 1 TR. F PI : J Activatory cell surface receptor protein on dendritic cells (Curagen gene calling) activated STAT3 on dendritic cells The nucleotide and polypeptide sequences of the identified DAPK-IPs are provided in Table F2.

Table F2. Nucleic Acid and Amino Acid Sequence Analysis of TRAF5 Interacting Proteins SEQ ID NO : 122 bp LCR ATGCTCCTGCCTTGGGCCACCTCTGCCCCCGGCCTGGCCTGGGGGCCTCTGGTGCTGGGC C GDB : 1230195 TCTTCGGGCTCCTGGCAGCATCGCAGCCCCAGGCGGTGCCTCCATATGCGTCGGAGAACC A DNA Sequence GACCTGCAGGGACCAGGAAAAGGAATACTATGAGCCCCAGCACCGCATCTGCTGCTCCCG C TGCCCGCCAGGCACCTATGTCTCAGCTAAATGTAGCCGCATCCGGGACACAGTTTGTGCC A CATGTGCCGAGAATTCCTACAACGAGCACTGGAACTACCTGACCATCTGCCAGCTGTGCC G CCCCTGTGACCCAGTGATGGGCCTCGAGGAGATTGCCCCCTGCACAAGCAAACGGAAGAC C CAGTGCCGCTGCCAGCCGGGAATGTTCTGTGCTGCCTGGGCCCTCGAGTGTACACACTGC G |AGCTACTTTCTGACTGCCCGCCTGGCACTGAAGCCGAGCTCAAAGATGAAGTTGGGAAG GG TAACAACCACTGCGTCCCCTGCAAGGCAGGGCACTTCCAGAATACCTCCTCCCCCAGCGC C CGCTGCCAGCCCCACACCAGGTGTGAGAACCAAGGTCTGGTGGAGGCAGCTCCAGGCACT G CCCAGTCCGACACAACCTGCAAAAATCCATTAGAGCCACTGCCCCCAGAGATGTCAGGAA C CATGCTGATGCTGGCCGTTCTGCTGCCACTGGCCTTCTTTCTGCTCCTTGCCACCGTCTT C TCCTGCATCTGGAAGAGCCACCCTTCTCTCTGCAGGAAACTGGGATCGCTGCTCAAGAGG C GTCCGCAGGGAGAGGGACCCAATCCTGTAGCTGGAAGCTGGGAGCCTCCGAAGGCCCATC C ATACTTCCCTGACTTGGTACAGCCACTGCTACCCATTTCTGGAGATGTTTCCCCAGTATC C ACTGGGCTCCCCGCAGCCCCAGTTTTGGAGGCAGGGGTGCCGCAACAGCAGAGTCCTCTG G ACCTGACCAGGGAGCCGCAGTTGGAACCCGGGGAGCAGAGCCAGGTGGCCCACGGTACCA A TGGCATTCATGTCACCGGCGGGTCTATGACTATCACTGGCAACATCTACATCTACAATGG A CCAGTACTGGGGGGACCACCGGGTCCTGGAGACCTCCCAGCTACCCCCGAACCTCCATAC C CCATTCCCGAAGAGGGGGACCCTGGCCCTCCCGGGCTCTCTACACCCCACCAGGAAGATG G CAAGGCTTGGCACCTAGCGGAGACAGAGCACTGTGGTGCCACACCCTCTAACAGGGGCCC A AGGAACCAATTTATCACCCATGACTGACGGAGTCTGAGAAAAGGCAGAAGAAGGGGGGCA C AAGGGCACTTTCTCCCTTGAGGCTGCCCTGCCCACGTGGGATTCACAGGGGCCTGAGTAG G l GCCCGGGGAAGCAGAGCCCTAAGGGATTAAGGCTCAGACACCTCTGAGAGCAGGTGGGCA CI TGGCTGGGTACGGTGCCCTCCACAGGACTCTCCCTACTGCCTGAGCAAACCTGAGGCCTC C CGGCAGACCCACCCACCCCCTGGGGCTGCTCAGCCTCAGGCACGGACAGGGCACATGATA C CAACTGCTGCCCACTACGGCACGCCGCACCGGAGCACGGCACCGAGGGAGCCGCCACACG G TCACCTGCAAGGACGTCACGGGCCCCTCTAAAGGATTCGTGGTGCTCATCCCCAAGCTTC A GAGACCCTTTGGGGTTCCACACTTCACGTGGACTGAGGTAGACCCTGCATGAAGATGAAA T TATAGGGAGGACGCTCCTTCCCTCCCCTCCTAGAGGAGAGGAAAGGGAGTCATTAACAAC T AGGGGGTTGGGTAGGATTCCTAGGTATGGGGAAGAGTTTTGGAAGGGGAGGAAAATGGCA A GTGTATTTATATTGTAACCACATGCAAATAAAAAGAATGGGACCTAAACTCGTGCCGCTC G _.. CGAATTCCTGCAG Q 1 No :. _. _... _... __ _ _ _.. __ LYRR ! MLLPWATSAPGLAWGPLVLGLFGLLAASQPQAVPPYASENQTCRDQEKEYYEPQHRICCS R ixSEQ IDNO : i435 aa n jLTßR MLLPWATSAPGLAWGPLVLGLFGLLAASQPQAVPPYASENQTCRDQEKEYYEPQHRICCS R | tGDB : 1230195 CPPGTYVSAKCSRIRDTVCATCAENSYNEHWNYLTICQLCRPCDPVMGLEEIAPCTSKRK T | Protein QCRCQPGMFCAAWALECTHCELLSDCPPGTEAELKDEVGKGNNHCVPCKAGHFQNTSSPS AI Sequence RCQPHTRCENQGLVEAAPGTAQSDTTCKNPLEPLPPEMSGTMLMLAVLLPLAFFLLLATV F ! i Sequence SCIWKSHPSLCRKLGSLLKRRPQGEGPNPVAGSWEPPKAHPYFPDLVQPLLPISGDVSPV S TGLPAAPVLEAGVPQQQSPLDLTREPQLEPGEQSQVAHGTNGIHVTGGSMTITGNIYIYN G PVLGGPPGPGDLPATPEPPYPIPEEGDPGPPGLSTPHQEDGKAWHLAETEHCGATPSNRG P iRNQFITHD lS ID NO : 23 8 b Human AGCGGGCTCCGGAGGGAAGTCCCGAGACAAAGGGAAACGCCGCCGCCGCCGCCCCGCTCG G deLlbiquitinatinghTCCTCCACCTGTCCGCTACGCTCGCCAGGGCTGCGGCCGCCC GAGGGACTTTGAACATGTC enzyme GGGGATCGCCCTCAGCAGACTCGCCCAGGAGAGGAAAGCATGGAGGAAAGACCACCCATT T DNA Sequence GGTTTCGTGGCTGTCCCAACAAAAAATCCCGATGGCACGATGAACCTCATGAACTGGGAG T GCGCCATTCCAGGAAAGAAAGGGACTCCGTGGGAAGGAGGCTTGTTTAAACTACGGATGC T TTTCAAAGATGATTATCCATCTTCGCCACCAAAATGTAAATTCGAACCACCATTATTTCA C CCGAATGTGTACCCTTCGGGGACAGTGTGCCTGTCCATCTTAGAGGAGGACAAGGACTGG A GGCCAGCCATCACAATCAAACAGATCCTATTAGGAATACAGGAACTTCTAAATGAACCAA A TATCCAAGACCCAGCTCAAGCAGAGGCCTACACGATTTACTGCCAAAACAGAGTGGAGTA C GAGAAAAGGGTCCGAGCACAAGCCAAGAAGTTTGCGCCCTCATAAGCAGCGACCTTGTGG C ATCGTCAAAAGGAAGGGATTGGTTTGGCAAGAACTTGTTTACAACATTTTTGCAAATCTA A AGTTGCTCCATACAATGACTAGTCACCTGGGGGGGTTGGGCGGGCGCCATCTTCCATTGC C GCCGCGGGTGTGCGGTCTCGATTCGCTGAATTGCCCGTTTCCATACAGGGTCTCTTCCTT C GGTCTTTTGTATTTTTGATTGTTATGTAAAACTCGCTTTTATTTTAATATTGATGTCAGT A TTTCAACTGCTGTAAAATTATAAACTTTTATACTTGGGTAAGTCCCCCAGGGGCGAGTTC C TCGCTCTGGGATGCAGGCATGCTTCTCACCGTGCAGAGCTGCACTTGGCCTCAGCTGGCT G TATGGAAATGCACCCTCCCTCCTGCCGCTCCTCTCTAGAACCTTCTAGAACCTGGGCTGT G JCTGCTTTTGAGCCTCAGACCCCAGGTCAGCATCTCGGTTCTGCGCCACTTCCTTTGTGT TT ATATGGCGTTTTGTCTGTGTTGCTGTTTAGAGTAAATAAACTGTTTATAT SEQ ID NO : 124 4158 aa d y_ ; _ ;.. ... XHuman MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAI PGKKGTPWEGGLFKLR Human MLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLN E PNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS j enzyms Protein Sequence SEQ ID NO 125 bpi'. Protein GGCGGAGCTGGGCGAATTAAAGCACATGGTGATGAGTTTCCGGGTGTCTGAGCTCCAGGT G inhibiting CTTCTTGGCTTTGCTGGCCGGAACAAGAGTGGACGGAAGCACGAGCTCCTGGCCAAGGCT C activated TGCACCTCCTGAAGTCCAGCTGTGCCCCTAGTGTCCAGATGAAGATCAAAGAGCTTTACC G STAT3 (PIAS3) ACGACGCTTTCCCCGGAAGACCCTGGGGCCCTCTGATCTCTCCCTTCTCTCTTTGCCCCC T DNA Sequence GGCACCTCTCCTGTAGGCTCCCCTGGTCCTCTAGCTCCCATTCCCCCAACGCTGTTGGCC C CTGGCACCCTGCTGGGCCCCAAGCGTGAGGTGGACATGCACCCCCCTCTGCCCCAGCCTG T GCACCCTGATGTCACCATGAAACCATTGCCCTTCTATGAAGTCTATGGGGAGCTCATCCG G CCCACCACCCTTGCATCCACTTCTAGCCAGCGGTTTGAGGAAGCGCACTTTACCTTTGCC C TCACACCCCAGCAAGTGCAGCAGATTCTTACATCCAGAGAGGTTCTGCCAGGAGCCAAAT G TGATTATACCATACAGGTGCAGCTAAGGTTCTGTCTCTGTGAGACCAGCTGCCCCCAGGA A GATTATTTTCCCCCCAACCTCTTTGTCAAGGTCAATGGGAAACTGTGCCCCCTGCCGGGT T ACCTTCCCCCAACCAAGAATGGGGCCGAGCCCAAGAGGCCCAGCCGCCCCATCAACATCA C ACCCCTGGCTCGACTCTCAGCCACTGTTCCCAACACCATTGTGGTCAATTGGTCATCTGA G TTCGGACGGAATTACTCCTTGTCTGTGTACCTGGTGAGGCAGTTGACTGCAGGAACCCTT C TACAAAAACTCAGAGCAAAGGGTATCCGGAACCCAGACCACTCGCGGGCACTGATCAAGG A GAAATTGACTGCTGACCCTGACAGTGAGGTGGCCACTACAAGTCTCCGGGTGTCACTCAT G TGCCCGCTAGGGAAGATGCGCCTGACTGTCCCTTGTCGTGCCCTCACCTGCGCCCACCTG C AGAGCTTCGATGCTGCCCTTTATCTACAGATGAATGAGAAGAAGCCTACATGGACATGTC C TGTGTGTGACAAGAAGGCTCCCTATGAATCTCTTATCATTGATGGTTTATTTATGGAGAT T CTTAGTTCCTGTTCAGATTGTGATGAGATCCAATTCATGGAAGATGGATCCTGGTGCCCA A TGAAACCCAAGAAGGAGGCATCTGAGGTTTGCCCCCCGCCAGGGTATGGGCTGGATGGCC T CCAGTACAGCCCAGTCCAGGGGGGAGATCCATCAGAGAATAAGAAGAAGGTCGAAGTTAT T GACTTGACAATAGAAAGCTCATCAGATGAGGAGGATCTGCCCCCTACCAAGAAGCACTGT T CTGTCACCTCAGCTGCCATCCCGGCCCTACCTGGAAGCAAAGGAGTCCTGACATCTGGCC A CCAGCCATCCTCGGTGCTAAGGAGCCCTGCTATGGGCACGTTGGGTGGGGATTTCCTGTC C AGTCTCCCACTACATGAGTACCCACCTGCCTTCCCACTGGGAGCCGACATCCAAGGTTTA G ATTTATTTTCATTTCTTCAGACAGAGAGTCAGCACTATGGCCCCTCTGTCATCACCTCAC T AGATGAACAGGATGCCCTTGGCCACTTCTTCCAGTACCGAGGGACCCCTTCTCACTTTCT G GGCCCACTGGCCCCCACGCTGGGGAGCTCCCACTGCAGCGCCACTCCGGCGCCCCCTCCT G GCCGTGTCAGCAGCATTGTGGCCCCTGGGGGGGCCTTGAGGGAGGGGCATGGAGGACCCC T GCCCTCAGGTCCCTCTTTGACTGGCTGTCGGTCAGACATCATTTCCCTGGACTGAGTTCC C TGGATTATGGAAACTTCGCTGTCCCCCAACACTGAGCAAGTATGCTGTGGAGTCCCAACC C CAGCTACTCTGATCCCTCTGGGGGCTCTGGCCAAGGGCCAGACAGACCTTCACAGATGCC T ACTTTTGGCCTCATCTCTGCCTGACAAGGCCAGCACCCAAAGGGTTAATATTTAACCTCT T TTTAAGGACACTGGGGTCTGTTTCTGGAAATGTTCTTTAGATGGTGGCACATTCCTTTGG G TATGTTAACCTAGGCAGTGGGAGGCAAATGGGATGGTATGTGAGCTAGGAGAAGGGCTGA A CCCTCAGCCTTGACTATGTCTAGAGCCTCTTGGGGAAGGGGCACCTCTCTTGAACCCCAA A TGCTCTCTCTTCTTATTACCCAAACCCATGGCTCTATTTCTTCTTCACATCCATTGTCTC T TCATGTCTATTCCATTCCCTTCGGCCAAACAGACAGGTGGAAAAACTGAGACAGGCAGTT T CAGAGATGGACAGAGAACTTTATTTTGGATTGTGGATGTGGACTTTTTTGTACATAAATA A GAAAAACCAAAATACTCCAAAGATGACTTCCCCTGCCTCCTACTCCAGTATGACAGAGGA G GATGTAAGGCCTTAGCCATGATCTGCAGGGGTCTGGGAGTCAGGCCCGGCCTATTGCTTG G GTCTCTCTCTATTTATATATCTAAGTTCACAGTGTTTCTTATTCCCCCTAAGCTTCTAGA G GCTCATGGCCCTGTAGTTAGGCCTGGCTCATTCTGCACCTTTCCAGGGAGGTGGAAGGAC C CTGTGCCCTCCTTCCCAATCTTCTTTTTCAGGCTCGCCAAGGCCTAGGACCTATGTTGTA A TTTTACTTTTTATTTCTAAAGTTGTAGTGAAGCTCTCACCCATAATAAAGGTTGTGAATG T TC _, _, _ : :. _.. : _. _.. : _... :.. ___. _.. :. : _,,,. : __ : _-_. :. _ :. _, :,, : __ : ; __ :, :., :.. _Z+__~_. 6,"_.,,,,. __, _,,, _.,, _,, _,,.,,.,.,, _, _.,,,,,,..,... _.,..,,,,,,,,,., _,,, _,.,,,,..,, _.,,,,,,,., __,,, _=,. _, : _, =' : ___ SEQ ID NO : 126. 1619 aa Protein MVMSFRVSELQVLLGFAGRNKSGRKHELLAKALHLLKSSCAPSVQMKIKELYRRRFPRKT L inhibiting GPSDLSLLSLPPGTSPVGSPGPLAPIPPTLLAPGTLLGPKREVDMHPPLPQPVHPDVTMK P activated LPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQVQQILTSREVLPGAKCDYTIQVQ L STAT3 (P1AS3) RFCLCETSCPQEDYFPPNLFVKVNGKLCPLPGYLPPTKNGAEPKRPSRPINITPLARLSA T Protein VPNTIVVNWSSEFGRNYSLSVYLVRQLTAGTLLQKLRAKGIRNPDHSRALIKEKLTADPD S EVATTSLRVSLMCPLGKMRLTVPCRALTCAHLQSFDAALYLQMNEKKPTWTCPVCDKKAP Y Sequence ESLIIDGLFMEILSSCSDCDEIQFMEDGSWCPMKPKKEASEVCPPPGYGLDGLQYSPVQG G DPSENKKKVEVIDLTIESSSDEEDLPPTKKHCSVTSAAIPALPGSKGVLTSGHQPSSVLR S PAMGTLGGDFLSSLPLHEYPPAFPLGADIQGLDLFSFLQTESQHYGPSVITSLDEQDALG H FFQYRGTPSHFLGPLAPTLGSSHCSATPAPPPGRVSSIVAPGGALREGHGGPLPSGPSLT G CRSDIISLD SEQIDNO : 127 1450bp-i Activatory cell CCACGCGTCCGGCTTCTTTGGGGGTGAAGAGATTGGGGAGGAATCTCCACCCCTGGGAGG C Activatory cell CCACGCGTCCGGCTTCTTTGGGGGTGAAGAGATTGGGGAGGAATCTCCACCCCTGGGAGG C surface receptor AGAAGCCAGGCATAGCGCGCTGGCTAGGACTCCAGTACCGTGAAGGGAGGCAGTGAGAGC A protein GACATCTGTGCCTCATTCCTGATCTCAAGGGGAAAGCAAGAACAAGGGAGGCTTCCTCAG G CC) 24499 0) ATCTCGAACCTGCGGAAGGAGGACCAGTCTGTGTACTTCTGCCAAGTCCAGCTGGACATA C AGATCAGGGAGGCTGTCGTGGCAGTCCATCAAGGGGACCCACCTCACCATCACCCAGGCC C TCAGGCAGCCCCTCCACAGGGCCCCTCTCCTGCCTGGACAGCTCTGCTGGTCTCCCCGTC C CCTGGAGAAGAACAAGGCCATGGGTCGGCCCCTGCTGCTGCCCCTGCTGCTCCTGCTGCA G CCGCCAGCATTTCTGCAGCCTGGTGGCTCCACAGGATCTGGTCCAAGCTACCTTTATGGG G TCACTCAACCAAAACACCTCTCAGCCTCCATGGGTGGCTCTGTGGAAATCCCCTTCTCCT T CTATTACCCCTGGGAGTTAGCCATAGTTCCCAACGTGAGAATATCCTGGAGACGGGGCCA C TTCCACGGGCAGTCCTTCTACAGCACAAGGCCGCCTTCCATTCACAAGGATTATGTGAAC C t GGCTCTTTCTGAACTGGACAGAGGGTCAGGAGAGCGGCTTCCTCAGGATCTCAAACCTGC G GAAGGAGGACCAGTCTGTGTATTTCTGCCGAGTCGAGCTGGACACCCGGAGATCAGGGAG G CAGCAGTTGCAGTCCATCAAGGGGACCAAACTCACCATCACCCAGGCTGTCACAACCACC A CCACCTGGAGGCCCAGCAGCACAACCACCATAGCCGGCCTCAGGGTCACAGAAAGCAAAG G GCACTCAGAATCATGGCACCTAAGTCTGGACACTGCCATCAGGGTTGCATTGGCTGTCGC T GTGCTCAAAACTGTCATTTTGGGACTGCTGTGCCTCCTCCTCCTGTGGTGGAGGAGAAGG A AAGGTAGCAGGGCGCCAAGCAGTGACTTCTGACCAACAGAGTGTGGGGAGAAGGGATGTG T ATTAGCCCCGGAGGACGTGATGTGAGACCCGCTTGTGAGTCCTCCACACTCGTTCCCCAT T GGCAAGATACATGGAGAGCACCCTGAGGACCTTTAAAAGGCAAAGCCGCAAGGCAGAAGG A GGCTGGGTCCCTGAATCACCGACTGGAGGAGAGTTACCTACAAGAGCCTTCATCCAGGAG C ATCCACACTGCAATGATATAGGAATGAGGTCTGAACTCCACTGAATTAAACCACTGGCAT T TGGGGGCTGTTTATTATAGCAGTGCAAAGAGTTCCTTTATCCTCCCCAAGGATGGAAAAA T ACAATTTATTTTGCTTACCAT ,-________s _.... _..... SEQ ID.. NO, :,, _2 g.. _......... ., . .. a. -27aa., , :-,. _r.. W : ____. __rv. _ _. _ _ !..... ID NO : 128 227 aa Activatory cell MGRPLLLPLLLLLQPPAFLQPGGSTGSGPSYLYGVTQPKHLSASMGGSVEIPFSFYYPWE L surface receptor AIVPNVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQESGFLRISNLRKEDQS V protein YFCRVELDTRRSGRQQLQSIKGTKLTITQAVTTTTTWRPSSTTTIAGLRVTESKGHSESW H |CG 124499-01 LSLDTAIRVALAVAVLKTVILGLLCLLLLWWRRRKGSRAPSSDF Protein Sequence SEQIDNO : 129 41581 bps TRAF5Splice 3ATGGCTTATTCAGAAGAGCATAAAGGTATGCCCTGTGGTTTCATCCGCCAGAATTCCGG CA variant ACTCCATTTCCTTGGACTTTGAGCCCAGTATAGAGTACCAGTTTGTGGAGCGGTTGGAAG A TRAF5 SV GCGCTACAAATGTGCCTTCTGCCACTCGGTGCTTCACAACCCCCACCAGACAGGATGTGG G CACCGCTTCTGCCAGCACTGCATCCTGTCCCTGAGAGAATTAAACACAGTGCCAATCTGC C DNA Sequence CTGTAGATAAAGAGGTCATCAAATCTCAGGAGGTTTTTAAAGACAATTGTTGCAAAAGAG A AGTCCTCAACTTATATGTATATTGCAGCAATGCTCCTGGATGTAATGCCAAGGTTATTCT G GGCCGGTACCAGGATCACCTTCAGCAGTGCTTATTTCAACCTGTGCAGTGTTCTAATGAG A AGTGCCGGGAGCCAGTCCTACGGAAAGACCTGAAAGAGCATTTGAGTGCATCCTGTCAGT T TCGAAAGGAAAAATGCCTTTATTGCAAAAAGGATGTGGTAGTCATCAATCTACAGAATCA T GAGGAAAACTTGTGTCCTGAATACCCAGTATTTTGTCCCAACAATTGTGCGAAGATTATT C TAAAAACTGAGGTAGATGAACACCTGGCTGTATGTCCTGAAGCTGAGCAAGACTGTCCTT T TAAGCACTATGGCTGTGCTGTAACGATTTCTGACTTACACAAGAGCCTAGAACAGAAAGA A AGTAAAATCCAGCAGCTAGCAGAAACTATAAAGAAACTTGAAAAGGAGTTCAAGCAGTTT G CACAGTTGTTTGGCAAAAATGGAAGCTTCCTCCCAAACATCCAGGTTTTTGCCAGTCACA T TGACAAGTCAGCTTGGCTAGAAGCTCAAGTGCATCAATTATTACAAATGGTTAACCAGCA A CAAAATAAATTTGACCTGAGACCTTTGATGGAAGCAGTTGATACAGTGAAACAGAAAATT A CCCTGCTAGAAAACAATGATCAAAGATTAGCCGTTTTAGAAGAGGAAACTAACAAACATG A TACCCACATTAATATTCATAAAGCACAGCTGAGTAAAAATGAAGAGCGATTTAAACTGCT G GAGGGTACTTGCTATAATGGAAAGCTCATTTGGAAGGTGACAGATTACAAGATGAAGAAG A GAGAGGCGGTGGATGGGCACACAGTGTCCATCTTCAGCCAGTCCTTCTACACCAGCCGCT G TGGCTACCGGCTCTGTGCTAGAGCATACCTGAATGGGGATGGGTCAGGGAGGGGGTCACA C CTGTCCCTATACTTTGTGGTCATGCGAGGAGAGTTTGACTCACTGTTGCAGTGGCCATTC A GGCAGAGGGTGACCCTGATGCTTCTGGACCAGAGTGGCAAAAAGAACATTATGGAGACCT T CAAACCTGACCCCAATAGCAGCAGCTTTAAAAGACCTGATGGGGAGATGAACATTGCATC T GGCTGTCCCCGCTTTGTGGCTCATTCTGTTTTGGAGAATGCCAAGAACGCCTACATTAAA G ATGACACTCTGTTCTTGAAAGTGGCCGTGGACTTAACTGACCTGGAGGATCTCTAG SEQ ID NO : 131 TRAF5 Sptice MAYSEEHKGMPCGFIRQNSGNSISLDFEPSIEYQFVERLEERYKCAFCHSVLHNPHQTGC G variant HRFCQHCILSLRELNTVPICPVDKEVIKSQEVFKDNCCKREVLNLYVYCSNAPGCNAKVI L TRAF5-SV GRYQDHLQQCLFQPVQCSNEKCREPVLRKDLKEHLSASCQFRKEKCLYCKKDVVVINLQN H Protein EENLCPEYPVFCPNNCAKIILKTEVDEHLAVCPEAEQDCPFKHYGCAVTISDLHKSLEQK E SKIQQLAETIKKLEKEFKQFAQLFGKNGSFLPNIQVFASHIDKSAWLEAQVHQLLQMVNQ Q QNKFDLRPLMEAVDTVKQKITLLENNDQRLAVLEEETNKHDTHINIHKAQLSKNEERFKL L EGTCYNGKLIWKVTDYKMKKREAVDGHTVSIFSQSFYTSRCGYRLCARAYLNGDGSGRGS H LSLYFVVMRGEFDSLLQWPFRQRVTLMLLDQSGKKNIMETFKPDPNSSSFKRPDGEMNIA S GCPRFVAHSVLENAKNAYIKDDTLFLKVAVDLTDLEDL SEQ ID NO : 131 1707 bp-i. TRAF5 ATGGCTTATTCAGAAGAGCATAAAGGTATGCCCTGTGGTTTCATCCGCCAGAATTCCGGC A v r TRAFS ATGGCTTATTCAGAAGAGCATAAAGGTATGCCCTGTGGTTTCATCCGCCAGAATTCCGGC A DNA Sequence ACTCCATTTCCTTGGACTTTGAGCCCAGTATAGAGTACCAGTTTGTGGAGCGGTTGGAAG A GCGCTACAAATGTGCCTTCTGCCACTCGGTGCTTCACAACCCCCACCAGACAGGATGTGG G CACCGCTTCTGCCAGCACTGCATCCTGTCCCTGAGAGAATTAAACACAGTGCCAATCTGC C CTGTAGATAAAGAGGTCATCAAATCTCAGGAGGTTTTTAAAGACAATTGTTGCAAAAGAG A AGTCCTCAACTTATATGTATATTGCAGCAATGCTCCTGGATGTAATGCCAAGGTTATTCT G GGCCGGTACCAGCAGGTCCCACTGGCCTGTTGTTATCTGTTGCAGGATCACCTTCAGCAG T GCTTATTTCAACCTGTGCAGTGTTCTAATGAGAAGTGCCGGGAGCCAGTCCTACGGAAAG A CCTGAAAGAGCATTTGAGTGCATCCTGTCAGTTTCGAAAGGAAAAATGCCTTTATTGCAA A AAGGATGTGGTAGTCATCAATCTACAGAATCATGAGGAAAACTTGTGTCCTGAATACCCA G TATTTTGTCCCAACAATTGTGCGAAGATTATTCTAAAAACTGAGGTAGATGAACACCTGG C TGTATGTCCTGAAGCTGAGCAAGACTGTCCTTTTAAGCACTATGGCTGTGCTGTAACGGA T AAACGGAGGAACCTGCAGCAACATGAGCATTCAGCCTTACGGGAGCACATGCGTTTGGTT T TAGAAAAGAATGTCCAATTAGAAGAACAGATTTCTGACTTACACAAGAGCCTAGAACAGA A AGAAAGTAAAATCCAGCAGCTAGCAGAAACTATAAAGAAACTTGAAAAGGAGTTCAAGCA G TTTGCACAGTTGTTTGGCAAAAATGGAAGCTTCCTCCCAAACATCCAGGTTTTTGCCAGT C ACATTGACAAGTCAGCTTGGCTAGAAGCTCAAGTGCATCAATTATTACAAATGGTTAACC A GCAACAAAATAAATTTGACCTGAGACCTTTGATGGAAGCAGTTGATACAGTGAAACAGAA A ATTACCCTGCTAGAAAACAATGATCAAAGATTAGCCGTTTTAGAAGAGGAAACTAACAAA C ATGATACCCACATTAATATTCATAAAGCACAGCTGAGTAAAAATGAAGAGCGATTTAAAC T GCTGGAGGGTACTTGCTATAATGGAAAGCTCATTTGGAAGGTGACAGATTACAAGATGAA G AAGAGAGAGGCGGTGGATGGGCACACAGTGTCCATCTTCAGCCAGTCCTTCTACACCAGC C GCTGTGGCTACCGGCTCTGTGCTAGAGCATACCTGAATGGGGATGGGTCAGGGAGGGGGT C ACACCTGTCCCTATACTTTGTGGTCATGCGAGGAGAGTTTGACTCACTGTTGCAGTGGCC A TTCAGGCAGAGGGTGACCCTGATGCTTCTGGACCAGAGTGGCAAAAAGAACATTATGGAG A CCTTCAAACCTGACCCCAATAGCAGCAGCTTTAAAAGACCTGATGGGGAGATGAACATTG C ATCTGGCTGTCCCCGCTTTGTGGCTCATTCTGTTTTGGAGAATGCCAAGAACGCCTACAT T AAAGATGACACTCTGTTCTTGAAAGTGGCCGTGGACTTAACTGACCTGGAGGATCTCTAG SEQ ID NO : 132 |568 aa 3i TRAF5 MAYSEEHKGMPCGFIRQNSGNSISLDFEPSIEYQFVERLEERYKCAFCHSVLHNPHQTGC G Protein HRFCQHCILSLRELNTVPICPVDKEVIKSQEVFKDNCCKREVLNLYVYCSNAPGCNAKVI L Sequence GRYQQVPLACCYLLQDHLQQCLFQPVQCSNEKCREPVLRKDLKEHLSASCQFRKEKCLYC K KDVVVINLQNHEENLCPEYPVFCPNNCAKIILKTEVDEHLAVCPEAEQDCPFKHYGCAVT D KRRNLQQHEHSALREHMRLVLEKNVQLEEQISDLHKSLEQKESKIQQLAETIKKLEKEFK Q FAQLFGKNGSFLPNIQVFASHIDKSAWLEAQVHQLLQMVNQQQNKFDLRPLMEAVDTVKQ K ITLLENNDQRLAVLEEETNKHDTHINIHKAQLSKNEERFKLLEGTCYNGKLIWKVTDYKM K KREAVDGHTVSIFSQSFYTSRCGYRLCARAYLNGDGSGRGSHLSLYFVVMRGEFDSLLQW P FRQRVTLMLLDQSGKKNIMETFKPDPNSSSFKRPDGEMNIASGCPRFVAHSVLENAKNAY I KDDTLFLKVAVDLTDLEDL

OTHER EMBODIMENTS Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.